



US011834467B2

(12) **United States Patent**
Lee et al.

(10) **Patent No.:** **US 11,834,467 B2**
(45) **Date of Patent:** **Dec. 5, 2023**

(54) **SUBSTITUTED INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS**

(71) Applicant: **1ST Biotherapeutics, Inc.**,
Gyeonggi-do (KR)

(72) Inventors: **Jinhwa Lee**, Gyeonggi-do (KR);
Suyeon Jo, Gyeonggi-do (KR);
Keonseung Lim, Gyeonggi-do (KR); **A Yeong Park**, Gyeonggi-do (KR);
Gadhe Changdev Gorakshnath, Seoul (KR); **Hwajung Nam**, Busan (KR);
Yeonguk Jeon, Gyeonggi-do (KR);
Yejin Hwang, Gyeonggi-do (KR); **Jae Eun Kim**, Gyeonggi-do (KR); **Misoon Kim**, Gyeonggi-do (KR); **Seung Mook Lim**, Gyeonggi-do (KR)

(73) Assignee: **1ST Biotherapeutics, Inc.**,
Gyeonggi-do (KR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 17 days.

(21) Appl. No.: **17/485,653**

(22) Filed: **Sep. 27, 2021**

(65) **Prior Publication Data**
US 2022/0098219 A1 Mar. 31, 2022

Related U.S. Application Data
(60) Provisional application No. 63/084,059, filed on Sep. 28, 2020.

(51) **Int. Cl.**
A61K 31/416 (2006.01)
C07D 231/56 (2006.01)
C07F 7/08 (2006.01)
C07D 487/04 (2006.01)
C07D 417/04 (2006.01)
C07D 417/14 (2006.01)
C07D 471/04 (2006.01)
C07D 513/04 (2006.01)
C07F 9/6558 (2006.01)

(52) **U.S. Cl.**
CPC **C07F 7/0812** (2013.01); **C07D 417/04** (2013.01); **C07D 417/14** (2013.01); **C07D 471/04** (2013.01); **C07D 487/04** (2013.01); **C07D 513/04** (2013.01); **C07F 9/65583** (2013.01); **C07B 2200/05** (2013.01)

(58) **Field of Classification Search**
CPC A61K 31/416; C07D 231/56
USPC 514/406; 548/361.1
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

8,450,321 B2	5/2013	Mitchell et al.
8,455,493 B2	6/2013	Mitchell et al.
8,778,935 B2	7/2014	Fernandez et al.
9,073,927 B2	7/2015	Fernandez et al.
9,212,191 B2	12/2015	Mitchell et al.
2010/0075965 A1	3/2010	Ni et al.
2018/0111939 A1	4/2018	Dymek et al.

FOREIGN PATENT DOCUMENTS

CN	109721620 A	5/2019	
WO	WO-2009/017822 A2	2/2009	
WO	WO-2010/008847 A2	1/2010	
WO	WO-2012/052745 A1	4/2012	
WO	WO-2020/170206 A1	8/2020	
WO	WO-2022064458 A1 *	3/2022 C07D 417/04

OTHER PUBLICATIONS


Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.*
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, 18.*
Hackam, et al. JAMA, 296(14), 2006, 1731-1732.*
International Search Report from corresponding PCT Application No. PCT/IB2021/058794, dated Dec. 24, 2021.
Written Opinion of the International Searching Authority from corresponding PCT Application No. PCT/IB2021/058794, dated Dec. 24, 2021.

* cited by examiner

Primary Examiner — Douglas M Willis
(74) *Attorney, Agent, or Firm* — Harness, Dickey & Pierce, P.L.C.

(57) **ABSTRACT**

The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.



24 Claims, No Drawings

1

**SUBSTITUTED INDAZOLES AS
HEMATOPOIETIC PROGENITOR KINASE 1
(HPK1) INHIBITORS**

CROSS-REFERENCE TO RELATED
APPLICATIONS

This application claims the benefit and priority to U.S. Provisional Patent Application No. 63/084,059, filed on 28 Sep. 2020. The entire disclosure of the application identified in this paragraph is incorporated herein by reference.

FIELD

The present disclosure is directed to inhibitors of hematopoietic progenitor kinase 1 (HPK1), pharmaceutical compositions comprising the inhibitors, methods of using the inhibitors for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.

BACKGROUND

Immunotherapy is treatment that uses the human body's own immune system to help fight cancer and other disorders. This relatively new approach has achieved remarkable clinical successes in the treatment of a variety of tumor types in recent years, especially with the treatment of immune checkpoint inhibitors and chimeric antigen T-cell therapy. The most investigated checkpoint inhibitors including CTLA4, PD-1, or PD-L1 inhibitors have demonstrated significant antitumor activity by overcoming immunosuppressive mechanisms at the tumor site.

Hematopoietic progenitor kinase 1 (HPK1, MAP4K1) is a serine/threonine kinase and a member of MAP4K. HPK1 is prominently expressed in subsets of hematopoietic cell lineages. HPK1 is a newly identified as a critical negative regulator in the activation of T lymphocytes and dendritic cells. It has been recently demonstrated that the important roles for kinase activity of HPK1 in anticancer immunity as a new intracellular checkpoint molecule as well as potential advantages of combination therapy with current checkpoint regimens. HPK1 inhibition is expected to have dual functions, 1. prolonged activation of T cells; 2. enhanced APC functions by dendritic cells. This dual targeting may synergistically work together for efficient immune responses in tumor microenvironment. Thus, HPK1 has been validated as a novel target for anticancer immunotherapy. Examples of cancers that are treatable using the compounds of the present disclosure include, but are not limited to, all forms of carcinomas, melanomas, blastomas, sarcomas, lymphomas and leukemias, including without limitation, bladder carcinoma, brain tumors, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, endometrial cancer, hepatocellular carcinoma, laryngeal cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma and thyroid cancer, acute lymphocytic leukemia, acute myeloid leukemia, ependymoma, Ewing's sarcoma, glioblastoma, medulloblastoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, rhabdoid cancer, and nephroblastoma (Wilm's tumor).

Inhibition of HPK1 with small molecule inhibitors has the potential for the treatment of cancer and other disorders [Hernandez, S., et. al., (2018) *Cell Reports* 25, 80-94].

SUMMARY

The present disclosure provides novel indazole compounds and pharmaceutically acceptable salts as effective HPK1 inhibitors and dual activators of T cell and dendritic cell.


2

One embodiment of the invention is a compound of Formula (I):

5

Formula (I)

10



15

or a pharmaceutically acceptable salt, hydrate, solvate thereof, wherein R^1 , R^2 , R^3 , R^4 , R^5 , Het, M, and L are as defined in the detailed descriptions.

20

In another embodiment, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

25

In yet another embodiment, there is provided a method of treating a subject with a disease or disorder associated with modulation of HPK1 comprising: administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

30

DETAILED DESCRIPTION

35

The following description is merely exemplary in nature and is not intended to limit the present disclosure, application, or uses.

40

Definitions

45

The generic terms used in the present disclosure are herein defined for clarity.

50

This specification uses the terms "substituent", "radical", "group", "moiety", and "fragment" interchangeably.

55

As used herein, the term "alkenyl" refers to a straight or branched hydrocarbonyl group with at least one site of unsaturation, i.e., a carbon-carbon, sp^2 double bond. In an embodiment, alkenyl has from 2 to 12 carbon atoms. In some embodiments, alkenyl is a C_2 - C_{10} alkenyl group or a C_2 - C_6 alkenyl group. Examples of alkenyl group include, but are not limited to, ethylene or vinyl ($-CH=CH_2$), allyl ($-CH_2CH=CH_2$), cyclopentenyl ($-C_5H_7$), and 5-hexenyl ($-CH_2CH_2CH_2CH_2CH=CH_2$).

60

As used herein, the term "alkoxy" is $RO-$ where R is alkyl. Non-limiting examples of alkoxy groups include methoxy, ethoxy and propoxy.

65

As used herein, the term "alkoxyalkyl" refers to an alkyl moiety substituted with an alkoxy group. Examples of alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl and ethoxyethyl.

70

As used herein, the term "alkoxycarbonyl" is $ROC(O)-$, where R is an alkyl group as defined herein. In various embodiments, R is a C_1 - C_{10} alkyl group or a C_1 - C_6 alkyl group.

75

As used herein, the term "alkyl" refers to a straight or branched chain hydrocarbonyl group. In an embodiment, alkyl has from 1 to 12 carbon atoms. In some embodiments, alkyl is a C_1 - C_{10} alkyl group or a C_1 - C_6 alkyl group. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl,

pentyl, hexyl, heptyl, octyl, nonyl and decyl. "lower alkyl" means alkyl having from 1 to 4 carbon atoms.

As used herein, if the term "C₁-C₆" is used, it means the number of carbon atoms is from 1 to 6. For example, C₁-C₆ alkyl means an alkyl which carbon number is any integer of from 1 to 6.

As used herein, the term "alkylamino" refers to an amino group substituted with one or more alkyl groups. "N-(alkyl) amino" is RNH— and "N,N-(alkyl)₂amino" is R₂N—, where the R groups are alkyl as defined herein and are the same or different. In various embodiments, R is a C₁-C₁₀ alkyl group or a C₁-C₆ alkyl group. Examples of alkylamino groups include methylamino, ethylamino, propylamino, butylamino, dimethylamino, diethylamino, and methylethylamino.

As used herein, the term "alkylaminoalkyl" refers to an alkyl moiety substituted with an alkylamino group, wherein alkylamino is as defined herein. Examples of alkylaminoalkyl groups include methylaminomethyl and ethylaminomethyl.

As used herein, the term "alkynyl" refers to a straight or branched carbon-chain group with at least one site of unsaturation, i.e., a carbon-carbon, sp triple bond. In an embodiment, alkynyl has from 2 to 12 carbon atoms. In some embodiments, alkynyl is a C₂-C₁₀ alkynyl group or a C₂-C₆alkynyl group. Examples of alkynyl groups include acetylenic (—C≡CH) and propargyl (—CH₂C≡CH).

As used herein, the term "aryl" refers to any monocyclic or bicyclic carbon ring of up to 7 atoms in each ring, wherein at least one ring is aromatic, or an aromatic ring system of 5 to 14 carbon atoms which includes a carbocyclic aromatic group fused with a 5- or 6-membered cycloalkyl group. Representative examples of aryl groups include, but are not limited to, phenyl, tolyl, xylyl, naphthyl, tetrahydronaphthyl, anthracenyl, fluorenyl, indenyl, azulenyl and indanyl. A carbocyclic aromatic group can be unsubstituted or optionally substituted.

As used herein, the term "cycloalkyl" is a hydrocarbyl group containing at least one saturated or partially unsaturated ring structure, and attached via a ring carbon. In various embodiments, it refers to a saturated or a partially unsaturated C₃-C₁₂ cyclic moiety, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl and cyclooctyl. "Cycloalkyloxy" is RO—, where R is cycloalkyl.

As used herein, the terms "halogen" and "halo" refers to chloro (—Cl), bromo (—Br), fluoro (—F) or iodo (—I). "Haloalkoxy" refers to an alkoxy group substituted with one or more halo groups and examples of haloalkoxy groups include, but are not limited to, —OCF₃, —OCHF₂ and —OCH₂F. "Haloalkoxyalkyl" refers to an alkyl moiety substituted with a haloalkoxy group, wherein haloalkoxy is as defined herein. Examples of haloalkoxyalkyl groups include trifluoromethoxymethyl, trifluoroethoxymethyl and trifluoromethoxyethyl. "Haloalkyl" refers to an alkyl moiety substituted with one or more halo groups. Examples of haloalkyl groups include —CF₃ and —CHF₂.

As used herein, the term "heteroalkyl" refers to a straight- or branched-chain alkyl group having from 2 to 14 carbons (in some embodiments, 2 to 10 carbons) in the chain, one or more of which has been replaced by a heteroatom selected from S, O, P and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, amides, alkyl sulfides, and the like.

As used herein, the term "heterocyclyl" includes the heteroaryls defined below and refers to a saturated or partially unsaturated monocyclic, bicyclic or tricyclic group

of 2 to 14 ring-carbon atoms and, in addition to ring-carbon atoms, 1 to 4 heteroatoms selected from P, N, O and S. In various embodiments the heterocyclic group is attached to another moiety through carbon or through a heteroatom, and is optionally substituted on carbon or a heteroatom. Examples of heterocyclyl include azetidiny, benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolaziny, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazoliny, quinolyl, quinoxaliny, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydroisoquinoliny, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidiny, 1,4-dioxanyl, hexahydroazepiny, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinoliny, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidiny, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof "Heterocyclyoxy" is RO—, where R is heterocyclyl. "Heterocyclylthio" is RS—, where R is heterocyclyl.

As used herein, the term "3- or 4-membered heterocyclyl" refers to a monocyclic ring having 3 or 4 ring atoms wherein at least one ring atom is heteroatom selected from the group consisting of N, O and S. Non-limiting examples of 3- or 4-membered heterocyclyl include aziridinyl, 2H-aziriny, oxiranyl, thiiranyl, azetidiny, 2,3-dihydroazetyl, azetyl, 1,3-diazetidiny, oxetanyl, 2H-oxoethyl, thietanyl, and 2H-thietyl.

As used herein, the term "heteroaryl" refers to a monocyclic, bicyclic or tricyclic ring having up to 7 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms in the ring selected from the group consisting of N, O and S. Non-limiting examples of heteroaryl include pyridyl, thienyl, furanyl, pyrimidyl, imidazolyl, pyranyl, pyrazolyl, thiazolyl, thiadiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, pyridazinyl, pyrazinyl, quinoliny, isoquinoliny, benzofuranyl, dibenzofuranyl, dibenzothiophenyl, benzothiophenyl, indolyl, benzothiazolyl, benzoaxazolyl, benzimidazolyl, isoindolyl, benzotriazolyl, purinyl, thianaphthenyl and pyrazinyl. Attachment of heteroaryl can occur via an aromatic ring, or, if heteroaryl is bicyclic or tricyclic and one of the rings is not aromatic or contains no heteroatoms, through a non-aromatic ring or a ring containing no heteroatoms. "Heteroaryl" is also understood to include the N-oxide derivative of any nitrogen containing heteroaryl. "Heteroaryloxy" is RO—, where R is heteroaryl.

As used herein, the term "hydroxyalkoxy" refers to an alkoxy group substituted with a hydroxyl group (—OH), wherein alkoxy is as defined herein. An example of hydroxyalkoxy is hydroxyethoxy.

As used herein, the term "hydroxyalkyl" refers to a linear or branched monovalent C₁-C₁₀ hydrocarbon group substituted with at least one hydroxy group and examples of hydroxyalkyl groups include, but are not limited to, hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl.

5

As used herein, the term “pharmaceutically acceptable” means suitable for use in pharmaceutical preparations, generally considered as safe for such use, officially approved by a regulatory agency of a national or state government for such use, or being listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.

As used herein, the term “pharmaceutically acceptable carrier” refers to a diluent, adjuvant, excipient, or carrier, or other ingredient which is pharmaceutically acceptable and with which a compound of the invention is administered.

As used herein, the term “pharmaceutically acceptable salt” refers to a salt which may enhance desired pharmacological activity. Examples of pharmaceutically acceptable salts include acid addition salts formed with inorganic or organic acids, metal salts and amine salts. Examples of acid addition salts formed with inorganic acids include salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid. Examples of acid addition salts formed with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxy-benzoyl)-benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethane-sulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methyl-bicyclo [2.2.2]oct-2-ene-1-carboxylic acid, gluco-heptonic acid, 4,4'-methylenebis(3-hydroxy-2-naphthoic) acid, 3-phenylpropionic acid, trimethyl-acetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxy-naphthoic acids, salicylic acid, stearic acid and muconic acid. Examples of metal salts include salts with sodium, potassium, calcium, magnesium, aluminum, iron, and zinc ions. Examples of amine salts include salts with ammonia and organic nitrogenous bases strong enough to form salts with carboxylic acids.

As used herein, the term “substituted” means any of above groups (i.e., alkyl, aryl, heteroaryl, heterocycle or cycloalkyl) wherein at least one hydrogen atom of the moiety being substituted is replaced with a substituent. In one embodiment, each carbon atom of the group being substituted is substituted with no more than two substituents. In another embodiment, each carbon atom of the group being substituted is substituted with no more than one substituent. In the case of a keto substituent, two hydrogen atoms are replaced with an oxygen which is attached to the carbon via a double bond. Unless specifically defined, substituents include halo, hydroxyl, (lower) alkyl, haloalkyl, mono- or di-alkylamino, aryl, heterocycle, $-\text{NO}_2$, $\text{B}(\text{OH})_2$, BPin, $-\text{NR}_a\text{R}_b$, $-\text{NR}_a\text{C}(\text{=O})\text{R}_b$, $-\text{NR}_a\text{C}(\text{=O})\text{NR}_a\text{R}_b$, $-\text{NR}_a\text{C}(\text{=O})\text{OR}_b$, $-\text{NR}_a\text{SO}_2\text{R}_b$, $-\text{OR}_a$, $-\text{CN}$, $-\text{C}(\text{=O})\text{R}_a$, $-\text{C}(\text{=O})\text{OR}_a$, $-\text{C}(\text{=O})\text{NR}_a\text{R}_b$, $-\text{OC}(\text{=O})\text{R}_a$, $-\text{OC}(\text{=O})\text{OR}_a$, $-\text{OC}(\text{=O})\text{NR}_a\text{R}_b$, $-\text{NR}_a\text{SO}_2\text{R}_b$, $-\text{PO}_3\text{R}_a$, $-\text{PO}(\text{OR}_a)(\text{OR}_b)$, $-\text{SO}_2\text{R}_a$, $-\text{S}(\text{O})\text{R}_a$, $-\text{SO}(\text{N})\text{R}_a$ (e.g., sulfoximine), $(\text{R}_a)\text{S}=\text{NR}_b$ (e.g., sulfilimine) and $-\text{SR}_a$, wherein R_a and R_b are the same or different and independently $-\text{H}$, halo, amino, alkyl, haloalkyl, aryl or heterocycle, or wherein R_a and R_b taken together with the nitrogen atom to which they are attached form a heterocycle. R_a and R_b may be in the plural based on atoms which those are attached to.

As used herein, the term “therapeutically effective amount” means when applied to a compound of the invention is intended to denote an amount of the compound that is sufficient to ameliorate, palliate, stabilize, reverse, slow or


6

delay the progression of a disorder or disease state, or of a symptom of the disorder or disease. In an embodiment, the method of the present invention provides for administration of combinations of compounds. In such instances, the “therapeutically effective amount” is the amount of a compound of the present invention in the combination sufficient to cause the intended biological effect.

As used herein, the term “treatment” or “treating” as used herein means ameliorating or reversing the progress or severity of a disease or disorder, or ameliorating or reversing one or more symptoms or side effects of such disease or disorder. “Treatment” or “treating”, as used herein, also means to inhibit or block, as in retard, arrest, restrain, impede or obstruct, the progress of a system, condition or state of a disease or disorder. For purposes of this invention, “treatment” or “treating” further means an approach for obtaining beneficial or desired clinical results, where “beneficial or desired clinical results” include, without limitation, alleviation of a symptom, diminishment of the extent of a disorder or disease, stabilized (i.e., not worsening) disease or disorder state, delay or slowing of a disease or disorder state, amelioration or palliation of a disease or disorder state, and remission of a disease or disorder, whether partial or total.

Compounds

The present disclosure provides a compound of Formula (I):



or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein:

X is O or S;

L is a bond, $-\text{O}-$, $-\text{S}-$, or $-\text{NR}^6-$;

R^1 is alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, wherein R^1 is optionally substituted with one or more substituents independently selected from R^7 ;

R^6 is $-\text{H}$ or C_{1-6} alkyl;

R^7 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, oxo, cyano, hydroxy, $-\text{C}(\text{O})\text{R}^9$, $-\text{C}(\text{O})\text{OR}^9$, $-\text{C}(\text{O})\text{NR}^{10}\text{R}^{11}$, $-\text{OR}^9$, $-\text{OC}(\text{O})\text{R}^9$, $-\text{OC}(\text{O})\text{NR}^{10}\text{R}^{11}$, $-\text{SR}^9$, $-\text{S}(\text{O})\text{R}^9$, $-\text{S}(\text{O})_2\text{R}^9$, $-\text{S}(\text{O})(=\text{NH})\text{R}^{10}$, $-\text{S}(\text{O})_2\text{NR}^{10}\text{R}^{11}$, $-\text{NR}^{10}\text{R}^{11}$, $-\text{N}(\text{R}^6)\text{NR}^{10}\text{R}^{11}$, $-\text{N}(\text{R}^6)\text{OR}^9$, $-\text{N}(\text{R}^6)\text{C}(\text{O})\text{R}^9$, $-\text{N}(\text{R}^6)\text{C}(\text{O})\text{OR}^9$, $-\text{N}(\text{R}^6)\text{C}(\text{O})\text{NR}^{10}\text{R}^{11}$, $-\text{N}(\text{R}^6)\text{S}(\text{O})_2\text{R}^9$, $-\text{N}(\text{R}^6)\text{S}(\text{O})_2\text{NR}^{10}\text{R}^{11}$, or $-\text{P}(\text{O})\text{R}^{12}\text{R}^{13}$;

R^9 is $-\text{H}$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;


Each R^{10} and R^{11} is independently $-\text{H}$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, or R^{10} and R^{11} are taken together with the nitrogen atom to which they are attached to form a 4- to 12-membered heterocyclyl optionally substituted with one or more groups selected from the group consisting of halo, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, $-\text{CN}$, $-\text{NO}_2$, $-\text{NR}^{10}\text{R}^{11}$, $-\text{NR}^{10}\text{C}(\text{=O})\text{R}^9$, $-\text{NR}^{10}\text{C}(\text{=O})\text{NR}^{10}\text{R}^{11}$, $-\text{NR}^{10}\text{C}$

7

(=O)OR⁹, —OR⁹, —C(=O)R⁹, —C(=O)OR⁹,
—C(=O)NR¹⁰R¹¹, —OC(=O)R⁹, —OC(=O)OR⁹,
and —OC(=O)NR¹⁰R¹¹;

Each R¹² and R¹³ is independently C₁₋₆ alkyl, C₁₋₆ alkoxy,
C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocyclyl, or R¹²
and R¹³ are taken together with the phosphorus atom to
which they are attached to form a 4- to 8-membered
heterocyclyl optionally substituted with one or more
groups selected from the group consisting of halo,
hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxy-
alkyl, —CN, —NO₂, —NR¹⁰R¹¹, —NR¹⁰C(=O)R⁹,
—NR¹⁰C(=O)NR¹⁰R¹¹, —NR¹⁰C(=O)OR⁹, —OR⁹,
—C(=O)R⁹, —C(=O)OR⁹, —C(=O)NR¹⁰R¹¹,
—OC(=O)R⁹, —OC(=O)OR⁹, and —OC(=O)
NR¹⁰R¹¹;

Het is selected from the group consisting of:



Each of R^a, R^b and R^c is independently —H, —D, halo,
—CF₃, —CF₂H, —CH₂F, —CN, —OR⁹ or
—NR¹⁰R¹¹;

R² is —H, —D, —CD₃, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆
alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halo,
hydroxyl, —CD₂OH, —CN, —NO₂, haloalkyl, trimethylsilylethoxymethyl,
—C(O)R⁹, —C(O)OR⁹,
—C(O)NR¹⁰R¹¹, —OR⁹, —OC(O)R⁹, —OC(O)
NR¹⁰R¹¹, —SR⁹, —S(O)R⁹, —S(O)₂R⁹, —S(O)
(=NH)R¹⁰, —S(O)₂NR¹⁰R¹¹, —NR¹⁰R¹¹, —N(R⁶)
NR¹⁰R¹¹, —N(R⁶)OR⁹, —N(R⁶)C(O)R⁹, —N(R⁶)C
(O)R⁹, —N(R⁶)C(O)OR⁹, —N(R⁶)C(O)NR¹⁰R¹¹,
—N(R⁶)S(O)₂R⁹, —N(R⁶)S(O)₂NR¹⁰R¹¹, or —P(O)
R¹²R¹³ wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkyl-
nyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is
optionally substituted with one or more groups selected
from the group consisting of halo, hydroxyl, alkyl,
alkenyl, alkynyl, haloalkyl, hydroxyalkyl, —CN,
—NO₂, —NR¹⁰R¹¹, —NR¹⁰C(=O)R⁹, —NR¹⁰C
(=O)NR¹⁰R¹¹, —NR¹⁰C(=O)OR⁹, —OR⁹,
—C(=O)R⁹, —C(=O)OR⁹, —C(=O)NR¹⁰R¹¹,
—OC(=O)R⁹, —OC(=O)OR⁹, and —OC(=O)
NR¹⁰R¹¹;

R³ is —H, —D, —CD₃, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆
alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halo,
cyano, hydroxy, —CH₂OH, —CD₂OH, —OH, —CN,

8

—NO₂, haloalkyl, —C(O)R⁹, —C(O)OR⁹, —C(O)
NR¹⁰R¹¹, —OR⁹, —OC(O)R⁹, —OC(O)NR¹⁰R¹¹,
—SR⁹, —S(O)R⁹, —S(O)₂R⁹, —S(O)(=NH)R¹⁰,
—S(O)₂NR¹⁰R¹¹, —NR¹⁰R¹¹, —N(R⁶)NR¹⁰R¹¹,
—N(R⁶)OR⁹, —N(R⁶)C(O)R⁹, —N(R⁶)C(O)OR⁹,
—N(R⁶)C(O)NR¹⁰R¹¹, —N(R⁶)S(O)₂R⁹, —N(R⁶)S
(O)₂NR¹⁰R¹¹, or —P(O)R¹²R¹³;

M is a bond, —O—, —S—, or —NR⁶—;

R⁶ is —H or C₁₋₆ alkyl;

R⁴ is —H, —D, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,
cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, cyano,
hydroxy, —C(O)R⁹, —C(O)OR⁹, —C(O)NR¹⁰R¹¹,
—S(O)₂R⁹, —S(O)(=NH)R¹⁰, —S(O)₂NR¹⁰R¹¹, or
—P(O)R¹²R¹³, wherein C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆
alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is
optionally substituted with one or more groups selected
from the group consisting of halo, hydroxyl, alkyl,
alkenyl, alkynyl, haloalkyl, hydroxyalkyl, —CN,
—CD₃, —NO₂, —NR¹⁰R¹¹, —NR¹⁰C(=O)R⁹,
—NR¹⁰C(=O)NR¹⁰R¹¹, —NR¹⁰C(=O)OR⁹,
—NR¹⁰S(O)₂R⁹, —OR⁹, —C(=O)R⁹, —C(=O)OR⁹,
—C(=O)NR¹⁰R¹¹, —OC(=O)R⁹, —OC(=O)OR⁹,
and —OC(=O)NR¹⁰R¹¹; and

R⁵ is —H, —D, —CD₃, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆
alkynyl, cycloalkyl, halo, hydroxyl, —CH₂OH,
—CD₂OH, —CN or haloalkyl.


In some embodiments, L is a bond, and R¹ is cycloalkyl
which is optionally substituted with one or more groups
selected from the group consisting of C₁₋₆ alkyl, C₂₋₆ alkenyl,
C₂₋₆ alkynyl, cycloalkyl, halo, cyano, hydroxy, —C(O)
R⁹, —C(O)OR⁹, —C(O)NR¹⁰R¹¹, —OR⁹, —OC(O)R⁹,
—OC(O)NR¹⁰R¹¹, —NR¹⁰R¹¹, —N(R⁶)NR¹⁰R¹¹, —N(R⁶)
OR⁹, —N(R⁶)C(O)R⁹, —N(R⁶)C(O)OR⁹, and —N(R⁶)C
(O)NR¹⁰R¹¹.

In some embodiments, each of R² and R³ is independently
—H, halo, alkylthio, haloalkyl, or alkyl.

In some embodiments, M is a bond, —O—, or —NR⁶—;
and R⁴ is —H, —D, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,
cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, cyano,
hydroxy, —C(O)R⁹, —C(O)NR¹⁰R¹¹, —S(O)₂R⁹, —S(O)
(=NH)R¹⁰, or —S(O)₂NR¹⁰R¹¹, wherein the C₁₋₆ alkyl,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, cycloalkyl, aryl, heteroaryl, or
heterocyclyl is optionally substituted with one or more
groups selected from the group consisting of halo, hydroxy,
alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, —CN,
—CD₃, —NR¹⁰R¹¹, —NR¹⁰S(O)₂R⁹, and —NR¹⁰C(=O)
R⁹.

In another embodiment, there is provided a compound of
Formula (II):

Formula (II)




wherein R¹, R², R³, R⁴, R⁵, R^a, R^b, M, and L are as
defined above for Formula (I).

9

In some embodiments, L is a bond; R¹ is cyclopropyl which is optionally substituted with one or more groups selected from the group consisting of halo, C₁₋₃ alkyl, C₁₋₃ hydroxyalkyl and C₁₋₃ haloalkyl; R² is —H, alkyl, halo, haloalkyl, or alkylthio; R³ is —H, alkyl, or halo; M is a bond, —O—, —S— or —NR⁶—; R⁴ is —H, halo, alkyl, hydroxyalkyl, haloalkyl, haloalkenyl, cycloalkyl, cyanoalkyl, aminocarbonylalkyl, acetamidoethyl, propionamidoethyl, formamidoethyl, cycloalkylalkyl, cycloalkyl(hydroxy)alkyl, hydroxycycloalkyl, methoxycycloalkyl, cycloalkyl(methoxy)methyl, alkoxyalkyl, alkenyl, methylsulfonamidoethyl, imidazolylethyl, dioxanyl, cyclobutanyl-carbonylaminoethyl, difluoroacetamidoethyl, trifluoroacetamidoethyl, methylthiomethyl, methylthioethyl, cyclopropylcarbonylamino(cyano)methyl, cyano(difluoroacetamido)methyl, propanyl-1,1,1,3,3,3-d6)amino, tetrahydrofuranyl, methylimidazolylethyl, furanyl, pyrrolyl, methylpyrrolyl, isoxazolyl, tetrazolylalkyl, methylpyrazolyl, or methylpyrazolylmethyl; and R⁵ is —H, alkyl, or halo. Non-limiting, exemplary compounds of Formula (II) include Examples 1 and 2 of Table 1.

In another embodiment, there is provided a compound of Formula (III):



Formula (III)


wherein R¹, R², R³, R⁴, R⁵, R^a, R^b, M, and L are as defined above for Formula (I).

In some embodiments, L is a bond; R¹ is cyclopropyl which is optionally substituted with one or more groups selected from the group consisting of halo, C₁₋₃ alkyl, C₁₋₃ hydroxyalkyl, and C₁₋₃ haloalkyl; R² is —H, alkyl, halo, haloalkyl, or halo; R³ is —H, alkyl, or halo; M is a bond, —O—, —S— or —NR⁶—; R⁴ is —H, halo, alkyl, hydroxyalkyl, haloalkyl, haloalkenyl, cycloalkyl, cyanoalkyl, aminocarbonylalkyl, acetamidoethyl, propionamidoethyl, formamidoethyl, cycloalkylalkyl, cycloalkyl(hydroxy)alkyl, hydroxycycloalkyl, methoxycycloalkyl, cycloalkyl(methoxy)methyl, alkoxyalkyl, alkenyl, methylsulfonamidoethyl, imidazolylethyl, dioxanyl, cyclobutanyl-carbonylaminoethyl, difluoroacetamidoethyl, trifluoroacetamidoethyl, methylthiomethyl, methylthioethyl, cyclopropylcarbonylamino(cyano)methyl, cyano(difluoroacetamido)methyl, propanyl-1,1,1,3,3,3-d6)amino, tetrahydrofuranyl, methylimidazolylethyl, furanyl, pyrrolyl, methylpyrrolyl, isoxazolyl, tetrazolylalkyl, methylpyrazolyl, or methylpyrazolylmethyl; and R⁵ is —H, alkyl, or halo. Non-limiting exemplary compounds of Formula (III) include Examples 3 and 23 of Table 1.

10

In another embodiment, there is provided a compound of Formula (IV):

Formula (IV)



wherein R¹, R², R³, R⁴, R⁵, R^a, R^b, M, and L are as defined above for Formula (I). Non-limiting exemplary compounds of Formula (IV) include Examples 24 and 307 of Table 1.

In some embodiments, L is a bond, and R¹ is cycloalkyl which is optionally substituted with one or more groups selected from the group consisting of C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, cycloalkyl, halo, cyano, hydroxy, —C(O)R⁹, —C(O)OR⁹, —C(O)NR¹⁰R¹¹, —OR⁹, —OC(O)R⁹, —OC(O)NR¹⁰R¹¹, —NR¹⁰R¹¹, —N(R⁶)NR¹⁰R¹¹, —N(R⁶)OR⁹, —N(R⁶)C(O)R⁹, —N(R⁶)C(O)OR⁹, and —N(R⁶)C(O)NR¹⁰R¹¹.

In some embodiments, L is a bond; R¹ is cycloalkyl which is optionally substituted with one or more groups selected from the group consisting of halo, C₁₋₃ alkyl, C₁₋₃ hydroxyalkyl and C₁₋₃ haloalkyl. In particular embodiments, the cycloalkyl is selected from cyclopropyl, cyclobutyl and cyclopentyl.

In some embodiments, L is a bond; R¹ is cyclopropyl which is optionally substituted with one or more groups selected from the group consisting of halo, C₁₋₃ alkyl, C₁₋₃ hydroxyalkyl and C₁₋₃ haloalkyl; R² is —H, alkyl, haloalkyl, or halo; R³ is —H, alkyl, or halo; M is a bond, —O—, or —NR⁶—; R⁴ is —H, halo, alkyl, monoalkylamino, or dialkylamino; R⁵ is —H, alkyl, or halo. In particular embodiments, L is a bond; R^a is —H; R^b is —H; R¹ is cyclopropyl substituted with chloro, fluoro, C₁₋₃ alkyl, C₁₋₃ hydroxyalkyl or C₁₋₃ haloalkyl; R² is —H, alkyl, chloro, or fluoro; R³ is —H, alkyl, chloro, or fluoro; M is a bond, or —NH—; R⁴ is —H, chloro, fluoro, methyl, ethyl, propyl, isopropyl, butyl, methylamino, or dimethylamino; and R⁵ is —H or alkyl. In particular embodiments, L is a bond; R^a is —H; R^b is —H; R¹ is cyclopropyl substituted with chloro or fluoro; R² is —H, chloro, or fluoro; R³ is —H, chloro, or fluoro; M is a bond, or —NH—; R⁴ is —H, chloro, fluoro, methyl, ethyl, propyl, or isopropyl; and R⁵ is —H. Non-limiting exemplary compounds having such substituents include Examples 61, 64, 84, 85, 86, 155, 156, and 157 of Table 1.

In some embodiments, L is a bond; R¹ is cyclopropyl which is optionally substituted with one or more groups selected from the group consisting of halo, C₁₋₃ alkyl, C₁₋₃ hydroxyalkyl and C₁₋₃ haloalkyl; R² is —H, alkyl, halo, haloalkyl, or alkylthio; R³ is —H, alkyl, or halo; M is a bond, —O—, —S— or —NR⁶—; R⁴ is —H, halo, alkyl, hydroxyalkyl, haloalkyl, haloalkenyl, cycloalkyl, monoalkylamino, or dialkylamino; and R⁵ is —H, alkyl, or halo. Non-limiting exemplary compounds having such substituents include Examples 33, 39, 40, 46, 82, 102, 141, 166, 228, and 286 of Table 1.

In some embodiments, L is a bond; R¹ is cyclopropyl which is optionally substituted with one or more groups selected from the group consisting of halo, C₁-C₃ alkyl, C₁-C₃ hydroxyalkyl and C₁-C₃ haloalkyl; R² is —H, alkyl, halo, haloalkyl, or alkylthio; R³ is —H, alkyl, or halo; M is a bond, —O—, —S— or —NR⁶—; R⁴ is —H, halo, alkyl, hydroxyalkyl, haloalkyl, haloalkenyl, cycloalkyl, cyanoalkyl, aminocarbonylalkyl, acetamidoethyl, propionamidoethyl, formamidoethyl, cycloalkylalkyl, cycloalkyl(hydroxy)alkyl, hydroxycycloalkyl, methoxycycloalkyl, cycloalkyl(methoxy)methyl, alkoxyalkyl, alkenyl, methylsulfonamidoethyl, imidazolylethyl, dioxanyl, cyclobutanyl-carbonylaminoethyl, difluoroacetamidoethyl, trifluoroacetamidoethyl, methylthiomethyl, methylthioethyl, cyclopropylcarbonylamino(cyano)methyl, cyano(difluoroacetamido)methyl, propanyl-1,1,1,3,3,3-d6)amino, tetrahydrofuranlyl, methylimidazolylethyl, furanyl, pyrrolyl, methylpyrrolyl, isoxazolyl, tetrazolylalkyl, methylpyrazolyl, or methylpyrazolylmethyl; and R⁵ is —H, alkyl, or halo. Non-limiting exemplary compounds having such substituents include Examples 26, 27, 34, 38, 41-44, 50, 58, 62, 63, 66, 68, 73, 77, 79, 80, 83, 87, 88, 90-92, 94, 96, 101, 105, 107, 110, 113, 116, 118-120, 128, 130, 131, 133, 134, 136, 141, 153, 160, 162, 166-168, 170, 173-176, 179, 181, 183, 186, 188, 190, 191, 194, 208, 210, 213, 215-219, 221, 223, 226, 228, 232, 235, 237, 248, 250, 252, 257, 261, 262, 264, 266, 268, 269, 272, 273, 284-290, 295, 300, and 302-305 of Table 1.

In an embodiment, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Medical Uses and Methods of Treatment Using the Compounds

The present disclosure provides a method of treating a subject with a disease or disorder associated with modulation of HPK1 comprising: administering to the subject in need thereof a therapeutically effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the disease or disorder associated with modulation of HPK1 is a cancer, metastasis, inflammation, or immune disease including autoimmune disease.

In some other embodiments, the disease is a cancer, metastasis, inflammation or auto-immune disease. In particular embodiments, the cancer is selected from the group consisting of carcinomas, melanomas, blastomas, sarcomas, lymphomas and leukemias, including without limitation, bladder carcinoma, brain tumors, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, endometrial cancer, hepatocellular carcinoma, laryngeal cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma and thyroid cancer, acute lymphocytic leukemia, acute myeloid leukemia, ependymoma, Ewing's sarcoma, glioblastoma, medulloblastoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, rhabdoid cancer, and nephroblastoma (Wilm's tumor).

In some embodiments, the autoimmune disease is an inflammatory bowel disease, Addison's disease, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, hemolytic anemia, autoimmune hepatitis, Behcet's disease, Berger's disease, bullous pemphigoid, cardiomyopathy, celiac sprue, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, cold agglutinin disease, type 1 diabetes, discoid lupus, essential mixed cryoglobulinemia, Graves' disease, Guillain-Barre

syndrome, Hashimoto's thyroiditis, hypothyroidism, autoimmune lymphoproliferative syndrome (ALPS), idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), juvenile arthritis, lichen planus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polychondritis, autoimmune polyglandular syndromes, polymyalgia rheumatica, polymyositis, dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-man syndrome, Takayasu arteritis, giant cell arteritis, ulcerative colitis, uveitis, vasculitis, or granulomatosis with polyangiitis.

In another embodiment, there is provided the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting HPK1 activity in a subject in need of inhibition of HPK1 activity. In some embodiments, the use includes treatment of a cancer or autoimmune disease.

Suitable subjects to be treated according to the present disclosure include mammalian subjects. Mammals according to the present disclosure include, but are not limited to, human, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. Subjects may be of either gender and at any stage of development. In one embodiment, the suitable subject to be treated according to the present disclosure is human.

The compounds of the present disclosure are generally administered in a therapeutically effective amount. The compounds of the present disclosure can be administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. An effective dosage is typically in the range of about 0.01 to about 1000 mg per kg body weight per day, preferably about 0.01 to about 500 mg/kg/day, in single or divided doses. Depending on age, species and disease or condition being treated, dosage levels below the lower limit of this range may be suitable. In other cases, still larger doses may be used without harmful side effects. Larger doses may also be divided into several smaller doses, for administration throughout the day. Methods for determining suitable doses are well known in the art to which the present disclosure pertains. For example, Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20th ed., 2000 can be used.

Pharmaceutical Compositions, Dosage Forms and Administration Routes

For the treatment of the diseases or conditions referred to above, the compounds described herein or pharmaceutically acceptable salts thereof can be administered as follows:

Oral Administration

The compounds of the present disclosure may be administered orally, including by swallowing, so that the compound enters the gastrointestinal tract, or absorbed into the blood stream directly from the mouth (e.g., buccal or sublingual administration). Suitable compositions for oral administration include solid, liquid, gel or powder formulations, and have a dosage form such as tablet, lozenge, capsule, granule or powder. Compositions for oral administration may be formulated as immediate or modified release, including delayed or sustained release, optionally with enteric coating. Liquid formulations can include solutions, syrups and suspensions, which can be used in soft or hard capsules. Such formulations may include a pharmaceu-

tically acceptable carrier, for example, water, ethanol, polyethylene glycol, cellulose, or an oil. The formulation may also include one or more emulsifying agents and/or suspending agents.

In a tablet dosage form the amount of drug present may be from about 0.05% to about 95% by weight, more typically from about 2% to about 50% by weight of the dosage form. In addition, tablets may contain a disintegrant, comprising from about 0.5% to about 35% by weight, more typically from about 2% to about 25% of the dosage form. Examples of disintegrants include, but are not limited to, lactose, starch, sodium starch glycolate, crospovidone, croscarmellose sodium, maltodextrin, or mixtures thereof.

Suitable lubricants, for use in a tablet, may be present in amounts from about 0.1% to about 5% by weight, and include, but are not limited to, talc, silicon dioxide, stearic acid, calcium, zinc or magnesium stearate, sodium stearyl fumarate and the like.

Suitable binders, for use in a tablet, include, but are not limited to, gelatin, polyethylene glycol, sugars, gums, starch, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and the like. Suitable diluents, for use in a tablet, include, but are not limited to, mannitol, xylitol, lactose, dextrose, sucrose, sorbitol, microcrystalline cellulose and starch.

Suitable solubilizers, for use in a tablet, may be present in amounts from about 0.1% to about 3% by weight, and include, but are not limited to, polysorbates, sodium lauryl sulfate, sodium dodecyl sulfate, propylene carbonate, diethyleneglycol monoethyl ether, dimethyl isosorbide, polyethylene glycol (natural or hydrogenated) castor oil, HCOR™ (Nikkol), oleyl ester, Gelucire™, caprylic/caprylic acid mono/diglyceride, sorbitan fatty acid esters, and Solutol HST™.

Parenteral Administration

Compounds of the present disclosure may be administered directly into the blood stream, muscle, or internal organs. Suitable means for parenteral administration include intravenous, intra-muscular, subcutaneous intraarterial, intraperitoneal, intrathecal, intracranial, and the like. Suitable devices for parenteral administration include injectors (including needle and needle-free injectors) and infusion methods.

Compositions for parenteral administration may be formulated as immediate or modified release, including delayed or sustained release. Most parenteral formulations are aqueous solutions containing excipients, including salts, buffering agents and isotonic agents. Parenteral formulations may also be prepared in a dehydrated form (e.g., by lyophilization) or as sterile non-aqueous solutions. These formulations can be used with a suitable vehicle, such as sterile water. Solubility-enhancing agents may also be used in preparation of parenteral solutions.

Transdermal Administration

Compounds of the present disclosure may be administered topically to the skin or transdermally. Formulations for this topical administration can include lotions, solutions, creams, gels, hydrogels, ointments, foams, implants, patches and the like. Pharmaceutically acceptable carriers for topical administration formulations can include water, alcohol, mineral oil, glycerin, polyethylene glycol and the like. Topical or transdermal administration can also be performed by electroporation, iontophoresis, phonophoresis and the like. Compositions for topical administration may be formulated as immediate or modified release, including delayed or sustained release.

Combination Therapy

A pharmaceutical composition according to the present disclosure may contain one or more additional therapeutic agents, for example, to increase the efficacy or decrease the side effects. In some embodiments, accordingly, a pharmaceutical composition further contains one or more additional therapeutic agents selected from active ingredients useful to treat or inhibit diseases mediated directly or indirectly by HPK1. Examples of such active ingredients are, without limitation, agents to treat cancer, metastasis, inflammation, or auto-immune pathogenesis. In some embodiments, the compound of Formula (I) is administered with anti-PD-1 agent, anti-PD-L1 agent, or anti-CTLA4 agent.

References for Preparing Pharmaceutical Compositions


Methods for preparing pharmaceutical compositions for treating or preventing a disease or condition are well known in the art to which the present disclosure pertains. For example, based on *Handbook of Pharmaceutical Excipients* (7th ed.), Remington: *The Science and Practice of Pharmacy* (20th ed.), *Encyclopedia of Pharmaceutical Technology* (3rd ed.), or *Sustained and Controlled Release Drug Delivery Systems* (1978), pharmaceutically acceptable excipients, carriers, additives and so on can be selected and then mixed with the compounds of the present disclosure for making the pharmaceutical compositions.

The present disclosure provides a compound having various pharmacological effects by inhibiting HPK1 activity, a pharmaceutical composition having the compound as an effective agent, a medical use, particularly for treating a disease or disorder modulated by HPK1, of the compound, and a method of treatment or prevention comprising administering the compound to a subject in need of such treatment or prevention. The compounds of the present disclosure and pharmaceutically acceptable salts thereof have good safety and high selectivity for HPK1, and thus exhibit superior property as a drug.

Compound Preparation

The following Preparative Examples illustrate the preparation of intermediate compounds that are useful for preparing compounds of formula (I). The novel intermediate compounds described herein, as well as the synthetic processes useful for preparing the intermediate compounds represent embodiments of the current invention.

Intermediate 1A. 1-(tetrahydro-2H-pyran-2-yl)-5-(thiophen-2-yl)-1H-indazol-4-yl trifluoromethanesulfonate



Step 1) 3-bromo-4-chloro-5-fluoro-2-methylaniline

To a solution of 3-bromo-5-fluoro-2-methylaniline (50 g, 245 mmol, 1 eq) in AcOH (100 mL) was added N-chlorosuccinimide (36 g, 270 mmol, 1.1 eq). The mixture was stirred at 25° C. for 16 hr. The mixture was concentrated under vacuum and the residue was extracted with Dichloro-

15

romethane (200 mL*2). The combined organic layers were washed with sat. NaHCO₃ 200 mL, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The crude product (66 g, crude) was obtained as a black oil.

Step 2) 4-bromo-5-chloro-6-fluoro-1H-indazole


To a solution of 3-bromo-4-chloro-5-fluoro-2-methylaniline (25.8 g, 108 mmol, 1 eq) in AcOH (1.96 L, 0.05 M), H₂O (0.065 L, 1.5 M) was added sodium nitrite (8.96 g, 130 mmol, 1.2 eq). The mixture was stirred at 25° C. for 16 hr. The mixture was concentrated under vacuum and the residue was extracted with Dichloromethane (1 L*2). The combined organic layers were washed with sat. NaHCO₃ (1 L), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The crude product (23.6 g, crude) was obtained as a brown solid.

Step 3) 4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

To a solution of 4-bromo-5-chloro-6-fluoro-1H-indazole (1.98 g, 7.97 mmol, 1 eq) in THP (40 mL) was added 3,4-dihydro-2H-pyran (2.18 ml, 23.9 mmol, 3 eq) and p-toluenesulfonic acid monohydrate (300 mg, 1.59 mmol, 0.2 eq). The reaction mixture was stirred 70° C. for 14 hours. The reaction mixture was extracted with Ethyl Acetate and dried over MgSO₄. The organic residue was purified by column chromatography (silical gel, Hex:Ethyl acetate=1:0 to 4:1). 4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (1.51 g, 4.54 mmol, 57% yield) was obtained.

¹H NMR (400 MHz, DMSO-d₆) δ 8.16 (s, 1H), 8.00 (dd, J=9.3, 1.1 Hz, 1H), 5.85 (dd, J=9.6, 2.5 Hz, 1H), 3.87 (d, J=12.6 Hz, 1H), 3.79-3.72 (m, 1H), 2.38-2.30 (m, 1H), 2.04-1.94 (m, 2H), 1.77-1.55 (m, 3H).

Intermediate 1B. 4-bromo-5-chloro-6-fluoro-7-iodo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole



Step 1)

4-bromo-5-chloro-6-fluoro-7-iodo-1H-indazole

To a solution of 4-bromo-5-chloro-6-fluoro-1H-indazole (2 g, 8.02 mmol) in sulfuric acid (1.7 mL) was added N-iodosuccinimide (2.7 g, 12.03 mmol) portionwise. The mixture was stirred at 0° C. for 3 h. After the reaction completed, the mixture was poured into ice water and quenched by solid NaOH and then extracted with Dichloromethane. The combined organic residue was concentrated in vacuo. (2.99 g, crude).

¹H NMR (400 MHz, DMSO-d₆) δ 13.91 (s, 1H), 8.27 (d, J=1.6 Hz, 1H).


16

Step 2) 4-bromo-5-chloro-6-fluoro-7-iodo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole

To a solution of 4-bromo-5-chloro-6-fluoro-7-iodo-1H-indazole (2.99 g, 7.97 mmol, 1 eq) in THF (40 mL) was added 3,4-dihydro-2H-pyran (2.18 ml, 23.9 mmol, 3 eq) and p-toluenesulfonic acid monohydrate (300 mg, 1.59 mmol, 0.2 eq). The reaction mixture was stirred 60° C. for 16 hours. The reaction mixture was extracted with Ethyl Acetate and dried over MgSO₄. The organic residue was purified by column chromatography (silical gel, Hex:Ethyl acetate=1:0 to 4:1). 4-bromo-5-chloro-6-fluoro-7-iodo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole (1.64 g, 7.97 mmol, 60.7% yield) was obtained.

¹H NMR (400 MHz, DMSO-d₆) δ 8.84 (s, 1H), 5.80 (dd, J=9.9, 2.7 Hz, 1H), 5.66 (s, 1H), 4.02 (t, J=6.6 Hz, 1H), 3.85-3.70 (m, 1H), 2.33-2.21 (m, 1H), 2.08-1.91 (m, 2H), 1.79-1.45 (m, 4H).

Intermediate 1C. 4-bromo-5-chloro-6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-7-amine



Step 1)

4-bromo-5-chloro-6-fluoro-7-nitro-1H-indazole

To a mixture of HNO₃ (12.63 g, 200.43 mmol, 9.02 mL, 5 eq) in H₂SO₄ (50 mL) stirred at 0° C. was added 4-bromo-5-chloro-6-fluoro-1H-indazole (10 g, 40.09 mmol, 1 eq) slowly. After the addition the mixture was stirred at 0° C. for 2 hr. TLC (Petroleum ether:Ethyl acetate=3:1) showed all the reactant was consumed and a main new point showed up. Poured the mixture into ice-water, extracted with ethyl acetate (50 mL*3), the combined organic phase was dried over Na₂SO₄, filtered and the filtrate was concentrated to obtain 4-bromo-5-chloro-6-fluoro-7-nitro-1H-indazole (12 g, crude) as a yellow solid.

Step 2) 4-bromo-5-chloro-6-fluoro-7-nitro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole

To a solution of 4-bromo-5-chloro-6-fluoro-7-nitro-1H-indazole (2.34 g, 7.97 mmol, 1 eq) in THF (40 mL) was added 3,4-dihydro-2H-pyran (2.18 ml, 23.9 mmol, 3 eq) and p-toluenesulfonic acid monohydrate (300 mg, 1.59 mmol, 0.2 eq). The reaction mixture was stirred 60° C. for 14 hours. The reaction mixture was extracted with Ethyl Acetate and dried over MgSO₄. The organic residue was purified by column chromatography (silical gel, Hex:Ethyl acetate=1:0 to 4:1). 4-bromo-5-chloro-6-fluoro-7-nitro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole (1.65 g, 4.35 mmol, 54.7% yield) was obtained.

Step 3) 4-bromo-5-chloro-6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-7-amine


To a solution of 4-bromo-5-chloro-6-fluoro-7-nitro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole (600 mg, 1.58 mmol,

17

1 eq) in EtOH (5 mL) and H₂O (5 mL) were added NH₄Cl (508.66 mg, 9.51 mmol, 6 eq) and Fe (531.04 mg, 9.51 mmol, 6 eq), then the reaction mixture was stirred at 80° C. for 1 hour. The reaction mixture was filtered, and the filtrate was diluted with ethyl acetate (20 mL), and the mixture was washed with water (20 mL*2), after then the organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO₂, Petroleum ether/Ethyl acetate=1:1). 4-bromo-5-chloro-6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-7-amine (390 mg, 1.12 mmol, 70.59% yield) was obtained as a yellow oil.

¹H NMR (400 MHz, DMSO-d₆) δ 8.41 (s, 1H), 5.85 (br s, 2H), 5.71 (br d, J=8.0 Hz, 1H), 4.00 (br d, J=11.3 Hz, 1H), 3.77-3.59 (m, 1H), 2.29-2.17 (m, 1H), 2.10-1.91 (m, 2H), 1.78-1.54 (m, 3H).

Intermediate 1D. 4-bromo-5-chloro-6-fluoro-N,N-dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-7-amine



Step 1)

4-bromo-5-chloro-6-fluoro-7-nitro-1H-indazole

To a solution of Intermediate 1A (900 mg, 3.61 mmol, 1 eq) in H₂SO₄ (10 mL) (98% purity) was added HNO₃ (419.69 mg, 4.33 mmol, 299.78 uL, 1.2 eq) (65% purity) dropwise at -15° C., then the reaction mixture was stirred at 0° C. for 2 hours. The reaction mixture was slowly poured into ice water (20 mL), then the mixture's pH was adjusted to pH=7 by using saturated aqueous solution of NaOH, after then the mixture was extracted with ethyl acetate (30 mL*2), the combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. 4-bromo-5-chloro-6-fluoro-7-nitro-1H-indazole (900 mg, crude) was obtained as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 14.36 (br s, 1H), 8.37 (br s, 1H).

Step 2) 4-bromo-5-chloro-6-fluoro-7-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

To a solution of 4-bromo-5-chloro-6-fluoro-7-nitro-1H-indazole (900 mg, 3.06 mmol, 1 eq) (crude) in DCM (10 mL) were added TsOH·H₂O (58.14 mg, 305.64 umol, 0.1 eq) and DHP (771.27 mg, 9.17 mmol, 838.34 uL, 3 eq), then the reaction mixture was stirred at 20° C. for 2 hours. The reaction mixture was diluted with dichloromethane (20 mL), and the mixture was washed with saturated aqueous solution of NaHCO₃ (15 mL*2), the organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=40/1 to 25:1, 4-bromo-5-chloro-6-fluoro-7-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole came out at Petroleum ether/Ethyl

18

acetate=40/1, 4-bromo-5-chloro-6-fluoro-7-nitro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole came out at Petroleum ether/Ethyl acetate=25/1). 4-bromo-5-chloro-6-fluoro-7-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (200 mg, 528.29 umol, 17.28% yield) was obtained as a brown solid. 4-bromo-5-chloro-6-fluoro-7-nitro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole (600 mg, 1.58 mmol, 51.85% yield) was obtained as a yellow solid.

4-bromo-5-chloro-6-fluoro-7-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (s, 1H), 5.50 (dd, J=2.8, 7.8 Hz, 1H), 3.45-3.38 (m, 2H), 2.35-2.27 (m, 1H), 2.23-2.14 (m, 1H), 1.92 (td, J=4.6, 13.6 Hz, 1H), 1.68 (ddt, J=4.0, 10.1, 13.9 Hz, 1H), 1.59-1.36 (m, 2H).

4-bromo-5-chloro-6-fluoro-7-nitro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole

¹H NMR (400 MHz, DMSO-d₆) δ 8.99 (s, 1H), 5.86 (dd, J=2.7, 9.7 Hz, 1H), 4.08-3.96 (m, 1H), 3.81-3.68 (m, 1H), 2.28-2.14 (m, 1H), 2.14-2.02 (m, 1H), 2.02-1.89 (m, 1H), 1.78-1.67 (m, 1H), 1.64-1.56 (m, 2H).

Step 3) 4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-7-amine


To a solution of 4-bromo-5-chloro-6-fluoro-7-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (200 mg, 528.29 umol, 1 eq) in EtOH (5 mL) and H₂O (5 mL) were added NH₄Cl (169.55 mg, 3.17 mmol, 6 eq) and Fe (177.03 mg, 3.17 mmol, 6 eq), then the reaction mixture was stirred at 80° C. for 2 hours. The reaction mixture was filtered, and the filtrate was concentrated to remove EtOH, then the mixture was diluted with ethyl acetate (20 mL), and the mixture was washed with water (20 mL*2), after then the organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. 4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-7-amine (140 mg, crude) was obtained as a yellow solid.

Step 4) 4-bromo-5-chloro-6-fluoro-N,N-dimethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-7-amine

To a solution of 4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-7-amine (120 mg, 344.24 umol, 1 eq) in THF (5 mL) was added NaH (34.42 mg, 860.59 umol, 60% purity, 2.5 eq) in portions at 0° C. under N₂, then the mixture was stirred at 0° C. for 30 mins under N₂, after then MeI (293.16 mg, 2.06 mmol, 128.58 uL, 6 eq) was added dropwise, and the reaction mixture was stirred at 20° C. for 12 hours under N₂. The reaction mixture was poured into saturated aqueous solution of NH₄Cl (20 mL), then the mixture was extracted with ethyl acetate (20 mL*2), the combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO₂, Petroleum ether/Ethyl acetate=5:1). Intermediate 1E (30 mg, 78.06 umol, 22.68% yield, 98% purity) was obtained as a yellow oil.

19


Intermediate 1E. 4-bromo-5-chloro-6-fluoro-N-isopropyl-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-7-amine



To a solution of Intermediate 1B (100 mg, 0.218 mmol, 1 eq) in 2-methyl-2-butanol (1.09 mL) was added Xantphos Pd G3 (21 mg, 21.8 μ mol, 0.1 eq) and Cs_2CO_3 (142 mg, 0.436 mmol, 2.0 eq). The mixture was degassed and purged with N_2 for 3 times, and then propan-2-amine (0.19 mL, 2.18 mmol, 10 eq) was added. The mixture was stirred at 90° C. for 3 hr in sealed tube. The reaction mixture was diluted with H_2O (40 mL), and then the mixture was extracted with DCM (50 mL*3). The combined organic layers were dried over Na_2SO_4 , filtered and the filtrate was concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (product came out at Hexane/Ethyl acetate=10/1) to afford Intermediate 1E (47 mg, 0.120 mmol, 55% yield) as beige color solid.

^1H NMR (400 MHz, DMSO-d_6) δ 8.43 (s, 1H), 5.74 (dd, $J=9.6, 2.5$ Hz, 1H), 5.29 (dd, $J=9.9, 3.3$ Hz, 1H), 4.63-4.57 (m, 1H), 3.99 (d, $J=11.0$ Hz, 1H), 3.74-3.68 (m, 1H), 2.23-2.17 (m, 1H), 2.05-1.95 (m, 2H), 1.74-1.57 (m, 3H), 1.23-1.18 (m, 6H).

Intermediate 1F. 4-bromo-5-chloro-6-fluoro-N-isopropyl-N-methyl-2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-7-amine



To a solution of Intermediate 1E (600 mg, 1.54 mmol, 1.0 eq) in Methanol (7.7 mL) was added formaldehyde (0.572 mL, 7.68 mmol, 5.0 eq) and acetic acid (88 μ L, 1.54 mmol, 1.0 eq). The mixture was stirred at room temperature for 10 min. Sodium cyanoborohydride (290 mg, 4.61 mmol, 3.0 eq) was added and then the mixture was stirred room temperature for 16 hr. The reaction mixture was quenched by H_2O and extracted with Ethyl acetate (150 mL*3). The combined organic layers were dried over Na_2SO_4 , filtered and the filtrate was concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (product came out at Hexane/Ethyl acetate=100/4) to afford Intermediate 1F (292 mg, 0.722 mmol, 47% yield) as brown color oil.


20

^1H NMR (400 MHz, DMSO-d_6) δ 8.51 (s, 1H), 5.75 (dd, $J=9.3, 2.7$ Hz, 1H), 4.14-4.05 (m, 1H), 4.00-3.93 (m, 1H), 3.78-3.67 (m, 1H), 2.92 (d, $J=4.4$ Hz, 3H), 2.23-2.20 (m, 1H), 2.05-1.95 (m, 2H), 1.75-1.60 (m, 3H), 1.17 (d, $J=6.6$ Hz, 6H).

Intermediate 1G. 4-bromo-5-chloro-N-ethyl-6-fluoro-N-methyl-1H-indazol-7-amine

10

15



Step 1)

4-bromo-5-chloro-6-fluoro-1H-indazol-7-amine

20

25

30

35

To a solution of 4-bromo-5-chloro-6-fluoro-7-nitro-1H-indazole (12 g, 40.75 mmol, 1 eq) in EtOH (100 mL) and H_2O (40 mL) was added Fe (6.83 g, 122.26 mmol, 3 eq) and NH_4Cl (6.54 g, 122.26 mmol, 3 eq). The reaction mixture was heated to 80° C. and reacted for 2 hr. The reaction mixture was filtered through a celite cake, the filtrate was concentrated to give the crude product. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate=20/1 to 3/1). 4-bromo-5-chloro-6-fluoro-1H-indazol-7-amine (5 g, 18.90 mmol, 46.39% yield) was obtained as a yellow solid.

Step 2) N-(4-bromo-5-chloro-6-fluoro-1H-indazol-7-yl)acetamide

40

45

50

To a solution 4-bromo-5-chloro-6-fluoro-1H-indazol-7-amine (3 g, 11.34 mmol, 1 eq) in AcOH (30 mL) was added Ac_2O (1.39 g, 13.61 mmol, 1.27 mL, 1.2 eq), the reaction mixture was heated to 80° C. and reacted for 3 hr. The solvent was removed under vacuum. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate=50/1 to 4/1) to obtain N-(4-bromo-5-chloro-6-fluoro-1H-indazol-7-yl)acetamide (3 g, 9.79 mmol, 86.29% yield) as a yellow solid.

Step 3) 4-bromo-5-chloro-N-ethyl-6-fluoro-1H-indazol-7-amine

55

60

65


To a solution of LAH (520.00 mg, 13.70 mmol, 1.5 eq) in THF (50 mL) was added a solution of N-(4-bromo-5-chloro-6-fluoro-1H-indazol-7-yl)acetamide (2.8 g, 9.13 mmol, 1 eq) in THF (100 mL) drop-wise under N_2 at 0° C., after the addition, the reaction mixture was allowed to warm to 25° C., and reacted for 16 hr. The mixture was poured into water (500 mL), extracted with ethyl acetate (100 mL*2), the combined organic phase was dried over Na_2SO_4 , filtered and the filtrate was concentrated to give the crude. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate=50/1 to 2/1) to obtain 4-bromo-5-chloro-N-ethyl-6-fluoro-1H-indazol-7-amine (1 g, 3.42 mmol, 37.42% yield) as a yellow solid.

21

Step 4) 4-bromo-5-chloro-N-ethyl-6-fluoro-N-methyl-1H-indazol-7-amine


To a solution of 4-bromo-5-chloro-N-ethyl-6-fluoro-1H-indazol-7-amine (1.4 g, 4.79 mmol, 1 eq) and HCHO (718.48 mg, 23.93 mmol, 659.16 uL, 5 eq) in MeOH (50 mL) was added NaBH₃CN (902.21 mg, 14.36 mmol, 3 eq) and AcOH (287.38 mg, 4.79 mmol, 273.70 uL, 1 eq). The reaction mixture was stirred at 25° C. for 16 hr. The solvent was removed under vacuum. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=50/1 to 5/1) to obtain 4-bromo-5-chloro-N-ethyl-6-fluoro-N-methyl-1H-indazol-7-amine (1.4 g, 4.57 mmol, 95.42% yield) as a white solid.

Intermediate 1H. 4-bromo-5-chloro-6-fluoro-7-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole



To a solution of 4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.5 g, 1.50 mmol, 1 eq) in THF (10 mL) was added dropwise LDA (2 M, 1.87 mL, 2.5 eq) at -78° C. After addition, the mixture was stirred at this temperature for 2.5 hr, and then MeI (319.12 mg, 2.25 mmol, 139.97 uL, 1.5 eq) was added dropwise at -78° C. The resulting mixture was stirred at 20° C. for 16 hr. The mixture was poured into saturated NH₄Cl and extracted with EA 20 mL. The organic layer was concentrated. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=20/1 to 10/1). We got the desired product 4-bromo-5-chloro-6-fluoro-7-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.38 g, 1.09 mmol, 72.93% yield) was obtained as white solid.

Intermediate 1I. 4-bromo-6-fluoro-N,N-dimethyl-5-(methylthio)-1H-indazol-7-amine



Step 1) 4-bromo-6-fluoro-7-nitro-1H-indazole

To a solution of 4-bromo-6-fluoro-1H-indazole (10 g, 46.51 mmol, 1 eq) in H₂SO₄ (80 mL) (98% purity) was added KNO₃ (4.70 g, 46.51 mmol, 1 eq) at 0° C. in portions, then the mixture was stirred at 0° C. for 1 h. The reaction

22

mixture was then poured into ice water (200 mL), and the mixture was extracted with ethyl acetate (100 mL*2), the combined organic layers were washed with saturated aqueous solution of NaHCO₃ (100 mL*2) and brine (100 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (200-300 mesh silica gel, Petroleum ether/Ethyl acetate=15/1 to 1/1, product 4-bromo-6-fluoro-7-nitro-1H-indazole came out at Petroleum ether/Ethyl acetate=8/1) to afford 4-bromo-6-fluoro-7-nitro-1H-indazole (2.7 g, 10.38 mmol, 22.32% yield) as yellow solid and crude product. The crude product was purified by MPLC (Petroleum ether/Ethyl acetate) to afford 4-bromo-6-fluoro-7-nitro-1H-indazole (3.57 g, 13.73 mmol, 29.52% yield) as yellow solid.

Step 2)

4-bromo-6-fluoro-5-iodo-7-nitro-1H-indazole

To a solution of 4-bromo-6-fluoro-7-nitro-1H-indazole (2.7 g, 10.38 mmol, 1 eq) in H₂SO₄ (30 mL) was added NIS (7.01 g, 31.15 mmol, 3 eq) at 25° C. The reaction mixture was stirred at 50° C. for 16 h. The reaction mixture was quenched by ice water (50 mL). Then the mixture was extracted with ethyl acetate (50 mL*3). The combined organic layers were washed with Na₂SO₃ aqueous solution (20 mL*2), NaHCO₃ aqueous solution (20 mL*2) and brine (20 mL), dried over sodium sulfate, filtered and the filtrate was concentrated in vacuum to give 4-bromo-6-fluoro-5-iodo-7-nitro-1H-indazole (3.4 g, 8.81 mmol, 84.85% yield) as yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 14.28 (br s, 1H), 8.30 (s, 1H).

Step 3)

4-bromo-6-fluoro-5-iodo-1H-indazol-7-amine

To a solution of 4-bromo-6-fluoro-5-iodo-7-nitro-1H-indazole (3.4 g, 8.81 mmol, 1 eq) in EtOH (50 mL) and H₂O (25 mL) was added NH₄Cl (2.83 g, 52.86 mmol, 6 eq), then Fe (2.95 g, 52.86 mmol, 6 eq) was added in portions at 60° C. The mixture was stirred at 80° C. for 1 h. The reaction mixture was filtered through celite while it was still hot. Then the filtrate was concentrated in vacuum to remove EtOH. The resulting aqueous phase was extracted with ethyl acetate (50 mL*2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and the filtrate was concentrated in vacuum to give a residue. The residue was purified by silica gel chromatography (MPLC, Petroleum ether/Ethyl acetate=5/1 to 2/1, product came out at Petroleum ether/Ethyl acetate=2/1) to afford 4-bromo-6-fluoro-5-iodo-1H-indazol-7-amine (2.2 g, 6.18 mmol, 70.16% yield) as gray solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.09 (br s, 1H), 7.86 (d, J=1.7 Hz, 1H), 5.62 (s, 2H).

Step 4) 4-bromo-6-fluoro-5-iodo-N,N-dimethyl-1H-indazol-7-amine

To a solution of 4-bromo-6-fluoro-5-iodo-1H-indazol-7-amine (2.2 g, 6.18 mmol, 1 eq) in MeOH (50 mL) was added AcOH (1.11 g, 18.54 mmol, 1.06 mL, 3 eq), HCHO (5.02 g, 61.81 mmol, 4.60 mL, 10 eq), then NaBH₃CN (3.88 g, 61.81 mmol, 10 eq) was added in portions under 40° C. Gas released and the temperature rise. The suspension was stirred at 25° C. for 16 h. The reaction mixture was poured into water (50 mL), then the mixture was concentrated to

23


remove MeOH, after then the mixture was extracted with ethyl acetate (50 mL*2), and the combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (200-300 mesh silica gel, Petroleum ether/Ethyl acetate=15/1 to 8/1, product came out at Petroleum ether/Ethyl acetate=8/1) to afford 4-bromo-6-fluoro-5-iodo-N,N-dimethyl-1H-indazol-7-amine (2.05 g, 5.34 mmol, 86.37% yield) as off-white solid.

Step 5) 4-bromo-6-fluoro-N,N-dimethyl-5-(methylthio)-1H-indazol-7-amine

To a 100 mL bottle equipped with a magnetic stir bar was added 4-bromo-6-fluoro-5-iodo-N,N-dimethyl-1H-indazol-7-amine (1.2 g, 3.13 mmol, 1 eq), NaSMe (328.56 mg, 4.69 mmol, 1.5 eq), Xantphos (361.65 mg, 625.02 umol, 0.2 eq), K₂CO₃ (1.30 g, 9.38 mmol, 3 eq), dioxane (20 mL) and Pd₂(dba)₃ (286.17 mg, 312.51 umol, 0.1 eq) sequentially. The bottle was evacuated and backfilled with nitrogen. Then the mixture was stirred at 90° C. for 16 h under nitrogen atmosphere. The residue was purified by silica gel chromatography (200-300 mesh silica gel, Petroleum ether/Ethyl acetate=20/1 to 8/1, product came out at Petroleum ether/Ethyl acetate=10/1) to afford 4-bromo-6-fluoro-N,N-dimethyl-5-(methylthio)-1H-indazol-7-amine (540 mg, 1.78 mmol, 56.81% yield) as orange solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.59 (br s, 1H), 8.00 (d, J=1.6 Hz, 1H), 2.91 (d, J=2.4 Hz, 6H), 2.39 (s, 3H).


Intermediate 1J. 4-bromo-6-fluoro-N,N-dimethyl-5-(trifluoromethyl)-1H-indazol-7-amine



To a solution of 4-bromo-6-fluoro-5-iodo-N,N-dimethyl-1H-indazol-7-amine (1.0 g, 2.61 mmol, 1 eq) and methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (1.00 g, 5.22 mmol, 664.45 uL, 2 eq) in DMF (10 mL) was added CuI (994.63 mg, 5.22 mmol, 2 eq). The mixture was stirred at 100° C. for 6 hr under N₂ atmosphere. The reaction mixture was filtered and the filtrate was diluted with water 50 mL and extracted with Ethyl acetate (50 mL*2). The combined organic layers were washed with brine (50 mL*3), dried over anhydrous Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (Petroleum ether: Ethyl acetate=1:0 to 10:1). 4-bromo-6-fluoro-N,N-dimethyl-5-(trifluoromethyl)-1H-indazol-7-amine (502 mg, 1.54 mmol, 58.91% yield) was obtained as a yellow solid.

24

Intermediate 1K.
4-bromo-5-ethyl-6-fluoro-1H-indazole



Step 1)

4-bromo-5-ethyl-6-fluoro-2-trityl-2H-indazole

To a solution of diisopropylamine (132.75 mg, 1.31 mmol, 185.41 uL, 1.2 eq) in THF (5 mL) was added slowly n-BuLi (2.5 M, 481.04 uL, 1.1 eq) at -78° C. for 0.5 hr under N₂ atmosphere. Then a solution of 4-bromo-6-fluoro-2-trityl-2H-indazole (500 mg, 1.09 mmol, 1 eq) in THF (2 mL) was added dropwise to the solution. After the mixture was stirred at -78° C. for 0.5 hr, a solution of EtI (204.62 mg, 1.31 mmol, 104.93 uL, 1.2 eq) in THF (2 mL) was added to the mixture and the solution was warmed to 15° C. and stirred for 2 hr under N₂ atmosphere. The reaction mixture was quenched by addition with saturated NH₄Cl aqueous 3 mL at 15° C., was diluted with water 20 mL and extracted with Ethyl acetate (30 mL*2). The combined organic layers were washed with brine (30 mL*2), dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure to give a residue. 4-bromo-5-ethyl-6-fluoro-2-trityl-2H-indazole (500 mg, crude) was obtained as a yellow solid.


Step 2) 4-bromo-5-ethyl-6-fluoro-1H-indazole

To a solution of 4-bromo-5-ethyl-6-fluoro-2-trityl-2H-indazole (500 mg, 1.03 mmol, 1 eq) in DCM (6 mL) was added TFA (3.08 g, 27.01 mmol, 2.00 mL, 26.22 eq). The mixture was stirred at 15° C. for 4 hr. The reaction mixture pH was adjusted to 7 with saturated NaHCO₃ aqueous, and the mixture was extracted with Dichloromethane (30 mL*2). The combined organic layers were washed with brine (30 mL*2), dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 40%-70%, 10 min). The fraction was concentrated under reduced pressure to remove ACN, the aqueous pH was adjusted to 7 with saturated NaHCO₃ aqueous. The aqueous was extracted with Ethyl acetate (10 mL*2). The combined organic layers were washed with brine (10 mL*2), dried over Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure to give a product. 4-bromo-5-ethyl-6-fluoro-1H-indazole (70 mg, 287.98 umol, 27.96% yield) was obtained as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.39 (br s, 1H), 8.01-7.98 (m, 1H), 7.41 (d, J=9.9 Hz, 1H), 2.83 (dq, J=2.4, 7.5 Hz, 2H), 1.14 (t, J=7.5 Hz, 3H).

25

Intermediate 1L. 4-bromo-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine



Step 1) 6-fluoro-5-nitro-1H-indazole

To a solution of 6-fluoro-1H-indazole (4.4 g, 32.32 mmol, 1 eq) in H₂SO₄ (30 mL) was added HNO₃ (2.44 g, 38.79 mmol, 1.75 mL, 1.2 eq) dropwise at -15° C., the reaction mixture was stirred at 0° C. for 2 hours. The reaction mixture was slowly poured into ice water (100 mL), then the mixture was extracted with ethyl acetate (100 mL*2), the combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 6-fluoro-5-nitro-1H-indazole (5.4 g, crude) was obtained as a yellow solid.

Step 2) 6-fluoro-5-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

To a mixture of 6-fluoro-5-nitro-1H-indazole (4.9 g, 27.05 mmol, 1 eq) (crude) in DCM (50 mL) were added DHP (6.83 g, 81.16 mmol, 7.42 mL, 3 eq) and TsOH·H₂O (514.60 mg, 2.71 mmol, 0.1 eq), and the reaction mixture was stirred at 15° C. for 1 hour. The reaction mixture was poured into saturated solution of NaHCO₃ (100 mL), then the mixture was extracted with dichloromethane (50 mL*2), the combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=20/1 to 15:16-fluoro-5-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (3 g, 11.31 mmol, 41.81% yield) was obtained as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.78 (d, J=7.3 Hz, 1H), 8.41 (s, 1H), 7.97 (d, J=12.1 Hz, 1H), 5.90 (dd, J=2.1, 9.7 Hz, 1H), 3.94-3.85 (m, 1H), 3.82-3.72 (m, 1H), 2.43-2.28 (m, 1H), 2.10-1.93 (m, 2H), 1.82-1.34 (m, 3H).

Step 3) 6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine

To a solution of 6-fluoro-5-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (2.9 g, 10.93 mmol, 1 eq) in MeOH (30 mL) was added wet Pd/C (300 mg, 10% purity) under N₂ atmosphere. The suspension was degassed and purged with H₂ for 3 times. The mixture was stirred under H₂ (15 Psi) at 15° C. for 4 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=15/1 to 8:1). 6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine (1.5 g, 5.87 mmol, 53.65% yield, 92% purity) was obtained as a brick-red solid.

¹H NMR (400 MHz, DMSO-d₆) δ 7.82 (s, 1H), 7.43 (d, J=11.6 Hz, 1H), 6.98 (d, J=8.6 Hz, 1H), 5.66 (dd, J=2.3, 9.7

26


Hz, 1H), 4.91 (s, 2H), 3.85 (br d, J=12.1 Hz, 1H), 3.77-3.62 (m, 1H), 2.42-2.27 (m, 1H), 2.07-1.96 (m, 1H), 1.95-1.86 (m, 1H), 1.76-1.63 (m, 1H), 1.59-1.51 (m, 2H); LCMS (electrospray) m/z 236.1 (M+H)+.

Step 4) 4-bromo-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine

To a solution of 6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine (1.45 g, 5.67 mmol, 1 eq) in MeCN (10 mL) was added NBS (1.21 g, 6.80 mmol, 1.2 eq) in portions at 0° C. The mixture was stirred at 0° C. for 2 hours. The reaction mixture was concentrated to give a residue. Then the residue was dissolved in ethyl acetate (30 mL), and the mixture was washed with brine (15 mL*2), the organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=20/1). 4-bromo-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine (1.3 g, 4.14 mmol, 72.98% yield) was obtained as a brown solid.

¹H NMR (400 MHz, DMSO-d₆) δ 7.80 (s, 1H), 7.60 (d, J=10.6 Hz, 1H), 5.71 (dd, J=2.5, 9.6 Hz, 1H), 5.15 (s, 2H), 3.88-3.82 (m, 1H), 3.76-3.68 (m, 1H), 2.36-2.27 (m, 1H), 2.02 (br dd, J=4.6, 8.5 Hz, 1H), 1.96-1.90 (m, 1H), 1.76-1.65 (m, 1H), 1.60-1.52 (m, 2H).

Intermediate 1M. 3-(4-bromo-5-chloro-6-fluoro-1H-indazol-7-yl)cyclopentan-1-ol



Step 1) 4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-7-carbaldehyde

To a mixture of Intermediate 1A (3 g, 8.99 mmol, 1 eq) in THF (60 mL) was added LDA (2 M, 17.99 mL, 4 eq) dropwise at -78° C. under N₂. The mixture was stirred at -78° C. for 1 h. After then, HCO₂Et (3.17 g, 35.97 mmol, 3.52 mL, 4 eq) in THF (8 mL) was added dropwise at -78° C., then the mixture was stirred at -78° C. for 2 h. The reaction mixture was quenched by addition of saturated NH₄Cl solution (20 mL) at -78° C., and then extracted with EA (30 mL*3). The combined organic layers were washed with brine (30 mL*2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=30/1 to 20/1). 4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-7-carbaldehyde (2.78 g, 7.69 mmol, 85.49% yield) was obtained as an off-white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 10.40 (s, 1H), 8.35 (s, 1H), 6.09 (dd, J=2.6, 8.9 Hz, 1H), 3.71-3.63 (m, 1H),

27

3.63-3.52 (m, 1H), 2.42-2.30 (m, 1H), 2.21-2.10 (m, 1H), 2.07-1.95 (m, 1H), 1.77-1.63 (m, 2H), 1.60-1.40 (m, 2H); LCMS (electrospray) m/z 278.9 (M+H)+.

Step 2) 1-(4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-7-yl)but-3-en-1-ol

To a mixture of 4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-7-carbaldehyde (2.2 g, 6.08 mmol, 1 eq) in THF (60 mL) was added allyl magnesium bromide (1 M, 9.13 mL, 1.5 eq) dropwise at 0° C. under N₂. The mixture was stirred at 0° C. for 2 h. The reaction mixture was quenched by addition of saturated NH₄Cl solution (20 mL) at 0° C., and then extracted with EA (30 mL*3). The combined organic layers were washed with brine (30 mL*2), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=10/1 to 5/1). 1-(4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-7-yl)but-3-en-1-ol (2 g, 4.95 mmol, 81.43% yield) was obtained as a colorless oil.

¹H NMR (400 MHz, DMSO-d₆) δ 8.25-8.21 (m, 1H), 8.20-8.18 (m, 1H), 6.61 (br d, J=9.0 Hz, 1H), 6.23 (d, J=4.0 Hz, 1H), 6.18 (br d, J=8.3 Hz, 1H), 5.95 (d, J=5.0 Hz, 1H), 5.90-5.75 (m, 2H), 5.36 (dt, J=4.3, 7.5 Hz, 1H), 5.30 (td, J=5.9, 7.9 Hz, 1H), 5.10-4.97 (m, 4H), 3.97 (br d, J=11.5 Hz, 1H), 3.89 (br d, J=11.3 Hz, 1H), 3.69-3.55 (m, 2H), 2.87-2.74 (m, 2H), 2.70-2.55 (m, 4H), 2.06 (br d, J=10.8 Hz, 3H), 1.96-1.87 (m, 1H), 0.90-0.78 (m, 1H); LCMS (electrospray) m/z 302.9 (M+H)+.

Step 3) 4-bromo-7-(3-bromocyclopentyl)-5-chloro-6-fluoro-1H-indazole

To a mixture of 1-(4-bromo-5-chloro-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-7-yl)but-3-en-1-ol (2 g, 4.95 mmol, 1 eq) in DCM (20 mL) was added Br₂ (1.19 g, 7.43 mmol, 383.11 uL, 1.5 eq) in DCM (2 mL) dropwise at -20° C. under N₂. The mixture was stirred at -10° C. for 3 h. The mixture was quenched by addition of Na₂SO₃ solution (30 mL), and then diluted with DCM (30 mL). The organic layer was washed with Na₂SO₃ solution (30 mL*2), dried over anhydrous Na₂SO₄, filtered and concentrated to obtain a residue. The residue was dissolved in MeOH (15 mL), and then K₂CO₃ (2.05 g, 14.86 mmol, 3 eq) was added and the resulting mixture was stirred at 20° C. for 16 h. The reaction was quenched by addition of water (20 mL), and extracted with EA (30 mL*3), dried by Na₂SO₄, filtered and concentrated to obtain a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=10/1 to 3/1). The crude product was purified by reversed-phase HPLC (0.1% FA condition). 4-bromo-7-(3-bromocyclopentyl)-5-chloro-6-fluoro-1H-indazole (300 mg, 752.91 umol, 15.20% yield) was obtained as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.44-13.37 (m, 2H), 8.14-8.11 (m, 2H), 5.71-5.67 (m, 1H), 5.44 (dt, J=1.2, 7.5 Hz, 1H), 4.97 (s, 1H), 4.83-4.76 (m, 2H), 4.47 (dd, J=3.7, 10.1 Hz, 1H), 4.22 (dd, J=5.5, 10.1 Hz, 1H), 4.15 (dd, J=2.3, 10.6 Hz, 1H), 3.20-3.13 (m, 1H), 2.69-2.64 (m, 1H), 2.34-2.27 (m, 2H); LCMS (electrospray) m/z 398.8 (M+H)+.

Step 4) 3-(4-bromo-5-chloro-6-fluoro-1H-indazol-7-yl)cyclopentyl Acetate

To a mixture of 4-bromo-7-(3-bromocyclopentyl)-5-chloro-6-fluoro-1H-indazole (100 mg, 250.97 umol, 1 eq) in

28

DMSO (2 mL) was added KOAc (73.89 mg, 752.91 umol, 3 eq) in one portion at 20° C. under N₂. The mixture was then heated to 70° C. and stirred for 3 h. The reaction was quenched by addition of water (15 mL), and then extracted with EA (20 mL*3), the combined organic layers were washed with brine (20 mL*2), dried by Na₂SO₄, filtered and concentrated to give a residue. 3-(4-bromo-5-chloro-6-fluoro-1H-indazol-7-yl)cyclopentyl acetate (100 mg, crude, brown oil) was used directly in the next step without further purification.


LCMS (electrospray) m/z 378.8 (M+H)+.

Step 5) 3-(4-bromo-5-chloro-6-fluoro-1H-indazol-7-yl)cyclopentan-1-ol

To a mixture of 3-(4-bromo-5-chloro-6-fluoro-1H-indazol-7-yl)cyclopentyl acetate (80 mg, 211.87 umol, 1 eq) in MeOH (4 mL) and H₂O (0.8 mL) was added K₂CO₃ (442.15 mg, 3.20 mmol, 15.1 eq) in one portion at 20° C. under N₂. The mixture was stirred at 20° C. for 2 h. The reaction mixture was quenched by addition of water (15 mL) at 20° C., and then extracted with ethyl acetate (20 mL*3). The combined organic layers were washed with brine (20 mL*1), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=3/1 to 1/2). 3-(4-bromo-5-chloro-6-fluoro-1H-indazol-7-yl)cyclopentan-1-ol (50 mg, 149.01 umol, 70.33% yield) was obtained as a white solid.

LCMS (electrospray) m/z 336.9 (M+H)+.

Intermediate 1N. 4-bromo-6-fluoro-N-isopropyl-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazol-7-amine



Step 1) 5-fluoro-2-iodo-4-(trifluoromethyl)aniline

To a solution of 3-fluoro-4-(trifluoromethyl)aniline (4 g, 22.33 mmol, 1 eq) in MeCN (40 mL) was added NIS (5.53 g, 24.57 mmol, 1.1 eq) at 15° C., then reaction mixture was stirred at 15° C. for 15 h. The reaction mixture was diluted with H₂O (100 mL) and extracted with EtOAc (100 mL*3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. 5-fluoro-2-iodo-4-(trifluoromethyl)aniline (5.6 g, crude) was obtained as a brown oil.

LCMS (electrospray) m/z 305.9 (M+H)+.

Step 2) 5-fluoro-2-methyl-4-(trifluoromethyl)aniline

To a solution of 5-fluoro-2-iodo-4-(trifluoromethyl)aniline (6.0 g, 19.67 mmol, 1 eq) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (8.82 g, 29.51 mmol, 9.82 mL, 42%

29

purity, 1.5 eq) in DME (60 mL) were added Pd(PPh₃)₄ (1.14 g, 983.57 μmol, 0.05 eq) and K₂CO₃ (8.16 g, 59.01 mmol, 3 eq) at 15° C., then reaction mixture was stirred at 100° C. for 60 h. The reaction mixture was concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=5/1 to 3/1, Petroleum ether/Ethyl acetate=2:1, Rf=0.3). 5-fluoro-2-methyl-4-(trifluoromethyl)aniline (1.6 g, 4.06 mmol, 20.64% yield, 49% purity) was obtained as a yellow oil.

LCMS (electrospray) m/z 194.1.9 (M+H)+.

Step 3) 6-fluoro-5-(trifluoromethyl)-1H-indazole

To a solution of 5-fluoro-2-methyl-4-(trifluoromethyl)aniline (1 g, 5.18 mmol, 1 eq) in AcOH (15 mL) were added NaNO₂ (357.25 mg, 5.18 mmol, 1 eq) and H₂O (3 mL) at 0° C., then the reaction mixture was stirred at 15° C. for 2 h. The reaction was quenched by addition of H₂O (60 mL) at 20° C. and the resulting mixture was extracted with EtOAc (50 mL*3). The combined organic layers were washed with H₂O (50 mL*3), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. Residue was purified by column (SiO₂, Petroleum ether/Ethyl acetate=10/1 to 5/1, Petroleum ether/Ethyl acetate=3:1, Rf=0.5). 6-fluoro-5-(trifluoromethyl)-1H-indazole (500 mg, 2.45 mmol, 47.31% yield) was obtained as a yellow solid.

LCMS (electrospray) m/z 205.2 (M+H)+.

Step 4)

6-fluoro-7-nitro-5-(trifluoromethyl)-1H-indazole

To a solution of 6-fluoro-5-(trifluoromethyl)-1H-indazole (500 mg, 2.45 mmol, 1 eq) in H₂SO₄ (5 mL, 95% purity) was added KNO₃ (249 mg, 2.46 mmol, 1.01 eq) at 0° C., then the reaction mixture was stirred at 15° C. for 15 hr. The reaction mixture was diluted with water (100 mL) and extracted with Ethyl acetate (50 mL*2). The combined organic layers were treated with saturated sodium bicarbonate solution until pH=7, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. 6-fluoro-7-nitro-5-(trifluoromethyl)-1H-indazole (500 mg) was obtained as a yellow solid.

LCMS (electrospray) m/z 250.2 (M+H)+.

Step 5) 6-fluoro-7-nitro-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazole

To a solution of 6-fluoro-7-nitro-5-(trifluoromethyl)-1H-indazole (500 mg, 2.01 mmol, 1 eq) in THF (10 mL) was added PPTS (50.44 mg, 200.71 μmol, 0.1 eq) and DHP (844.13 mg, 10.04 mmol, 917.53 μL, 5 eq) at 0° C., then the reaction mixture was stirred at 60° C. for 15 hr. The reaction mixture was diluted with solvent H₂O (50 mL) and extracted with EtOAc (50 mL*3). The combined organic layers were washed with H₂O (50 mL*3), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. 6-fluoro-7-nitro-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazole (1 g, crude) was obtained as yellow oil.

Step 6) 6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazol-7-amine

To a solution of 6-fluoro-7-nitro-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazole (800 mg, 2.40 mmol, 1 eq) and H₂O (2 mL) in EtOH (10 mL) was added NH₄Cl

30

(642.08 mg, 12.00 mmol, 5 eq) and Fe (268.13 mg, 4.80 mmol, 2 eq) at 0° C., then the reaction mixture was stirred at 60° C. for 1 hr. The reaction mixture was diluted with H₂O (20 mL) and extracted with EtOAc (20 mL*3). The combined organic layers were washed with H₂O (30 mL*2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=10/1 to 5/1, Petroleum ether/Ethyl acetate=3:1, Rf=0.3). 6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazol-7-amine (500 mg, 1.65 mmol, 68.68% yield) was obtained as a yellow solid

LCMS (electrospray) m/z 220.2 (M+H)+.

Step 7) 4-bromo-6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazol-7-amine

To a solution of 6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazol-7-amine (200 mg, 659.51 μmol, 1 eq) in DMF (1 mL) was added NBS (129.12 mg, 725.46 μmol, 1.1 eq) at 20° C., then the reaction mixture was stirred at 20° C. for 2 hr. The reaction mixture was diluted with H₂O (10 mL) and extracted with EtOAc (10 mL*3). The combined organic layers were washed with H₂O (10 mL*2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. 4-bromo-6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazol-7-amine (120 mg, crude) was obtained as a yellow solid.

LCMS (electrospray) m/z 297.9 (M+H)+.

Step 8) 4-bromo-6-fluoro-N-isopropyl-5-(trifluoromethyl)-1H-indazol-7-amine

To a solution of 4-bromo-6-fluoro-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazol-7-amine (100 mg, 335.53 μmol, 1 eq) in MeOH (1 mL) were added AcOH (40.30 mg, 671.06 μmol, 38.38 μL, 2 eq) and acetone (97.44 mg, 1.68 mmol, 123.34 μL, 5 eq) at 20° C., NaBH₃CN (105.42 mg, 1.68 mmol, 5 eq) was then added and the reaction mixture was stirred at 20° C. for 2 hr. After then, acetone (97.44 mg, 1.68 mmol, 123.34 μL, 5 eq), NaBH₃CN (105.43 mg, 1.68 mmol, 5 eq) and AcOH (60.45 mg, 1.01 mmol, 57.57 μL, 3 eq) were added to the mixture and the reaction mixture was stirred at 20° C. for 20 hr. The reaction mixture was diluted with H₂O (10 mL) and extracted with EtOAc (10 mL*3). The combined organic layers were washed with H₂O (10 mL*2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (Petroleum ether: Ethyl acetate=3:1, Rf=0.4). 4-bromo-6-fluoro-N-isopropyl-5-(trifluoromethyl)-1H-indazol-7-amine (60 mg, 165.83 μmol, 49.42% yield, 94% purity) was obtained as a white solid.

LCMS (electrospray) m/z 340.1 (M+H)+.

Step 9) 4-bromo-6-fluoro-N-isopropyl-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazol-7-amine


To a solution of 4-bromo-6-fluoro-N-isopropyl-5-(trifluoromethyl)-1H-indazol-7-amine (50 mg, 147.01 μmol, 1 eq) in THF (1 mL) were added PPTS (3.69 mg, 14.70 μmol, 0.1 eq) and DHP (61.83 mg, 735.05 μmol, 67.21 μL, 5 eq) at 0° C., then the reaction mixture was stirred at 60° C. for 2 hr. The reaction mixture was diluted with H₂O (50 mL) and extracted with EtOAc (50 mL*3). The combined organic layers were washed with H₂O (50 mL*3), dried over

31

Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. Residue was purified by prep-TLC (Petroleum ether:Ethyl acetate=5:1, Rf=0.6). 4-bromo-6-fluoro-N-isopropyl-2-(tetrahydro-2H-pyran-2-yl)-5-(trifluoromethyl)-2H-indazol-7-amine (50 mg, 117.86 μmol, 80.17% yield) was obtained as a yellow oil.

LCMS (electrospray) m/z 424.1 (M+H)+.

Intermediate 1O. 4-bromo-5-cyclopropyl-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole



Step 1) 3-bromo-5-fluoro-2-methylaniline

To a mixture of 1-bromo-5-fluoro-2-methyl-3-nitrobenzene (23 g, 98.28 mmol, 1 eq) in EtOH (80 mL) and H₂O (80 mL) was added Fe (27.44 g, 491.41 mmol, 5 eq) and NH₄Cl (26.29 g, 491.41 mmol, 5 eq). The mixture was stirred at 100° C. for 3 h. The mixture was filtered and the filtrate was concentrated at reduced pressure to remove EtOH. The resulting mixture was extracted with DCM (50 mL*3). The combined organic phase was washed with brine (50 mL*2), dried over Na₂SO₄, filtered and concentrated at reduced pressure to give a residue to give 3-bromo-5-fluoro-2-methylaniline (20.6 g, crude) as yellow liquid.

¹H NMR (400 MHz, DMSO-d₆) δ 6.59 (br d, J=8.4 Hz, 1H), 6.42 (br d, J=11.2 Hz, 1H), 5.51 (br s, 2H), 2.09 (s, 3H).

Step 2) 3-bromo-5-fluoro-4-iodo-2-methylaniline

To a mixture of 3-bromo-5-fluoro-2-methylaniline (18 g, 88.22 mmol, 1 eq) (crude) in CH₃CN (150 mL) was added NIS (19.85 g, 88.22 mmol, 1 eq) in portions at 0° C. The mixture was stirred at 30° C. for 3 h. After 3 h, LCMS showed compound 2 was retained and desired mass was detected, too. Then the mixture was stirred at 30° C. for another 12 h. LCMS showed there was no compound 2 remained and one main peak with desired mass was detected. The mixture was quenched with saturated Na₂SO₃ (200 mL) and the resulting mixture was extracted with EtOAc (50 mL*3). The combined organic phase was washed with brine (50 mL*2), dried over Na₂SO₄, filtered and concentrated at reduced pressure to give a residue. The residue was purified by silica gel chromatography (1000 mesh silica gel, Petroleum ether/Ethyl acetate=50/1, 30/1; TLC (Petroleum ether:Ethyl acetate=10:1; Rf=0.28)) to give 3-bromo-5-fluoro-4-iodo-2-methylaniline (22 g, 66.68 mmol, 75.58% yield) as brown solid.

¹H NMR (400 MHz, DMSO-d₆) δ 6.55 (d, J=10.5 Hz, 1H), 5.67 (s, 2H), 2.25 (d, J=0.8 Hz, 3H).

Step 3) 4-bromo-6-fluoro-5-iodo-1H-indazole

To a mixture of 3-bromo-5-fluoro-4-iodo-2-methylaniline (22 g, 66.68 mmol, 1 eq) in CH₃COOH (200 mL) was added

32

NaNO₂ (5.52 g, 80.02 mmol, 1.2 eq) which was dissolved water (40 mL) at 0° C. The mixture was stirred at 30° C. for 16 h. The mixture was poured into saturated NaHCO₃ (1000 mL) and the resulting mixture was extracted with EtOAc (200 mL*3). The combined organic phase was washed with brine (100 mL*2), dried over Na₂SO₄, filtered and concentrated at reduced pressure to give a residue. The residue was purified by silica gel chromatography (1000 mesh silica gel, Petroleum ether/Ethyl acetate=15/1, 5/1) to give 4-bromo-6-fluoro-5-iodo-1H-indazole (7.5 g, 22.00 mmol, 32.99% yield) as brown solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.58 (br s, 1H), 8.00 (s, 1H), 7.51 (d, J=8.1 Hz, 1H), 3.32 (s, 1H).

Step 4) 4-bromo-6-fluoro-5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

To a mixture of 4-bromo-6-fluoro-5-iodo-1H-indazole (7.5 g, 22.00 mmol, 1 eq) and 4-methylbenzenesulfonic acid; hydrate (418.47 mg, 2.20 mmol, 0.1 eq) in DCM (100 mL) was added DHP (5.55 g, 66.00 mmol, 6.03 mL, 3 eq) slowly. The mixture was stirred at 30° C. for 1 h. The mixture was washed with saturated NaHCO₃ (30 mL*3) and brine (30 mL*3). The organic phase was dried over Na₂SO₄, filtered and concentrated at reduced pressure to give a residue. The residue was purified by silica gel chromatography (1000 mesh silica gel, Petroleum ether/Ethyl acetate=100/1, 50/1) to give 4-bromo-6-fluoro-5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (7.4 g, 17.41 mmol, 79.14% yield) as yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.06 (s, 1H), 7.80 (dd, J=0.7, 8.4 Hz, 1H), 5.83 (dd, J=2.4, 9.6 Hz, 1H), 3.88-3.85 (m, 1H), 3.80-3.70 (m, 2H), 2.40-2.27 (m, 1H), 2.07-1.94 (m, 2H), 1.81-1.63 (m, 2H), 1.62-1.53 (m, 2H).


Step 5) 4-bromo-5-cyclopropyl-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

To a mixture of 4-bromo-6-fluoro-5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (1.5 g, 3.53 mmol, 1 eq) and cyclopropylboronic acid (303.14 mg, 3.53 mmol, 1 eq) in dioxane (10 mL) and H₂O (2.5 mL) was added Na₂CO₃ (748.10 mg, 7.06 mmol, 2 eq) and Pd(dppf)Cl₂ (258.23 mg, 352.91 μmol, 0.1 eq) under N₂. The mixture was stirred at 80° C. for 16 h. The mixture was concentrated at reduced pressure to give a residue. The residue was purified by prep-TLC (Petroleum ether:Ethyl acetate=20:1) to give 4-bromo-5-cyclopropyl-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.21 g, 619.10 μmol, 17.54% yield) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.98 (d, J=0.6 Hz, 1H), 7.20 (d, J=10.4 Hz, 1H), 5.61 (dd, J=2.8, 9.1 Hz, 1H), 4.03-3.94 (m, 1H), 3.76-3.69 (m, 1H), 2.55-2.42 (m, 1H), 2.19-2.06 (m, 2H), 1.91-1.86 (m, 1H), 1.81-1.64 (m, 3H), 1.12-1.05 (m, 2H), 0.87-0.81 (m, 2H).

Intermediate 1P.

4-bromo-6-fluoro-5-isopropyl-1H-indazole



33

Step 1) 4-bromo-6-fluoro-5-(prop-1-en-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

To a mixture of 4-bromo-6-fluoro-5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (1.5 g, 3.53 mmol, 1 eq) and potassium; trifluoro(isopropenyl)boranuide (626.67 mg, 4.23 mmol, 1.2 eq) in dioxane (10 mL) and H₂O (2 mL) was added Pd(dppf)Cl₂ (258.23 mg, 352.91 umol, 0.1 eq) and Na₂CO₃ (748.10 mg, 7.06 mmol, 2 eq) under N₂. The mixture was stirred at 80° C. for 16 h. The mixture was concentrated at reduced pressure to give a residue. The residue was purified by silica gel chromatography (1000 mesh silica gel, Petroleum ether/Ethyl acetate=100/1, 50/1; TLC (Petroleum ether:Ethyl acetate=10:1; Rf=0.61)) to give 0.9 g of yellow oil. This oil was purified by prep-TLC (Petroleum ether:Ethyl acetate=20:1) to give 4-bromo-6-fluoro-5-(prop-1-en-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.55 g, 1.62 mmol, 45.94% yield) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J=0.6 Hz, 1H), 7.28 (d, J=0.9 Hz, 0.5H), 7.26 (d, J=0.7 Hz, 0.5H), 5.64 (dd, J=2.8, 9.0 Hz, 1H), 5.46 (t, J=1.6 Hz, 1H), 5.01 (s, 1H), 4.05-3.97 (m, 1H), 3.80-3.69 (m, 1H), 2.57-2.42 (m, 1H), 2.19-2.09 (m, 2H), 2.07 (s, 3H), 1.81-1.66 (m, 4H).

Step 2) 4-bromo-6-fluoro-5-isopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

To a solution of 4-bromo-6-fluoro-5-(prop-1-en-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.4 g, 1.18 mmol, 1 eq) in MeOH (10 mL) was added PtO₂ under N₂. The suspension was degassed under vacuum and purged with H₂ several times. The mixture was stirred under H₂ (15 Psi) at 30° C. for 2.5 h. The mixture was filtered and the filtrate was concentrated at reduced pressure to give a residue. The residue was purified by silica gel chromatography (300-400 mesh silica gel, Petroleum ether/Ethyl acetate=50/1) to give 4-bromo-6-fluoro-5-isopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.3 g, 879.20 umol, 74.56% yield) as colorless oil.


Step 3) 4-bromo-6-fluoro-5-isopropyl-1H-indazole

To a solution of 4-bromo-6-fluoro-5-isopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.3 g, 879.20 umol, 1 eq) in DCM (1 mL) was added TFA (2.30 g, 20.14 mmol, 1.49 mL, 22.91 eq). The mixture was stirred at 30° C. for 0.5 h. The mixture was concentrated at reduced pressure to give a residue. The residue was diluted with DCM (10 mL) and the resulting mixture was adjusted pH to about 8 with TEA. The mixture was concentrated at reduced pressure to give a residue. The residue was purified by silica gel chromatography (300-400 mesh silica gel, Petroleum ether/Ethyl acetate=30/1, 5/1) to give 4-bromo-6-fluoro-5-isopropyl-1H-indazole (0.2 g, 777.90 umol, 88.48% yield) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 7.11 (d, J=11.2 Hz, 1H), 3.75-3.63 (m, 1H), 1.38 (dd, J=1.7, 7.1 Hz, 6H).

34

Intermediate 1Q.
4-bromo-6-fluoro-5-methoxy-1H-indazole



Step 1)

2-bromo-4-fluoro-3-methoxy-1-methylbenzene

To a solution of 2-bromo-6-fluoro-3-methylphenol (4.8 g, 23.41 mmol, 1 eq) in acetone (50 mL) were added K₂CO₃ (6.47 g, 46.82 mmol, 2 eq) and iodomethane (9.97 g, 70.24 mmol, 4.37 mL, 3 eq), and the mixture was stirred at 25° C. for 1 hour. The reaction mixture was concentrated to give a residue. The residue was dissolved in ethyl acetate (50 mL), and the mixture was filtered, and the filtrate was concentrated to give a residue (4.6 g, 21.00 mmol, 89.70% yield) as a yellow oil.

¹H NMR (400 MHz, CHLOROFORM-d) δ 7.05-6.85 (m, 2H), 3.95 (d, J=1.2 Hz, 3H), 2.38 (s, 3H).

Step 2)

3-bromo-1-fluoro-2-methoxy-4-methyl-5-nitrobenzene

To a solution of 2-bromo-4-fluoro-3-methoxy-1-methylbenzene (4.4 g, 20.09 mmol, 1 eq) in H₂SO₄ (40 mL) (98%) was added KNO₃ (2.23 g, 22.10 mmol, 1.1 eq) in portions at 0° C., and the mixture was stirred at 25° C. for 1 hour. The reaction mixture was poured slowly into ice water (200 mL), then the mixture was extracted with ethyl acetate (200 mL*2), the combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. 3-bromo-1-fluoro-2-methoxy-4-methyl-5-nitrobenzene (4.6 g, crude) was obtained as a brown oil.

¹H NMR (400 MHz, CHLOROFORM-d) δ 7.70 (d, J=10.9 Hz, 1H), 4.08 (d, J=2.7 Hz, 3H), 2.61 (d, J=1.1 Hz, 3H).

Step 3)

3-bromo-5-fluoro-4-methoxy-2-methylaniline

To a solution of 3-bromo-1-fluoro-2-methoxy-4-methyl-5-nitrobenzene (4.6 g, 17.42 mmol, 1 eq) in EtOH (30 mL) and H₂O (30 mL) were added Fe (5.84 g, 104.53 mmol, 6 eq) and NH₄Cl (5.59 g, 104.53 mmol, 6 eq), and the mixture was stirred at 80° C. for 2 hours. The reaction mixture was filtered, and the filtrate was concentrated to remove EtOH, then the mixture was diluted with EA (50 mL), and the mixture was washed with water (20 mL*2), after then the organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. 3-bromo-5-fluoro-4-methoxy-2-methylaniline (3.5 g, crude) was obtained as a brown oil.

¹H NMR (400 MHz, CHLOROFORM-d) δ 6.44 (d, J=11.9 Hz, 1H), 3.83 (s, 3H), 3.76-3.48 (m, 2H), 2.24 (d, J=1.0 Hz, 3H).

Step 4) 4-bromo-6-fluoro-5-methoxy-1H-indazole

To a mixture of 3-bromo-5-fluoro-4-methoxy-2-methylaniline (3.5 g, 14.95 mmol, 1 eq) (crude) in AcOH (20 mL)

35

was added a solution of NaNO_2 (1.24 g, 17.94 mmol, 1.2 eq) in H_2O (4 mL) dropwise at 0°C ., then the mixture was stirred at 25°C . for 12 hr. The reaction mixture was diluted with ice water (100 mL), and the mixture was adjusted to pH 7 by using KOH, then the mixture was extracted with EA (100 mL*2), the combined organic layers were washed with brine (50 mL*2), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate=20/1 to 15/1). 4-bromo-6-fluoro-5-methoxy-1H-indazole (600 mg, 2.45 mmol, 16.37% yield) was obtained as a brown solid.


^1H NMR (400 MHz, DMSO-d_6) δ 13.44 (br s, 1H), 8.00 (s, 1H), 7.52 (br d, $J=10.4$ Hz, 1H), 3.84 (s, 3H).

Synthesis of Formula (I) Compounds

Synthetic methods A to F were used to prepare the compounds of the following. Below, the illustrating synthetic examples of some compounds of the present disclosure are described, and other compounds can be prepared by the similar method to the one described below with different starting or reacting materials


Synthetic Method A

Example 1. (1S,2S)-2-fluoro-N-(5-(5-methyl-1H-indazol-4-yl)pyrazolo[1,5-a]pyrimidin-2-yl)cyclopropane-1-carboxamide



36

-continued



Step 1) methyl 5-amino-1-(3-methoxy-3-oxoprop-1-en-1-yl)-1H-pyrazole-3-carboxylate

To a solution of Compound 1 (9.1 g, 64.48 mmol, 1 eq) in EtOH (700 mL) was added methyl propiolate (27.11 g, 322.40 mmol, 26.84 mL, 5 eq). The mixture was stirred at 90°C . for 16 hr. The reaction mixture was concentrated under reduced pressure until all solid precipitated out, filtered and concentrated under reduced pressure to give a crude product. Compound 2 (7.8 g, crude) was obtained as a yellow solid.

^1H NMR (400 MHz, DMSO-d_6) δ 8.09 (d, $J=14.8$ Hz, 1H), 7.05 (s, 1H), 6.68 (br s, 2H), 6.63 (d, $J=14.8$ Hz, 1H), 3.88 (s, 3H), 3.76 (s, 3H).

Step 2) ethyl 5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate

Compound 2 (3.9 g, 17.32 mmol, 1 eq) in EtOH (15 mL) was added EtONa (1.77 g, 25.98 mmol, 1.5 eq). The mixture was stirred at 90°C . for 16 hr. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was diluted with water 200 mL and extracted with Ethyl acetate (200 mL*2). The water layer was filtered and the obtained filter cake was concentrated under reduced pressure to give Compound 3 (5.4 g, crude) as a yellow solid.

^1H NMR (400 MHz, DMSO-d_6) δ 12.62 (br s, 1H), 7.99 (d, $J=7.5$ Hz, 1H), 6.58 (s, 1H), 5.82 (d, $J=7.5$ Hz, 1H), 4.35 (q, $J=7.1$ Hz, 2H), 1.34 (t, $J=7.2$ Hz, 3H).

37

Step 3) ethyl 5-chloropyrazolo[1,5-a]pyrimidine-2-carboxylate

To a solution of Compound 3 (1 g, 4.83 mmol, 1 eq) in MeCN (5 mL) were added N,N-dimethylaniline (1.17 g, 9.65 mmol, 1.22 mL, 2 eq), benzyl(triethyl) ammonium; chloride (5.50 g, 24.13 mmol, 5 eq) and POCl₃ (7.40 g, 48.27 mmol, 4.49 mL, 10 eq) under N₂ atmosphere. The reaction mixture was stirred at 100° C. for 16 hr under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was quenched by water (100 mL) and treated with saturated sodium bicarbonate solution until pH=7. Then the mixture was extracted with Ethyl acetate (100 mL*2). The combined organic layers were washed with brine 100 mL, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silical gel, Petroleum ether:Ethyl acetate=1:0 to 1:1). Compound 4 (900 mg, 3.99 mmol, 82.64% yield) was obtained as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.63 (d, J=4.5 Hz, 1H), 7.61 (d, J=4.5 Hz, 1H), 7.36 (s, 1H), 4.40 (d, J=7.1 Hz, 2H), 1.36 (t, J=7.1 Hz, 3H).

Step 4) ethyl 5-(5-methyl-1H-indazol-4-yl)pyrazolo[1,5-a]pyrimidine-2-carboxylate

To a mixture of Compound 4 (900 mg, 3.99 mmol, 1 eq), (5-methyl-1H-indazol-4-yl)boronic acid (701.95 mg, 3.99 mmol, 1 eq) and Na₂CO₃ (845.55 mg, 7.98 mmol, 2 eq) in dioxane (5 mL) and H₂O (1 mL) was added Pd(dppf)Cl₂ (145.93 mg, 199.44 μmol, 0.05 eq) under N₂ atmosphere. The mixture was stirred at 80° C. for 16 hr under N₂ atmosphere. The reaction mixture was diluted with water 100 mL and extracted with Ethyl acetate (50 mL*2). The combined organic layers were washed with brine 50 mL, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silical gel, Petroleum ether:Ethyl acetate=1:0 to 0:1). Compound 5 (450 mg, 1.40 mmol, 35.10% yield) was obtained as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.28 (s, 1H), 8.81-8.78 (m, 1H), 7.71 (d, J=8.5 Hz, 1H), 7.66 (s, 1H), 7.44 (d, J=8.5 Hz, 1H), 7.34 (d, J=4.1 Hz, 1H), 7.31 (s, 1H), 4.30 (q, J=7.1 Hz, 2H), 2.14 (s, 3H), 1.27 (t, J=7.1 Hz, 3H).

Step 5) 5-(5-methyl-1H-indazol-4-yl)pyrazolo[1,5-a]pyrimidine-2-carboxylic acid

To a solution of Compound 5 (450 mg, 1.40 mmol, 1 eq) in THF (5 mL) and H₂O (5 mL) was added LiOH·H₂O (117.53 mg, 2.80 mmol, 2 eq). The mixture was stirred at 45° C. for 2 hr. The reaction mixture was diluted with water 100 mL and extracted with Ethyl acetate (100 mL*2). The combined water layers were treated with HCl (1M) until pH 4, stirred until all solid was precipitated out, filtered and concentrated under reduced pressure to give a residue. Compound 6 (330 mg, crude) was obtained as a yellow solid.

¹H NMR (400 MHz, DMSO-d₄) δ 13.51-13.06 (m, 1H), 8.77 (d, J=4.2 Hz, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.66 (d, J=0.9 Hz, 1H), 7.43 (d, J=8.7 Hz, 1H), 7.31 (d, J=4.2 Hz, 1H), 7.24 (s, 1H), 2.14 (s, 3H).

Step 6) 5-(5-methyl-1H-indazol-4-yl)pyrazolo[1,5-a]pyrimidin-2-amine

To a solution of Compound 6 (230 mg, 784.23 μmol, 1 eq) in toluene (2 mL) was added TEA (87.29 mg, 862.66 μmol,

38

120.07 μL, 1.1 eq) and DPPA (237.40 mg, 862.66 μmol, 186.93 μL, 1.1 eq) under N₂ atmosphere. The mixture was stirred at 110° C. for 16 hr. H₂O (1.00 g, 55.51 mmol, 1 mL, 70.78 eq) was added to the mixture under N₂ atmosphere. The mixture was stirred at 110° C. for 3 hr under N₂ atmosphere. The reaction mixture was diluted with water 50 mL and extracted with Ethyl acetate (50 mL*2). The combined organic layers were washed with brine 50 mL, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (Petroleum ether:Ethyl acetate=0:1). Compound 7 (70 mg, 264.87 μmol, 33.77% yield) was obtained as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.19 (s, 1H), 8.32 (d, J=4.3 Hz, 1H), 7.63-7.59 (m, 2H), 7.35 (d, J=8.6 Hz, 1H), 6.71 (d, J=4.4 Hz, 1H), 5.79 (s, 1H), 5.71-5.63 (m, 2H), 2.15 (s, 3H).


Step 7) (1S,2S)-2-fluoro-N-(5-(5-methyl-1H-indazol-4-yl)pyrazolo[1,5-a]pyrimidin-2-yl)cyclopropane-1-carboxamide

To a solution of Compound 7 (70 mg, 264.87 μmol, 1 eq), (1S,2S)-2-fluorocyclopropanecarboxylic acid (33.08 mg, 317.84 μmol, 1.2 eq) and 3-methylpyridine (123.33 mg, 1.32 mmol, 128.95 μL, 5 eq) in MeCN (2 mL) was added MsCl (45.51 mg, 397.30 μmol, 30.75 μL, 1.5 eq) at 0° C. under N₂ atmosphere. The mixture was stirred at 25° C. for 16 hr under N₂ atmosphere. The reaction mixture was added dropwise into water 20 mL and extracted with Ethyl acetate (20 mL*2). The combined organic layers were washed with brine 20 mL, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (Petroleum ether:Ethyl acetate=0:1). Then the residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25 mm*10 μm; mobile phase: [water (0.1% TFA)-ACN]; B %: %-%, 10 min) and lyophilized. Example 1 (4.3 mg, 12.27 μmol, 4.63% yield, 100% purity) was obtained as a yellow solid.


¹H NMR (400 MHz, METHANOL-d₄) δ 8.57 (d, J=4.3 Hz, 1H), 7.66 (d, J=8.6 Hz, 1H), 7.64 (d, J=2.3 Hz, 1H), 7.44 (d, J=8.8 Hz, 1H), 7.13 (s, 1H), 7.04 (d, J=4.3 Hz, 1H), 4.75-4.61 (m, 1H), 2.26 (s, 3H), 1.98-1.90 (m, 1H), 1.83-1.72 (m, 1H), 1.19-1.11 (m, 1H).

Synthetic Method B

Example 3. (1S,2S)-2-fluoro-N-(6-(5-methyl-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)cyclopropane-1-carboxamide



39



Step 1) N-(6-chloropyridazin-3-yl)-4-methylbenzenesulfonamide

To a solution of Compound 8 (25 g, 192.98 mmol, 1 eq) in pyridine (300 mL) was added TsCl (40.47 g, 212.28 mmol, 1.1 eq), then the mixture was stirred at 90° C. for 6 hr under N₂. Water (100 mL) was poured into the mixture and the mixture was extracted with ethyl acetate (50 mL*3), then the organic phase was dried with anhydrous sodium sulfate (Na₂SO₄), filtered and concentrated in vacuum to obtain Compound 9 (56.5 g, crude) as a gray solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.67-8.59 (m, 1H), 7.82-7.77 (m, 2H), 7.61-7.54 (m, 1H), 7.52-7.46 (m, 1H), 7.38 (d, J=8.3 Hz, 2H), 2.35 (s, 3H).

Step 2) (E)-2-(3-chloro-6-(tosylimino)pyridazin-1(6H)-yl)acetamide

To a solution of Compound 9 (53 g, 186.79 mmol, 1 eq) in DMF (300 mL) was added DIPEA (26.56 g, 205.47 mmol,

40

35.79 mL, 1.1 eq) and 2-bromoacetamide (28.35 g, 205.47 mmol, 1.1 eq), then the mixture was stirred at 25° C. for 20 hr. Water (1000 mL) was added to the mixture and the mixture was filtered, the filter cake was collected and concentrated under vacuum to give Compound 10 (40 g, 117.38 mmol, 62.84% yield) as a brown solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.00 (d, J=9.8 Hz, 1H), 7.79 (d, J=9.8 Hz, 1H), 7.70 (br d, J=7.1 Hz, 3H), 7.38 (br s, 1H), 7.32 (br d, J=7.8 Hz, 2H), 4.88-4.77 (m, 2H), 2.40-2.30 (m, 3H).

Step 3) N-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2,2-trifluoroacetamide

To a solution of Compound 10 (35 g, 102.70 mmol, 1 eq) in DCE (250 mL) was added TFAA (258.85 g, 1.23 mol, 171.43 mL, 12 eq), then the mixture was stirred at 60° C. for 3 hr. Water (1000 mL) was added to the mixture and then adequate NaHCO₃ was added to the mixture to adjust the pH 8, then the mixture was filtered and the filter cake was collected, then extracted with water (500 mL) and ethyl acetate (500 mL), then the organic phase was dried with Na₂SO₄ and concentrated under vacuum to obtain Compound 11 (21 g, 79.37 mmol, 77.28% yield) as a white solid.

¹H NMR (400 MHz, DMSO-d₄) δ 12.88-12.57 (m, 1H), 8.41 (s, 1H), 8.19 (d, J=9.4 Hz, 1H), 7.43 (d, J=9.4 Hz, 1H).

Step 4) 6-chloroimidazo[1,2-b]pyridazin-2-amine

To a solution of Compound 11 (21 g, 79.37 mmol, 1 eq) in MeOH (200 mL) and H₂O (200 mL) was added K₂CO₃ (54.85 g, 396.84 mmol, 5 eq), then the mixture was stirred at 75° C. for 3 hr. Water (100 mL) was poured into the mixture and the mixture was extracted with ethyl acetate (50 mL*3), then the organic phase was dried with Na₂SO₄, filtered and concentrated in vacuum to give Compound 60 (13.5 g, crude).

¹H NMR (400 MHz, DMSO-d₆) δ 7.68 (d, J=9.2 Hz, 1H), 7.36 (s, 1H), 7.03 (d, J=9.2 Hz, 1H), 5.65 (s, 2H).

Step 5) (1S,2S)-N-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide

To a solution of Compound 12 (2 g, 11.86 mmol, 1 eq), (1S,2S)-2-fluorocyclopropanecarboxylic acid (1.56 g, 14.24 mmol, 1.2 eq) in DCM (50 mL) was added EDCI (3.41 g, 17.80 mmol, 1.5 eq), then the mixture was stirred at 25° C. for 16 hr. The mixture was concentrated under vacuum to give a residue. Then water (100 mL) was poured into the mixture and the mixture was extracted with ethyl acetate (50 mL*3), then the organic phase was dried with Na₂SO₄, filtered and concentrated in vacuum to give Compound 13 (3.8 g, crude) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 11.37-11.22 (m, 1H), 8.32-8.23 (m, 1H), 8.07 (d, J=9.4 Hz, 1H), 7.72-7.64 (m, 1H), 5.07-4.80 (m, 1H), 2.21-2.12 (m, 1H), 1.73-1.61 (m, 1H), 1.13-1.05 (m, 1H).

Step 6) (1S,2S)-2-fluoro-N-(6-(5-methyl-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)cyclopropane-1-carboxamide. 2 TFA

To a solution of Compound 13 (170 mg, 667.59 umol, 1 eq), Na₂CO₃ (141.51 mg, 1.34 mmol, 2 eq) in dioxane (6 mL) and H₂O (2 mL) was added (5-methyl-1H-indazol-4-yl)boronic acid (117.48 mg, 667.59 umol, 1 eq) and Pd(dppf)Cl₂ (48.85 mg, 66.76 umol, 0.1 eq), then the mix-


41

ture was stirred at 90° C. for 16 hr under N₂. The reaction mixture was purified by prep-HPLC (column: Phenomenex luna C18 150*25 mm*10 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 19%-49%, 10 min) to obtain Example 3 (56.8 mg, 93.88 umol, 14.06% yield, 95.6% purity, 2TFA) as a light yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 11.27 (s, 1H), 8.31 (s, 1H), 8.10 (d, J=9.3 Hz, 1H), 7.84 (d, J=0.9 Hz, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.38 (dd, J=8.9, 16.1 Hz, 2H), 5.08-4.82 (m, 1H), 2.38 (s, 3H), 2.23-2.14 (m, 1H), 1.77-1.62 (m, 1H), 1.23-1.12 (m, 1H).

Synthetic Method C

Example 24. (1S,2S)-2-fluoro-N-(6-(5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropanecarboxamide. 2 TFA



Step 1) (1S,2S)-N-(6-bromoimidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropanecarboxamide

To a solution of (1S,2S)-2-fluorocyclopropanecarboxylic acid (537.41 mg, 5.16 mmol, 1.1 eq) and Compound 14 (1 g, 4.69 mmol, 1 eq) in NMP (20 mL) was added T₃P (2.99 g, 9.39 mmol, 2.79 mL, 2 eq) and DIPEA (1.42 g, 11.03 mmol, 1.92 mL, 2.35 eq). The reaction mixture was stirred at 25° C. for 16 hrs. Water (15 mL) was added and the aqueous phase was extracted with EtOAc (10 mL*2). The combined organic phase was washed with saturated brine (10 mL*2) and concentrated in vacuum. The crude product was purified by reverse flash (MeCN/H₂O. 0.05% TFA) to give Compound 15 (750 mg, 2.51 mmol, 53.42% yield) as a light yellow solid.

42

¹H NMR (400 MHz, DMSO-d₆) δ 11.39 (s, 1H), 8.93 (d, J=1.2 Hz, 1H), 8.75 (s, 1H), 8.29 (s, 1H), 5.17-4.76 (m, 1H), 2.23-2.11 (m, 1H), 1.67 (tdd, J=3.3, 6.9, 19.9 Hz, 1H), 1.25-1.13 (m, 1H).


Step 2) (1S,2S)-2-fluoro-N-(6-(5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropanecarboxamide. 2 TFA

To a solution of (5-methyl-1H-indazol-4-yl)boronic acid (58.84 mg, 334.34 umol, 1 eq) in dioxane/H₂O (3 mL) were added Pd(dppf)Cl₂ (12.23 mg, 16.72 umol, 0.05 eq), Compound 15 (100 mg, 334.34 umol, 1 eq) and Na₂CO₃ (70.87 mg, 668.67 umol, 2 eq) under N₂. The mixture was stirred at 90° C. for 3 hrs. Water (10 mL) was added and the aqueous phase was extracted with EtOAc (10 mL*2). The combined organic phase was washed with saturated brine (10 mL*2), and concentrated in vacuum. The crude product was purified by prep-HPLC (column: Phenomenex luna C18 150*25 mm*10 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 13%-43%, 10 min) to give Example 24 (38.2 mg, 62.74 umol, 18.77% yield, 95% purity, 2TFA) as a light yellow solid.

¹H NMR (400 MHz, DMSO-d₄) δ 11.48-11.28 (m, 1H), 9.06 (s, 1H), 8.83 (d, J=1.3 Hz, 1H), 8.36 (s, 1H), 7.91 (d, J=0.9 Hz, 1H), 7.52 (d, J=8.3 Hz, 1H), 7.33 (d, J=8.6 Hz, 1H), 5.15-4.79 (m, 1H), 2.43-2.35 (m, 3H), 2.26-2.14 (m, 1H), 1.78-1.62 (m, 1H), 1.37-1.06 (m, 1H).

Synthetic Method D

Example 25. (1S,2S)-N-(6-(5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropanecarboxamide. 2 TFA



43

Step 1) (1S,2S)-2-fluoro-N-(6-(tributylstannyl)imidazo[1,2-a]pyrazin-2-yl)cyclopropanecarboxamide

To a solution of tributyl(tributylstannyl)stannane (1.16 g, 2.01 mmol, 1.00 mL, 3 eq) and Compound 16 (200 mg, 668.67 μ mol, 1 eq) in dioxane (3 mL) was added Pd(PPh₃)₄ (38.63 mg, 33.43 μ mol, 0.05 eq) and TBAI (246.99 mg, 668.67 μ mol, 1 eq) under N₂. The reaction mixture was stirred at 110° C. for 32 hrs. The reaction was filtered and the filtrate was concentrated to give product. The crude product was purified by prep-TLC (Petroleum ether:Ethyl acetate=1:1) to give Compound 17 (130 mg, 255.28 μ mol, 38.18% yield) as a white solid.



Step 2) (1S,2S)-N-(6-(5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropanecarboxamide. 2 TFA

To a solution of 4-bromo-5-ethyl-6-fluoro-1H-indazole (40 mg, 164.56 μ mol, 1 eq) and Compound 17 (92.18 mg, 181.01 μ mol, 1.1 eq) in EtOH (2 mL) was added Ad₂n-BuP-Pd-G3 (11.98 mg, 16.46 μ mol, 0.1 eq) under N₂. The reaction mixture was stirred at 90° C. for 16 hrs. The reaction mixture was concentrated in vacuum. The crude product was purified by prep-HPLC (column: Phenomenex Luna C18 150*25 mm*10 μ m; mobile phase: [water (0.1% TFA)-ACN]; B %: 24%-54%, 10 min) to give Example 25 (10 mg, 16.22 μ mol, 9.86% yield, 99% purity, 2TFA) as a white solid.

¹H NMR (400 MHz METHANOL-d₄) δ 8.99 (s, 1H), 8.71 (s, 1H), 8.42 (s, 1H), 7.83 (s, 1H), 7.36 (d, J=10.4 Hz, 1H), 5.00-4.97 (m, 1H), 2.76-2.72 (m, 2H), 2.16-2.15 (m, 1H), 1.86-1.79 (m, 1H), 1.26-1.24 (m, 1H), 1.19-1.16 (m, 3H).


Synthetic Method E

Example 61. (1S,2S)-N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide



44

-continued



15

20


25

30

To a solution of Compound 17 (456 mg, 0.896 mmol, 1.3 eq) and Intermediate 1E (269 mg, 0.689 mmol) in EtOH (3.44 mL) was added Ad₂nBuP-Pd-G3 (50 mg, 0.0689 mmol, 0.1 eq). The mixture was degassed and purged with N₂ for 3 times, and then stirred at 90° C. for 16 hr under N₂ atmosphere. The reaction mixture was concentrated in vacuum. The crude product was purified by silica gel chromatography (product came out at Ethyl acetate) to afford Example 61 (86 mg, 0.162 mmol, 24% yield) as yellow color solid.

Synthetic Method F

Example 64. (1S,2S)-N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide



40


45


50

55

60

65





Step 1) 4-bromo-5-chloro-6-fluoro-7-(prop-1-en-2-yl)-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole

To a solution of Intermediate 1B (2 g, 4.35 mmol, 1 eq), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (877.73 mg, 5.22 mmol, 1.2 eq) in dioxane (0.4 mL) and H₂O (0.1 mL) was added Na₂CO₃ (922.69 mg, 8.71 mmol, 2 eq) and Pd(dppf)Cl₂ (159.25 mg, 217.64 μmol, 0.05 eq) under N₂ atmosphere. The mixture was stirred at 80° C. for 16 hr under N₂ atmosphere. The reaction mixture was diluted with water 100 mL and extracted with Ethyl acetate (100 mL*2). The combined organic layers were washed with brine 100 mL, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silical gel, Petroleum ether:Ethyl acetate=1:0 to 20:1). Compound 18 (870 mg, 2.33 mmol, 53.49% yield) was obtained as a yellow oil

46

Step 2)

4-bromo-5-chloro-6-fluoro-7-isopropyl-1H-indazole

To a solution of Compound 18 (400 mg, 1.07 mmol, 1 eq) in MeOH (0.5 mL) was added PtO₂ (40.00 mg, 176.15 μmol, 1.65 e-1 eq) under N₂. The suspension was degassed under vacuum and purged with H₂ several times. The mixture was stirred under H₂ (15 psi) at 25° C. for 1 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silical gel, Petroleum ether:Ethyl acetate=1:0 to 4:1). Compound 19 (240 mg, 823.19 μmol, 76.90% yield) was obtained as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.73 (br s, 1H), 8.09 (s, 1H), 3.59-3.49 (m, 1H), 1.39 (d, J=6.9 Hz, 6H).

Step 3) (1S,2S)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide

To a solution of Compound 19 (70 mg, 240.10 μmol, 1 eq), Compound 17 (134.50 mg, 264.11 μmol, 1.1 eq) in EtOH (1 mL) was added Ad₂nBuP-Pd-G3 (17.49 mg, 24.01 μmol, 0.1 eq) under N₂ atmosphere. The mixture was stirred at 80° C. for 12 hr under N₂ atmosphere. 5 mL saturated KF aqueous solution was added to quench the reaction mixture. The mixture was dissolved into water (20 mL) and extracted with Ethyl acetate (20 mL*2). The combined organic layers were washed with brine 20 mL, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Unisil 3-100 C18 Ultra 150*50 mm*3 μm; mobile phase: [water (0.225% FA)-ACN]; B %: 40%-60%, 10 min) and lyophilized. Example 64 (15 mg, 34.12 μmol, 14.21 yield, 98% purity) was obtained as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.52 (br s, 1H), 11.40 (s, 1H), 9.14-8.87 (m, 2H), 8.38 (s, 1H), 8.04 (br s, 1H), 5.17-4.75 (m, 1H), 3.66-3.59 (m, 1H), 2.19 (td, J=7.0, 13.6 Hz, 1H), 1.75-1.62 (m, 1H), 1.45 (br d, J=7.0 Hz, 6H), 1.20 (tdd, 7=6.3, 8.9, 12.3 Hz, 1H); LCMS (electrospray) m/z 431.2 (M+H⁺).

Table 1 below shows the compounds of Examples along with general synthetic methods used to make the compound and characterization data.

TABLE 1

Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
1	<p>(1S,2S)-2-fluoro-N-(5-(5-methyl-1H-indazol-4-yl)pyrazolo[1,5-a]pyrimidin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, METHANOL-d ₄) δ 8.57 (d, J = 4.3 Hz, 1H), 7.66 (d, J = 8.6 Hz, 1H), 7.64 (d, J = 2.3 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 7.13 (s, 1H), 7.04 (d, J = 4.3 Hz, 1H), 4.75-4.61 (m, 1H), 2.26 (s, 3H), 1.98-1.90 (m, 1H), 1.83-1.72 (m, 1H), 1.19-1.11 (m, 1H); LCMS (electrospray) m/z 351.2 (M + H) ⁺ .	A

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
2	 <p>(1S,2S)-N-(5-(5-ethyl-6,7-difluoro-1H-indazol-4-yl)pyrazolo[1,5-a]pyrimidin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, METHANOL-d ₄) δ 8.89 (d, J = 7.0 Hz, 1H), 7.93 (d, J = 3.1 Hz, 1H), 7.10 (d, J = 7.1 Hz, 1H), 7.05 (s, 1H), 4.96 (dt, J = 3.8, 6.2 Hz, 1H), 4.80 (dt, J = 3.8, 6.3 Hz, 1H), 2.88-2.80 (m, 2H), 2.15-2.07 (m, 1H), 2.03 (s, 1H), 1.88-1.76 (m, 1H), 1.28-1.19 (m, 4H); LCMS (electrospray) m/z 401.2 (M + H ⁺).	A
3	 <p>CF₃COOH</p> <p>CF₃COOH</p> <p>(1S,2S)-2-fluoro-N-(6-(5-methyl-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)cyclopropane-1-carboxamide. 2 TFA</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.27 (s, 1H), 8.31 (s, 1H), 8.10 (d, J = 9.3 Hz, 1H), 7.84 (d, J = 0.9 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.38 (dd, J = 8.9, 16.1 Hz, 2H), 5.08-4.82 (m, 1H), 2.38 (s, 3H), 2.23-2.14 (m, 1H), 1.77-1.62 (m, 1H), 1.23-1.12 (m, 1H); LCMS (electrospray) m/z 351.1 (M + H ⁺).	B
4	 <p>CF₃COOH</p> <p>CF₃COOH</p> <p>(1S,2S)-N-(6-(5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 2 TFA</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.31 (s, 1H), 8.32 (s, 1H), 8.13 (d, J = 9.2 Hz, 1H), 7.82 (s, 1H), 7.50 (d, J = 10.4 Hz, 1H), 7.39 (d, J = 9.1 Hz, 1H), 5.24-4.78 (m, 1H), 2.67-2.62 (m, 2H), 2.25-2.14 (m, 1H), 1.77-1.60 (m, 1H), 1.25-1.18 (m, 1H), 1.14 (br t, J = 7.3 Hz, 3H); LCMS (electrospray) m/z 383.1 (M + H ⁺).	B
5	 <p>CF₃COOH</p> <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.31 (s, 1H), 8.34 (s, 1H), 8.14 (d, J = 9.8 Hz, 1H), 7.88 (d, J = 0.9 Hz, 1H), 7.50 (d, J = 9.9 Hz, 1H), 7.42 (d, J = 9.3 Hz, 1H), 5.13-4.83 (m, 1H), 2.27 (d, J = 2.6 Hz, 3H), 2.23-2.16 (m, 1H), 1.78-1.61 (m, 1H), 1.28-1.12 (m, 1H); LCMS (electrospray) m/z 369.1 (M + H ⁺).	B

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
6	 <p>(1S,2S)-N-(6-(5-ethyl-6,7-difluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.95 (br s, 1H), 11.32 (s, 1H), 8.32 (s, 1H), 8.14 (d, J = 9.3 Hz, 1H), 7.95 (br s, 1H), 7.38 (d, J = 9.2 Hz, 1H), 5.07-4.85 (m, 1H), 2.71-2.66 (m, 2H), 2.19 (quin, J = 6.9 Hz, 1H), 1.75-1.62 (m, 1H), 1.25-1.19 (m, 1H), 1.16 (t, J = 7.5 Hz, 3H); LCMS (electrospray) m/z 401.1 (M + H ⁺).	B
7	 <p>(1S,2S)-N-(6-(7-(dimethylamino)-5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.27 (br s, 1H), 11.29 (s, 1H), 8.29 (s, 1H), 8.10 (d, J = 9.3 Hz, 1H), 7.79 (br t, J = 4.4 Hz, 1H), 7.35 (d, J = 9.3 Hz, 1H), 5.08-4.83 (m, 1H), 2.99 (br d, J = 1.5 Hz, 6H), 2.61 (br d, J = 5.7 Hz, 2H), 2.22-2.15 (m, 1H), 1.73-1.62 (m, 1H), 1.24-1.18 (m, 1H), 1.15 (t, J = 7.4 Hz, 3H); LCMS (electro- spray) m/z 426.3 (M + H ⁺).	B
8	 <p>(1S,2S)-N-(6-(6,7-difluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.90 (s, 1H), 11.30 (s, 1H), 8.33 (s, 1H), 8.13 (d, J = 9.3 Hz, 1H), 8.03 (br s, 1H), 7.40 (d, J = 9.2 Hz, 1H), 5.07-4.86 (m, 1H), 2.32 (d, J = 2.9 Hz, 3H), 2.22-2.15 (m, 1H), 1.74-1.64 (m, 1H), 1.20 (br dd, J = 9.2, 12.3 Hz, 1H); LCMS (electro- spray) m/z 387.2 (M + H ⁺).	B
9	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.46 (br s, 1H), 11.29 (s, 1H), 8.23 (s, 1H), 8.12-8.10 (m, 1H), 7.92 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 9.3 Hz, 1H), 5.05-4.84 (m, 1H), 2.31 (s, 3H), 2.19 (br s, 1H), 1.75-1.64 (m, 1H), 1.22-1.15 (m, 1H); LCMS (electrospray) m/z 400.9 (M + H ⁺).	B

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
10	 <p>CF₃COOH Cl F</p> <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 TFA</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.33 (s, 1H), 8.36 (s, 1H), 8.18 (d, J = 9.3 Hz, 1H), 8.03 (s, 1H), 7.79 (dd, J = 1.0, 9.2 Hz, 1H), 7.52 (d, J = 9.4 Hz, 1H), 5.09-4.84 (m, 1H), 2.24-2.15 (m, 1H), 1.74-1.63 (m, 1H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 389.3 (M + H ⁺).	B
11	 <p>H₂N F</p> <p>(1S,2S)-N-(6-(5-amino-6-fluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.43-11.12 (m, 1H), 8.39-8.34 (m, 1H), 8.04 (s, 1H), 7.87 (s, 1H), 7.56 (d, J = 9.4 Hz, 1H), 7.46-7.40 (m, 1H), 5.55-5.47 (m, 2H), 5.10-4.76 (m, 1H), 2.24 (br d, J = 8.9 Hz, 1H), 1.76-1.60 (m, 1H), 1.28-1.12 (m, 1H); LCMS (electrospray) m/z 370.2 (M + H ⁺).	B
12	 <p>(1S,2S)-N-(6-(5-ethyl-7-(ethyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.24 (s, 1H), 11.30 (s, 1H), 8.30 (s, 1H), 8.11 (d, J = 9.3 Hz, 1H), 7.78 (s, 1H), 7.37 (d, J = 9.3 Hz, 1H), 5.11-4.82 (m, 1H), 3.24 (br d, J = 6.8 Hz, 2H), 2.96 (d, J = 2.0 Hz, 3H), 2.62 (br d, J = 7.5 Hz, 2H), 2.23-2.13 (m, 1H), 1.72-1.57 (m, 1H), 1.23 (br s, 1H), 1.14 (t, J = 7.4 Hz, 3H), 1.07 (t, J = 7.0 Hz, 3H); LCMS (electrospray) m/z 440.2 (M + H ⁺).	B
13	 <p>(1S,2S)-N-(6-(7-ethoxy-5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.58 (br s, 1 H) 11.31 (s, 1 H) 8.31 (s, 1 H) 8.11 (d, J = 9.29 Hz, 1 H) 7.85 (s, 1 H) 7.37 (d, J = 9.29 Hz, 1 H) 4.84-5.06 (m, 1 H) 4.31-4.41 (m, 2 H) 2.60-2.69 (m, 2 H) 2.18 (dt, J = 13.83, 6.82 Hz, 1 H) 1.62-1.73 (m, 1 H) 1.40 (t, J = 6.96 Hz, 3 H) 1.18-1.24 (m, 1 H) 1.15 (t, J = 7.34 Hz, 3 H); LCMS (electrospray) m/z 427.1 (M + H ⁺).	B

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
14	 <p>(1S,2S)-N-(6-(5-chloro-7-ethoxy-6-fluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, METHANOL-d ₄) δ 8.44-8.39 (s, 1H), 8.03-7.93 (m, 2H), 7.55-7.45 (d, 1H), 4.80-4.57 (m, 1H), 4.50-4.42 (m, 2H), 4.51-4.41 (m, 2H), 2.17-2.07 (m, 1H), 1.83-1.71 (m, 1H), 1.51-1.44 (t, 3H), 1.23-1.15 (m, 1H); LCMS (electrospray) m/z 433.2 (M + H ⁺).	B
15	 <p>(1S,2S)-N-(6-(5-chloro-7-(ethyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.36-11.29 (s, 1H), 8.39-8.31 (s, 1H), 8.19-8.09 (d, 1H), 8.03-7.98 (s, 1H), 7.54-7.46 (d, 1H), 5.13-4.86 (dm, 1H), 3.06-2.98 (s, 3H), 2.24-2.16 (m, 1H), 1.77-1.62 (m, 1H), 1.23-1.16 (m, 1H), 1.13-1.08 (t, 3H); LCMS (electrospray) m/z 433.2 (M + H ⁺).	B
16	 <p>(1S,2S)-N-(6-(7-(dimethylamino)-6-fluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.17 (s, 1H), 11.36-11.21 (m, 1H), 8.33-8.28 (m, 1H), 8.12 (s, 1H), 7.84 (s, 1H), 7.40-7.34 (m, 1H), 5.10-4.84 (m, 1H), 2.98 (d, J = 1.7 Hz, 6H), 2.24 (d, J = 3.4 Hz, 3H), 2.22-2.13 (m, 1H), 1.77-1.60 (m, 1H), 1.29-1.12 (m, 1H); LCMS (electrospray) m/z 412.1 (M + H ⁺).	B
17	 <p>(1S,2S)-N-(6-(7-ethoxy-6-fluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.54 (br s, 1H), 11.30 (s, 1H), 8.32 (s, 1H), 8.11 (d, J = 9.3 Hz, 1H), 7.89 (s, 1H), 7.39 (d, J = 9.3 Hz, 1H), 5.07-4.85 (m, 1H), 4.34 (br d, J = 7.0 Hz, 2H), 2.27 (d, J = 2.9 Hz, 3H), 2.18 (br s, 1H), 1.74-1.62 (m, 1H), 1.39 (t, J = 7.0 Hz, 3H), 1.26-1.16 (m, 1H); LCMS (electrospray) m/z 418.1 (M + H ⁺).	B

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
18	 <p>(1S,2S)-N-(6-(7-(dimethylamino)-6-fluoro-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.79 (br s, 1H), 11.32 (s, 1H), 8.29 (s, 1H), 8.12 (d, J = 9.3 Hz, 1H), 7.90 (s, 1H), 7.36 (d, J = 9.3 Hz, 1H), 5.09-4.78 (m, 1H), 3.04 (br s, 6H), 2.23-2.09 (m, 1H), 1.75-1.60 (m, 1H), 1.27-1.12 (m, 1H); LCMS (electrospray) m/z 466.1 (M + H ⁺).	B
19	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methylthio)-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.94-13.79 (m, 1H), 11.39-11.28 (m, 1H), 8.36 (s, 1H), 8.17 (d, J = 9.3 Hz, 1H), 8.14-8.08 (m, 1H), 7.55-7.49 (m, 1H), 5.08-4.85 (m, 1H), 2.60 (s, 3H), 2.25-2.14 (m, 1H), 1.76-1.62 (m, 1H), 1.28-1.14 (m, 1H); LCMS (electrospray) m/z 435.1 (M + H ⁺).	B
20	 <p>(1S,2S)-N-(6-(6,7-difluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.18 (s, 1H), 11.28 (s, 1H), 8.32 (s, 1H), 8.12-8.08 (m, 2H), 7.45-7.43 (m, 1H), 5.06-4.85 (m, 1H), 2.35 (s, 3H), 2.19-2.17 (m, 1H), 1.72-1.65 (m, 1H), 1.23-1.17 (m, 1H); LCMS (electrospray) m/z 419.0 (M + H ⁺).	B
21	 <p>(1S,2S)-N-(6-(5-chloro-7-(dimethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.53 (br s, 1H), 11.31 (s, 1H), 8.33 (s, 1H), 8.13 (br d, J = 9.4 Hz, 1H), 7.98 (br s, 1H), 7.47 (d, J = 9.3 Hz, 1H), 5.07-4.84 (m, 1H), 3.03 (br s, 6H), 2.23-2.14 (m, 1H), 1.74-1.62 (m, 1H), 1.25-1.14 (m, 1H); LCMS (electrospray) m/z 432.1 (M + H ⁺).	B

TABLE 1-continued





Ex #	Structure/Name	1H NMR/MS (M + 1)	Method
22	 <p data-bbox="371 684 683 747">(1S,2S)-N-(6-(5-chloro-6,7-difluoro-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 432 1089 600">¹H NMR (400 MHz, DMSO-d₆) δ 14.27 (br s, 1H), 11.33 (s, 1H), 8.36 (s, 1H), 8.19 (s, 1H), 8.18-8.15 (m, 1H), 7.50 (d, J = 9.3 Hz, 1H), 5.07-4.85 (m, 1H), 2.24-2.15 (m, 1H), 1.76-1.61 (m, 1H), 1.25-1.14 (m, 1H); LCMS (electrospray) m/z 406.8 (M + H⁺).</p>	B
23	 <p data-bbox="391 1062 664 1150">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methylthio)-1H-indazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 793 1089 982">¹H NMR (400 MHz, DMSO-d₆) δ 13.84 (br s, 1H), 11.34 (s, 1H), 8.36 (s, 1H), 8.17 (d, J = 9.2 Hz, 1H), 8.09 (s, 1H), 7.53 (d, J = 9.2 Hz, 1H), 5.05-4.86 (m, 1H), 2.59 (s, 3H), 2.24-2.15 (m, 1H), 1.71-1.61 (m, 1H), 1.20-1.17 (m, 1H); LCMS (electrospray) m/z 435.0 (M + H⁺).</p>	B
24	 <p data-bbox="380 1465 680 1528">(1S,2S)-2-fluoro-N-(6-(5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide. 2 TFA</p>	<p data-bbox="813 1197 1089 1407">¹H NMR (400 MHz, DMSO-d₆) δ 11.48-11.28 (m, 1H), 9.06 (s, 1H), 8.83 (d, J = 1.3 Hz, 1H), 8.36 (s, 1H), 7.91 (d, J = 0.9 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.33 (d, J = 8.6 Hz, 1H), 5.15-4.79 (m, 1H), 2.43-2.35 (m, 3H), 2.26-2.14 (m, 1H), 1.78-1.62 (m, 1H), 1.37-1.06 (m, 1H); LCMS (electrospray) m/z 351.1 (M + H⁺).</p>	C
25	 <p data-bbox="380 1843 683 1923">(1S,2S)-N-(6-(5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 2 TFA</p>	<p data-bbox="813 1575 1089 1743">¹H NMR (400 MHz, METHANOL-d₄) δ 8.99 (s, 1H), 8.71 (s, 1H), 8.42 (s, 1H), 7.83 (s, 1H), 7.36 (d, J = 10.4 Hz, 1H), 5.00-4.97 (m, 1H), 2.76-2.72 (m, 2H), 2.16-2.15 (m, 1H), 1.86-1.79 (m, 1H), 1.26-1.24 (m, 1H), 1.19-1.16 (m, 3H); LCMS (electrospray) m/z 383.1 (M + H⁺).</p>	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
26	 <p>(1S,2S)-N-(6-(7-(dimethylamino)-5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.15 (br s, 1H), 11.35 (s, 1H), 9.01 (d, J = 0.6 Hz, 1H), 8.76 (d, J = 1.3 Hz, 1H), 8.35 (s, 1H), 7.83 (s, 1H), 5.08-4.84 (m, 1H), 2.97 (br d, J = 1.1 Hz, 6H), 2.64 (br dd, J = 2.0, 7.4 Hz, 2H), 2.23- 2.15 (m, 1H), 1.74-1.63 (m, 1H), 1.24-1.17 (m, 1H), 1.12 (t, J = 7.3 Hz, 3H); LCMS (electrospray) m/z 426.4 (M + H) ⁺ .	D
27	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5,7-bis(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide. 2 HCl</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.39 (s, 1H), 9.04 (s, 1H), 8.89 (d, J = 1.5 Hz, 1H), 8.38 (s, 1H), 8.03 (s, 1H), 5.10-4.78 (m, 1H), 2.56 (s, 3H), 2.31-2.27 (m, 3H), 2.26-2.14 (m, 1H), 1.74-1.63 (m, 1H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 447.1 (M + H) ⁺ .	D
28	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide. 2 TFA</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.37 (s, 1H), 9.04-9.01 (m, 1H), 8.87 (d, J = 1.4 Hz, 1H), 8.36 (s, 1H), 7.94 (d, J = 0.9 Hz, 1H), 7.54 (dd, J = 0.8, 9.4 Hz, 1H), 5.12-4.82 (m, 1H), 2.26 (s, 3H), 2.22-2.13 (m, 1H), 1.75-1.61 (m, 1H), 1.19 (tdd, J = 6.3, 9.0, 12.4 Hz, 1H); LCMS (electrospray) m/z 401.1 (M + H) ⁺ .	D
29	 <p>(1S,2S)-N-(6-(5-ethyl-6,7-difluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.86 (br s, 1H), 11.38 (s, 1H), 9.03 (d, J = 0.6 Hz, 1H), 8.82 (d, J = 1.4 Hz, 1H), 8.36 (s, 1H), 8.02 (br s, 1H), 5.09-4.83 (m, 1H), 2.72 (br d, J = 9.0 Hz, 2H), 2.18 (br d, J = 7.1 Hz, 1H), 1.76-1.62 (m, 1H), 1.22 (br d, J = 9.0 Hz, 1H), 1.15 (t, J = 7.4 Hz, 3H); LCMS (electrospray) m/z 401.2 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
30	 <p>CF₃COOH</p> <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-methyl-7-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide. 1 TFA</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.47 (s, 1H), 9.13 (s, 1H), 8.92 (d, J = 1.2 Hz, 1H), 8.42 (s, 1H), 7.97 (d, J = 1.0 Hz, 1H), 7.44 (d, J = 10.0 Hz, 1H), 5.06-4.88 (m, 1H), 2.29 (d, J = 2.6 Hz, 3H), 2.25-2.14 (m, 1H), 1.77-1.63 (m, 1H), 1.29-1.16 (m, 1H); LCMS (electrospray) m/z 369.3 (M + H) ⁺ .	D
31	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.42 (br s, 1H), 11.37 (s, 1H), 9.05 (s, 1H), 8.87 (d, J = 1.3 Hz, 1H), 8.35 (s, 1H), 8.02 (s, 1H), 5.09-4.80 (m, 1H), 2.52 (br s, 3H), 2.29 (d, J = 3.0 Hz, 3H), 2.19 (br dd, J = 5.9, 7.8 Hz, 1H), 1.76-1.62 (m, 1H), 1.24-1.17 (m, 1H); LCMS (electrospray) m/z 415.3 (M + H) ⁺ .	D
32	 <p>CF₃COOH</p> <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 TFA</p>	¹ H NMR (400 MHz, DMSO-d ₆) 13.59 (s, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.03 (s, 1H), 8.39 (s, 1H), 8.10-8.06 (m, 1H), 7.74-7.70 (m, 1H), 5.06-4.87 (m, 1H), 2.23-2.18 (m, 1H), 1.24-1.20 (m, 1H); LCMS (electrospray) m/z 389.1 (M + H) ⁺ .	D
33	 <p>(1S,2S)-N-(6-(5-chloro-7-(dimethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.62-13.27 (m, 1H), 11.39 (s, 1H), 9.05 (s, 1H), 8.93 (d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.00 (br s, 1H), 5.12-4.80 (m, 1H), 3.01 (br s, 6H), 2.25-2.13 (m, 1H), 1.77-1.61 (m, 1H), 1.27-1.14 (m, 1H); LCMS (electrospray) m/z 432.3 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
34	 <p>(1S,2S)-N-(6-(5-chloro-7-ethoxy-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.90-13.65 (m, 1H), 11.39 (s, 1H), 9.05 (s, 1H), 8.97 (d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.06 (s, 1H), 5.06-4.86 (m, 1H), 4.44-4.39 (m, 2H), 2.22-2.15 (m, 1H), 1.74-1.64 (m, 1H), 1.41 (t, J = 7.0 Hz, 3H), 1.25-1.18 (m, 1H); LCMS (electrospray) m/z 433.2 (M + H ⁺).	D
35	 <p>(1S,2S)-N-(6-(6,7-difluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.87-13.72 (m, 1H), 11.45-11.28 (m, 1H), 9.04 (s, 1H), 8.91-8.78 (m, 1H), 8.45-8.32 (m, 1H), 8.11-7.90 (m, 1H), 5.10-4.82 (m, 1H), 2.71-2.57 (m, 1H), 2.33 (br d, J = 2.9 Hz, 3H), 2.24-2.14 (m, 1H), 1.75-1.64 (m, 1H), 1.26-1.16 (m, 1H); LCMS (electrospray) m/z 387.0 (M + H ⁺).	D
36	 <p>(1S,2S)-N-(6-(6,7-difluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.30-13.89 (m, 1H), 11.43-11.32 (m, 1H), 9.07-9.00 (m, 1H), 8.88 (d, J = 1.4 Hz, 1H), 8.43-8.36 (m, 1H), 8.10 (d, J = 3.1 Hz, 1H), 5.10-4.82 (m, 1H), 2.32 (s, 3H), 2.24-2.14 (m, 1H), 1.73-1.62 (m, 1H), 1.29-1.15 (m, 1H); LCMS (electrospray) m/z 419.1 (M + H ⁺).	D
37	 <p>(1S,2S)-N-(6-(5-ethyl-6-fluoro-7-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.05-11.89 (m, 1H), 9.95-9.84 (m, 1H), 9.49 (s, 1H), 8.97 (d, J = 1.5 Hz, 1H), 8.82 (s, 1H), 8.43 (s, 1H), 5.56-5.25 (m, 1H), 3.32 (dq, J = 2.3, 7.4 Hz, 2H), 3.08 (s, 3H), 2.41-2.30 (m, 2H), 1.81-1.70 (m, 5H); LCMS (electrospray) m/z 428.12 (M + H ⁺).	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
38	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.76 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.02 (d, J = 1.5 Hz, 1H), 8.40 (s, 1H), 8.13 (s, 1H), 5.08-4.86 (m, 1H), 2.59 (s, 3H), 2.21-2.17 (m, 1H), 1.74-1.64 (m, 1H), 1.24-1.18 (m, 1H); LCMS (electrospray) m/z 435 (M + H ⁺).	D
39	 <p>(1S,2S)-N-(6-(7-(dimethylamino)-6-fluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.41-13.32 (m, 1H), 11.36 (s, 1H), 9.01 (d, J = 0.8 Hz, 1H), 8.80 (d, J = 1.4 Hz, 1H), 8.36 (s, 1H), 7.95-7.86 (m, 1H), 5.07-4.85 (m, 1H), 2.99 (d, J = 1.5 Hz, 6H), 2.28 (s, 3H), 2.22-2.14 (m, 1H), 1.73-1.63 (m, 1H), 1.23-1.17 (m, 1H); LCMS (electrospray) m/z 444 (M + H ⁺).	D
40	 <p>(1S,2S)-N-(6-(7-(dimethylamino)-6-fluoro-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.39 (s, 1H), 8.98 (s, 1H), 8.81 (d, J = 1.4 Hz, 1H), 8.33 (s, 1H), 7.98 (s, 1H), 5.21-4.77 (m, 1H), 3.03 (d, J = 2.4 Hz, 6H), 2.24-2.13 (m, 1H), 1.76-1.60 (m, 1H), 1.20 (tdd, J = 6.1, 9.1, 12.4 Hz, 1H); LCMS (electrospray) m/z 466.1 (M + H ⁺).	D
41	 <p>(1S,2S)-N-(6-(5-chloro-7-(ethyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.53-13.35 (m, 1H), 11.42-11.37 (m, 1H), 9.09-9.04 (m, 1H), 8.99-8.94 (m, 1H), 8.41-8.36 (m, 1H), 8.07-7.97 (m, 1H), 5.10-4.85 (m, 1H), 3.30 (br d, J = 7.0 Hz, 2H), 3.03-2.97 (m, 3H), 2.24-2.14 (m, 1H), 1.76-1.62 (m, 1H), 1.19 (s, 1H), 1.12-1.07 (m, 3H); LCMS (electrospray) m/z 446.1 (M + H ⁺).	D

TABLE 1-continued





Ex #	Structure/Name	1H NMR/MS (M + 1)	Method
42	 <p data-bbox="370 688 683 779">(1S,2S)-N-(6-(7-(ethyl(methyl)amino)-6-fluoro-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 401 1084 611">¹H NMR (400 MHz, DMSO-d₆) δ 13.80-13.59 (m, 1H), 11.39 (s, 1H), 8.98 (s, 1H), 8.84 (d, J = 1.3 Hz, 1H), 8.33 (s, 1H), 8.00 (br s, 1H), 5.07-4.84 (m, 1H), 3.29 (br d, J = 7.3 Hz, 2H), 3.00 (d, J = 1.7 Hz, 3H), 2.24-2.14 (m, 1H), 1.75-1.64 (m, 1H), 1.24-1.17 (m, 1H), 1.09 (t, J = 7.1 Hz, 3H); LCMS (electrospray) m/z 480.3 (M + H⁺).</p>	D
43	 <p data-bbox="370 1052 683 1136">(1S,2S)-N-(6-(5-ethyl-7-(ethyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 814 1084 1066">¹H NMR (400 MHz, DMSO-d₆) δ 13.12 (s, 1H), 11.35 (s, 1H), 9.07-8.96 (m, 1H), 8.78 (d, J = 1.4 Hz, 1H), 8.39-8.28 (m, 1H), 7.83 (s, 1H), 5.10-4.81 (m, 1H), 3.21 (br s, 2H), 2.94 (d, J = 1.5 Hz, 3H), 2.64 (br d, J = 2.0 Hz, 1H), 2.21-2.16 (m, 1H), 1.73-1.64 (m, 1H), 1.20-1.17 (m, 1H), 1.12 (t, J = 7.5 Hz, 3H), 1.06 (t, J = 7.0 Hz, 3H); LCMS (electrospray) m/z 440.1 (M + H⁺).</p>	D
44	 <p data-bbox="370 1465 683 1528">(1S,2S)-N-(6-(7-ethoxy-5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 1171 1084 1402">¹H NMR (400 MHz, DMSO-d₆) δ 13.44 (br s, 1H), 11.36 (s, 1H), 9.02 (s, 1H), 8.79 (d, J = 1.4 Hz, 1H), 8.35 (s, 1H), 7.89 (s, 1H), 5.07-4.85 (m, 1H), 4.33 (q, J = 6.4 Hz, 2H), 2.70-2.63 (m, 2H), 2.19 (td, J = 6.9, 13.6 Hz, 1H), 1.74-1.63 (m, 1H), 1.39 (t, J = 7.0 Hz, 3H), 1.24-1.17 (m, 1H), 1.13 (t, J = 7.4 Hz, 3H); LCMS (electrospray) m/z 427.0 (M + H⁺).</p>	D
45	 <p data-bbox="370 1848 683 1932">(1S,2S)-N-(6-(7-(ethyl(methyl)amino)-6-fluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 1564 1084 1795">¹H NMR (400 MHz, DMSO-d₆) δ 13.11 (s, 1H), 11.36 (s, 1H), 9.03 (d, J = 0.6 Hz, 1H), 8.80 (d, J = 1.2 Hz, 1H), 8.33 (s, 1H), 7.90 (s, 1H), 5.11-4.82 (m, 1H), 3.26-3.17 (m, 2H), 2.94 (d, J = 1.6 Hz, 3H), 2.25 (d, J = 3.2 Hz, 3H), 2.22-2.15 (m, 1H), 1.77-1.61 (m, 1H), 1.25-1.14 (m, 1H), 1.06 (t, J = 7.1 Hz, 3H); LCMS (electrospray) m/z 425.18 (M + H⁺).</p>	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
46	 <p>(1S,2S)-N-(6-(7-(dimethylamino)-6-fluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.53-12.84 (m, 1H), 11.37 (s, 1H), 9.04 (s, 1H), 8.79 (d, J = 1.3 Hz, 1H), 8.35 (s, 1H), 7.91 (s, 1H), 5.14-4.78 (m, 2H), 2.97 (d, J = 2.2 Hz, 6H), 2.25 (d, J = 3.3 Hz, 3H), 2.20-2.16 (m, 1H), 1.76-1.62 (m, 1H), 1.25-1.15 (m, 1H); LCMS (electrospray) m/z 412.2 (M + H ⁺).	D
47	 <p>(1S,2S)-N-(6-(7-ethoxy-6-fluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.20-13.68 (m, 1H) 11.26-11.47 (m, 1H) 9.03 (s, 1H) 8.81 (d, J = 1.25 Hz, 1H) 8.34 (s, 1H) 7.96 (s, 1H) 4.84-5.09 (m, 1H) 4.33 (q, J = 7.00 Hz, 2 H) 2.28 (d, J = 3.00 Hz, 3 H) 2.14-2.23 (m, 1 H) 1.62-1.75 (m, 1 H) 1.39 (t, J = 7.00 Hz, 3 H) 1.20 (ddt, J = 12.37, 9.05, 6.24, 6.24 Hz, 1 H); LCMS (electrospray) m/z 413.1 (M + H ⁺).	D
48	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-methyl-7-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.62 (br s, 1H), 11.42 (s, 1H), 9.08 (s, 1H), 8.94 (d, J = 1.2 Hz, 1H), 8.37 (s, 1H), 8.19 (s, 1H), 5.09-4.83 (m, 1H), 2.32 (d, J = 2.9 Hz, 3H), 2.24-2.15 (m, 1H), 1.76-1.63 (m, 1H), 1.26-1.15 (m, 1H); LCMS (electrospray) m/z 437.2 (M + H ⁺).	D
49	 <p>(1S,2S)-N-(6-(5-bromo-6,7-difluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, METHANOL-d ₄) δ 9.04-8.94 (m, 1H), 8.82 (d, J = 1.5 Hz, 1H), 8.44-8.36 (m, 1H), 8.01 (br s, 1H), 5.00-4.95 (m, 1H), 2.17-2.11 (m, 1H), 1.89-1.76 (m, 1H), 1.30-1.21 (m, 1H); LCMS (electrospray) m/z 451.0 (M + H ⁺).	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
50	 <p>(1S,2S)-N-(6-(7-(ethyl(methyl)amino)-6-fluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.34 (br s, 1H), 8.04 (d, J = 1.3 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.68 (s, 1H), 7.49 (dd, J = 1.7, 8.3 Hz, 1H), 5.16-4.94 (m, 1H), 3.23 (q, J = 7.1 Hz, 2H), 2.95 (d, J = 2.0 Hz, 3H), 2.28-2.22 (m, 1H), 2.20 (s, 3H), 1.82-1.68 (m, 1H), 1.31 (tdd, J = 6.2, 8.9, 12.6 Hz, 1H), 1.07 (t, J = 7.1 Hz, 3H); LCMS (electrospray) m/z 474 (M + H ⁺).	D
51	 <p>(1S,2S)-N-(6-(5-chloro-6,7-difluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.33-13.89 (m, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.4 Hz, 1H), 8.39 (s, 1H), 8.20 (br s, 1H), 5.09-4.85 (m, 1H), 2.19 (td, J = 7.0, 14.2 Hz, 1H), 1.76-1.63 (m, 1H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 407.2 (M + H ⁺).	D
52	 <p>(1S,2S)-N-(6-(5-bromo-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 TFA</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.41 (s, 1H), 11.43-11.36 (m, 1H), 9.11-9.05 (m, 1H), 8.97 (d, J = 1.5 Hz, 1H), 8.38 (s, 1H), 7.99 (s, 1H), 7.69-7.65 (m, 1H), 5.21-4.77 (m, 1H), 2.25-2.13 (m, 1H), 1.74-1.63 (m, 1H), 1.25-1.18 (m, 1H); LCMS (electrospray) m/z 435.0 (M + H ⁺).	D
53	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.71 (br s, 1H), 11.40 (s, 1H), 9.01 (s, 1H), 8.91 (d, J = 1.3 Hz, 1H), 8.35 (s, 1H), 8.08 (s, 1H), 7.77 (d, J = 11.4 Hz, 1H), 5.18-4.81 (m, 1H), 2.25-2.15 (m, 1H), 1.78-1.54 (m, 1H), 1.28-1.09 (m, 1H); LCMS (electrospray) m/z 423.1 (M + H ⁺).	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
54	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(pyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.15 (s, 1H), 11.37 (s, 1H), 9.03 (s, 1H), 8.89 (s, 1H), 8.36 (s, 1H), 7.95 (s, 1H), 5.08-4.84 (m, 1H), 3.99-3.88 (m, 1H), 3.79-3.62 (m, 4H), 2.27-2.12 (m, 1H), 2.04-1.86 (m, 5H), 1.78-1.60 (m, 1H), 1.30-1.18 (m, 1H); LCMS (electrospray) m/z 458.1 (M + H) ⁺ .	D
55	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(piperidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.36 (s, 1H), 11.41 (s, 1H), 9.05 (d, J = 4.9 Hz, 1H), 8.95 (d, J = 1.1 Hz, 1H), 8.37 (d, J = 4.4 Hz, 1H), 8.01 (s, 1H), 5.14-4.81 (m, 1H), 3.30-3.08 (m, 4H), 2.26-2.10 (m, 1H), 1.79-1.71 (m, 4H), 1.71-1.55 (m, 3H), 1.26-1.15 (m, 1H); LCMS (electrospray) m/z 472.1 (M + H) ⁺ .	D
56	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((3-hydroxypropyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.14 (s, 1H), 11.38 (s, 1H), 9.02 (s, 1H), 8.89 (s, 1H), 8.35 (s, 1H), 7.94 (s, 1H), 5.64 (s, 1H), 5.11-4.80 (m, 1H), 4.68 (s, 1H), 3.63-3.48 (m, 4H), 2.25-2.10 (m, 1H), 1.78-1.63 (m, 3H), 1.32-1.10 (m, 1H); LCMS (electrospray) m/z 462.1 (M + H) ⁺ .	D
57	 <p>(1S,2S)-N-(6-(7-(azetidin-1-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.03 (s, 1H), 11.38 (s, 1H), 9.02 (s, 1H), 8.88 (s, 1H), 8.36 (s, 1H), 7.97 (s, 1H), 5.11-4.82 (m, 1H), 4.49-4.34 (s, 4H), 2.36 (q, J = 7.3 Hz, 2H), 2.25-2.13 (m, 1H), 1.76-1.63 (m, 1H), 1.22-1.13 (m, 1H); LCMS (electrospray) m/z 444.1 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
58	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.49 (s, 1H), 11.41 (s, 1H), 9.05 (s, 1H), 8.96 (s, 1H), 8.36 (s, 1H), 8.00 (s, 1H), 5.03-4.83 (m, 1H), 3.01 (br, 4H), 2.17-2.14 (m, 1H), 1.69-1.62 (m, 1H), 1.19-1.14 (m, 1H) 0.64-0.59 (m, 2H), 0.48-0.45 (m, 2H); LCMS (electrospray) m/z 458.1 (M + H) ⁺ .	D
59	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.50 (s, 1H), 11.38 (s, 1H), 9.01 (s, 1H), 8.87 (s, 1H), 8.34 (s, 1H), 7.92 (s, 1H), 5.03-4.83 (m, 1H), 3.15 (t, J = 4.6 Hz, 3H), 2.17-2.14 (m, 1H), 1.69-1.62 (m, 1H), 1.19-1.14 (m, 1H); LCMS (electrospray) m/z 418.1 (M + H) ⁺ .	D
60	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-thiomorpholino-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.43 (s, 1H), 11.41 (s, 1H), 9.06 (s, 1H), 8.96 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.03 (d, J = 1.6 Hz, 1H), 5.08-4.85 (m, 1H), 3.52-3.44 (s, 4H), 2.91-2.86 (m, 4H), 2.26-2.12 (m, 1H), 1.78-1.60 (m, 1H), 1.31-1.12 (m, 1H); LCMS (electrospray) m/z 490.1 (M + H) ⁺ .	D
61	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.18 (s, 1H), 11.37 (s, 1H), 9.03 (s, 1H), 8.91 (d, J = 1.6 Hz, 1H), 8.35 (s, 1H), 7.97 (s, 1H), 5.21 (d, J = 10.0 Hz, 1H), 5.06-4.86 (m, 1H), 4.05 (m, 1H), 2.20-2.15 (m, 1H), 1.72-1.65 (m, 1H), 1.28-1.16 (m, 7H); LCMS (electrospray) m/z 446.10 (M + H) ⁺ .	E

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
62	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(isopropyl(methyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.38 (s, 1H), 11.41 (s, 1H), 9.06 (s, 1H), 8.97 (d, J = 1.2 Hz, 1H), 8.37 (s, 1H), 8.01 (s, 1H), 5.06-4.86 (m, 1H), 3.56 (m, 1H), 2.90 (d, J = 2.8 Hz, 3H), 2.20-2.17 (m, 1H), 1.72-1.65 (m, 1H), 1.23-1.13 (m, 7H); LCMS (electrospray) m/z 460.10 (M + H) ⁺ .	E
63	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.46 (br s, 1H), 11.41 (s, 1H), 9.08 (dd, J = 0.7, 1.3 Hz, 1H), 9.00 (d, J = 1.5 Hz, 1H), 8.39 (s, 1H), 8.07 (s, 1H), 5.64 (s, 1H), 5.39 (s, 1H), 5.13-4.78 (m, 1H), 2.22 (s, 3H), 2.21-2.13 (m, 1H), 1.76-1.62 (m, 1H), 1.21 (tdd, J = 6.2, 9.0, 12.5 Hz, 1H); LCMS (electrospray) m/z 429.2 (M + H) ⁺ .	D
64	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.52 (br s, 1H), 11.40 (s, 1H), 9.14-8.87 (m, 2H), 8.38 (s, 1H), 8.04 (br s, 1H), 5.17-4.75 (m, 1H), 3.66-3.59 (m, 1H), 2.19 (td, J = 7.0, 13.6 Hz, 1H), 1.75-1.62 (m, 1H), 1.45 (br d, J = 7.0 Hz, 6H), 1.20 (tdd, J = 6.3, 8.9, 12.3 Hz, 1H); LCMS (electrospray) m/z 431.2 (M + H) ⁺ .	F
65	 <p>(1S,2S)-N-(6-(5-chloro-7-((1-cyanoethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.16 (s, 1H), 11.19 (s, 1H), 9.01 (s, 1H), 8.91 (s, 1H), 8.35 (s, 1H), 8.02 (s, 1H), 6.03 (s, 1H), 5.16-4.77 (m, 2H), 2.32-2.11 (m, 1H), 1.81-1.64 (m, 4H), 1.24-1.09 (m, 1H); LCMS (electrospray) m/z 457.10 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
66	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1H-pyrrol-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.61 (s, 1H), 11.29 (s, 1H), 9.08 (s, 1H), 9.02 (d, J = 1.1 Hz, 1H), 8.42 (s, 1H), 8.16 (s, 1H), 7.23 (s, 2H), 6.42 (s, 2H), 5.12-4.79 (m, 1H), 2.28-2.14 (m, 1H), 1.79-1.63 (m, 1H), 1.32-1.19 (m, 1H); LCMS (electrospray) m/z 454.10 (M + H) ⁺ .	D
67	 <p>(1S,2S)-N-(6-(7-amino-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.89 (s, 1H), 11.32 (s, 1H), 8.98 (s, 1H), 8.85 (d, J = 1.6 Hz, 1H), 8.31 (s, 1H), 7.89 (d, J = 1.6 Hz, 1H), 5.79 (s, 2H), 5.06-4.78 (m, 1H), 2.20-2.09 (m, 1H), 1.73-1.56 (m, 1H), 1.18-1.13 (m, 1H); LCMS (electrospray) m/z 404.05 (M + H) ⁺ .	D
68	 <p>(1S,2S)-N-(6-(5-chloro-7-((cyanomethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.18 (s, 1H), 11.25 (s, 1H), 9.02 (s, 1H), 8.92 (s, 1H), 8.35 (s, 1H), 8.02 (s, 1H), 6.66-6.18 (m, 1H), 5.08-4.48 (m, 3H), 2.27-2.14 (m, 1H), 1.79-1.61 (m, 1H), 1.20-1.09 (m, 1H); LCMS (electrospray) m/z 443.10 (M + H) ⁺ .	D
69	 <p>(1S,2S)-N-(6-(7-((2H-tetrazol-2-yl)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.93 (s, 1H), 11.42 (s, 1H), 9.09 (s, 1H), 9.06 (d, J = 1.1 Hz, 1H), 9.00 (s, 1H), 8.39 (s, 1H), 8.17 (s, 1H), 6.37 (s, 2H), 5.07-4.86 (m, 1H), 2.22-2.15 (m, 1H), 1.73-1.63 (m, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 471.10 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
70	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-hydroxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.87 (br s, 1H), 11.39 (s, 1H), 9.06 (s, 1H), 8.97 (s, 1H), 8.38 (s, 1H), 7.97 (s, 1H), 6.05 (br s, 1H), 5.13-4.82 (m, 1H), 2.19 (br s, 1H), 1.70 (s, 6H), 1.63 (br s, 1H), 1.21 (br s, 1H); LCMS (electrospray) m/z 447.0 (M + H) ⁺ .	D
71	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-vinyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.96 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.03 (d, J = 1.4 Hz, 1H), 8.39 (s, 1H), 8.15 (br s, 1H), 7.11 (dd, J = 11.8, 17.9 Hz, 1H), 6.39-6.22 (m, 1H), 5.84 (d, J = 11.9 Hz, 1H), 5.12-4.80 (m, 1H), 2.26-2.12 (m, 1H), 1.77-1.60 (m, 1H), 1.21 (tdd, J = 6.3, 9.1, 12.4 Hz, 1H); LCMS (electrospray) m/z 415.1 (M + H) ⁺ .	D
72	 <p>(1S,2S)-N-(6-(7-acetyl-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.68 (br s, 1H), 11.42 (s, 1H), 9.10 (s, 2H), 8.49-8.37 (m, 1H), 8.17 (s, 1H), 5.09-4.84 (m, 1H), 2.77 (d, J = 6.2 Hz, 3H), 2.25-2.12 (m, 1H), 1.74-1.62 (m, 1H), 1.27-1.21 (m, 1H); LCMS (electrospray) m/z 431.1 (M + H) ⁺ .	D
73	 <p>(1S,2S)-N-(6-(5-chloro-7-cyclopropyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.74 (s, 1H), 11.39 (s, 1H), 9.06 (s, 1H), 8.96 (d, J = 1.4 Hz, 1H), 8.38 (s, 1H), 8.04 (br s, 1H), 5.18-4.72 (m, 1H), 2.25-2.11 (m, 2H), 1.76-1.62 (m, 1H), 1.25-1.19 (m, 1H), 1.18-1.10 (m, 2H), 1.06-0.92 (m, 2H); LCMS (electrospray) m/z 429.3 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
74	 <p>(1S,2S)-N-(6-(5-chloro-7-(2-ethoxypropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.93 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.3 Hz, 1H), 8.39 (s, 1H), 8.01 (s, 1H), 5.11-4.84 (m, 1H), 3.29-3.03 (m, 2H), 2.20 (td, J = 7.0, 13.7 Hz, 1H), 1.75 (br d, J = 3.3 Hz, 6H), 1.68 (br dd, J = 3.8, 7.1 Hz, 1H), 1.25-1.18 (m, 1H), 1.14 (t, J = 7.0 Hz, 3H); LCMS (electrospray) m/z 475.1 (M + H) ⁺ .	D
75	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.98 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 8.99 (d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.00 (s, 1H), 5.13-4.81 (m, 1H), 3.18 (s, 3H), 2.19 (td, J = 7.0, 13.7 Hz, 1H), 1.72 (br d, J = 2.4 Hz, 6H), 1.69-1.60 (m, 1H), 1.24-1.18 (m, 1H); LCMS (electrospray) m/z 461.0 (M + H) ⁺ .	D
76	 <p>(1S,2S)-N-(6-(7-(tert-butylamino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.36 (s, 1H), 11.41 (s, 1H), 9.05 (s, 1H), 8.98 (d, J = 1.1 Hz, 1H), 8.36 (s, 1H), 7.98 (s, 1H), 5.07-4.86 (m, 1H), 4.49 (s, 1H), 2.21-2.15 (m, 1H), 1.72-1.63 (m, 1H), 1.28-1.18 (m, 10H); LCMS (electrospray) m/z 460.10 (M + H) ⁺ .	D
77	 <p>(1S,2S)-N-(6-(5-chloro-(cyclopropylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.98 (s, 1H), 11.36 (s, 1H), 9.02 (s, 1H), 8.89 (d, J = 1.1 Hz, 1H), 8.35 (s, 1H), 7.94 (s, 1H), 6.15 (s, 1H), 5.06-4.86 (m, 1H), 3.17-3.13 (m, 1H), 2.22-2.15 (m, 1H), 1.73-1.63 (m, 1H), 1.23-1.16 (m, 2H), 0.85-0.80 (m, 2H), 0.64-0.61 (m, 2H); LCMS (electrospray) m/z 444.10 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
78	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-fluoropyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.17 (s, 1H), 11.24 (s, 1H), 9.01 (s, 1H), 8.87 (s, 1H), 8.39 (s, 1H), 8.01 (brs, 1H), 5.63-5.34 (m, 1H), 5.09-4.74 (m, 1H), 4.51-3.46 (m, 4H), 2.38-2.03 (m, 3H), 1.85-1.59 (m, 1H), 1.31-1.09 (m, 1H); LCMS (electrospray) m/z 476.10 (M + H) ⁺ .	D
79	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-methyl-1H-pyrrol-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.41 (s, 1H), 11.43 (s, 1H), 9.10 (s, 1H), 9.06 (d, J = 1.1 Hz, 1H), 8.41 (s, 1H), 8.11 (d, J = 0.8 Hz, 1H), 7.09 (t, J = 1.9 Hz, 1H), 6.40 (q, J = 1.8 Hz, 1H), 6.27 (t, J = 3.0 Hz, 1H), 5.08-4.87 (m, 1H), 3.55 (d, J = 1.1 Hz, 3H), 2.23-2.16 (m, 1H), 1.74-1.64 (m, 1H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 469.1 (M + H) ⁺ .	D
80	 <p>(1S,2S)-N-(6-(7-(1-(2H-tetrazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.74 (s, 1H), 11.43 (s, 1H), 9.09 (s, 1H), 9.04 (d, J = 1.1 Hz, 2H), 8.39 (s, 1H), 8.16 (s, 1H), 6.79 (q, J = 7.1 Hz, 1H), 5.07-4.86 (m, 1H), 2.28 (d, J = 6.6 Hz, 3H), 2.22-2.15 (m, 1H), 1.72-1.65 (m, 1H), 1.23-1.18 (m, 2H); LCMS (electrospray) m/z 485.10 (M + H) ⁺ .	D
81	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(prop-1-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.11-13.58 (m, 1H), 11.41 (s, 1H), 9.12-8.97 (m, 2H), 8.47 (s, 1H), 8.39 (s, 1H), 8.12 (s, 1H), 5.13-4.80 (m, 1H), 2.26 (s, 3H), 2.22-2.16 (m, 1H), 1.74-1.63 (m, 1H), 1.24-1.16 (m, 1H); LCMS (electrospray) m/z 427.3 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
82	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.19 (s, 1H), 11.37 (s, 1H), 9.04 (d, J = 0.8 Hz, 1H), 8.82 (d, J = 1.4 Hz, 1H), 8.34 (s, 1H), 7.93 (s, 1H), 5.09-4.86 (m, 1H), 3.64-3.54 (m, 1H), 2.26 (d, J = 3.0 Hz, 3H), 2.21-2.15 (m, 1H), 1.77-1.63 (m, 1H), 1.44 (d, J = 7.0 Hz, 6H), 1.27-1.16 (m, 1H); LCMS (electrospray) m/z 411.2 (M + H) ⁺ .	D
83	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-methyl-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.13 (s, 1H), 11.38 (s, 1H), 9.05 (s, 1H), 8.84 (d, J = 1.4 Hz, 1H), 8.45 (s, 1H), 8.35 (s, 1H), 7.96 (s, 1H), 5.56 (s, 1H), 5.32 (s, 1H), 5.07-4.85 (m, 1H), 2.27 (d, J = 2.9 Hz, 3H), 2.23-2.17 (m, 4H), 1.77-1.62 (m, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 409.2 (M + H) ⁺ .	D
84	 <p>(1R,2S)-N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.39 (s, 1H), 11.47 (s, 1H), 9.03 (s, 1H), 8.90 (d, J = 1.2 Hz, 1H), 8.30 (s, 1H), 8.06-7.77 (m, 1H), 5.31-5.14 (m, 1H), 5.07-4.77 (m, 1H), 4.05 (br s, 1H), 1.67-1.48 (m, 1H), 1.33-1.26 (m, 1H), 1.23 (d, J = 6.2 Hz, 6H), 1.22-1.18 (m, 1H); LCMS (electrospray) m/z 446.2 (M + H) ⁺ .	D
85	 <p>(1S,2R)-N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.21 (br s, 1H), 11.47 (s, 1H), 9.03 (s, 1H), 8.90 (d, J = 1.3 Hz, 1H), 8.35-8.22 (m, 1H), 8.07-7.89 (m, 1H), 5.29-5.18 (m, 1H), 5.04-4.77 (m, 1H), 4.04 (br s, 1H), 1.65-1.48 (m, 1H), 1.33-1.26 (m, 1H), 1.26-1.19 (m, 7H); LCMS (electrospray) m/z 446.1 (M + H) ⁺ .	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
86	 <p>(1R,2R)-N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.20 (br s, 1H), 11.36 (s, 1H), 9.02 (s, 1H), 8.90 (d, J = 1.3 Hz, 1H), 8.35 (s, 1H), 7.96 (br s, 1H), 5.27-5.15 (m, 1H), 5.08-4.78 (m, 1H), 4.22-3.84 (m, 1H), 2.18 (td, J = 7.0, 13.9 Hz, 1H), 1.78-1.59 (m, 1H), 1.23 (d, J = 6.3 Hz, 6H), 1.22-1.16 (m, 1H); LCMS (electro- spray) m/z 446.1 (M + H) ⁺ .	D
87	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-propyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.62 (br s, 1H), 11.39 (s, 1H), 9.08-9.04 (m, 1H), 8.99 (d, J = 1.5 Hz, 1H), 8.48 (s, 1H), 8.38 (s, 1H), 8.03 (s, 1H), 5.09-4.83 (m, 1H), 2.98 (br t, J = 7.4 Hz, 2H), 2.24-2.14 (m, 1H), 1.75-1.65 (m, 3H), 1.20 (tdd, J = 6.3, 9.0, 12.4 Hz, 1H), 0.97 (t, J = 7.3 Hz, 3H); LCMS (electrospray) m/z 431.3 (M + H) ⁺ .	D
88	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-methyl-1H-pyrrol-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.95 (s, 1H), 11.42 (s, 1H), 9.10 (s, 1H), 9.08 (d, J = 1.5 Hz, 1H), 8.42 (s, 1H), 8.20 (s, 1H), 6.97 (s, 1H), 6.27 (t, J = 3.1 Hz, 1H), 6.13 (d, J = 1.1 Hz, 1H), 5.12-4.84 (m, 1H), 2.24-2.16 (m, 1H), 2.06 (s, 3H), 1.77-1.64 (m, 1H), 1.26-1.16 (m, 1H); LCMS (electrospray) m/z 468.2 (M + H) ⁺ .	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
89	 <p>1-(5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)-N,N-dimethyl-1H-pyrrole-3-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.15 (s, 1H), 11.42 (s, 1H), 9.10 (s, 1H), 9.05 (s, 1H), 8.43 (s, 1H), 8.32-8.24 (m, 1H), 7.66 (s, 1H), 7.29 (s, 1H), 6.69-6.64 (m, 1H), 5.12-4.80 (m, 1H), 3.23-2.89 (m, 6H), 2.20 (dt, J = 13.8, 6.8 Hz, 1H), 1.78-1.62 (m, 1H), 1.29-1.14 (m, 1H); LCMS (electrospray) m/z 525.1 (M + H) ⁺ .	D
90	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-hydroxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.57 (s, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 8.98 (d, J = 1.1 Hz, 1H), 8.39 (s, 1H), 8.04 (s, 1H), 5.08-4.86 (m, 2H), 3.88-3.75 (m, 2H), 3.65-3.56 (m, 1H), 2.20 (td, J = 7.0, 13.8 Hz, 1H), 1.76-1.64 (m, 1H), 1.40 (d, J = 7.1 Hz, 3H), 1.21 (tdd, J = 6.3, 9.0, 12.4 Hz, 1H); LCMS (electrospray) m/z 447.3 (M + H) ⁺ .	D
91	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.54 (s, 1H), 11.41 (s, 1H), 9.08 (d, J = 0.6 Hz, 1H), 9.00 (d, J = 1.5 Hz, 1H), 8.39 (s, 1H), 8.05 (br s, 1H), 5.09-4.85 (m, 1H), 3.85-3.75 (m, 2H), 3.73-3.66 (m, 1H), 3.25 (s, 3H), 2.25-2.16 (m, 1H), 1.76-1.64 (m, 1H), 1.41 (br d, J = 6.4 Hz, 3H), 1.21 (tdd, J = 6.3, 9.1, 12.4 Hz, 1H); LCMS (electrospray) m/z 461.3 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
92	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-fluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.72 (s, 1H), 11.39 (s, 1H), 9.07 (d, J = 0.6 Hz, 1H), 9.01 (d, J = 1.4 Hz, 1H), 8.38 (s, 1H), 8.05 (s, 1H), 5.13-4.84 (m, 2H), 3.38-3.35 (m, 2H), 2.23-2.14 (m, 1H), 1.74-1.63 (m, 1H), 1.46-1.37 (m, 3H), 1.24-1.15 (m, 1H); LCMS (electrospray) m/z 449.4 (M + H) ⁺ .	D
93	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(isobutylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.21 (br s, 1H), 11.37 (s, 1H), 9.02 (s, 1H), 8.89 (s, 1H), 8.46 (s, 1H), 8.35 (s, 1H), 7.96 (br s, 1H), 5.74 (br s, 1H), 5.09-4.83 (m, 1H), 2.18 (td, J = 7.1, 13.7 Hz, 1H), 1.94-1.77 (m, 1H), 1.77-1.60 (m, 1H), 1.32-1.11 (m, 1H), 0.94 (d, J = 6.6 Hz, 6H); LCMS (electrospray) m/z 460.2 (M + H) ⁺ .	D
94	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(propylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.16 (br s, 1H), 11.37 (s, 1H), 9.02 (s, 1H), 8.89 (s, 1H), 8.35 (s, 1H), 7.95 (br s, 1H), 5.65 (br s, 1H), 5.07-4.85 (m, 1H), 3.53-3.42 (m, 2H), 2.18 (td, J = 6.9, 13.9 Hz, 1H), 1.75-1.64 (m, 1H), 1.63-1.56 (m, 2H), 1.24-1.15 (m, 1H), 0.95 (t, J = 7.4 Hz, 3H); LCMS (electrospray) m/z 446.2 (M + H) ⁺ .	D
95	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((E)-prop-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.77 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.5 Hz, 1H), 8.42-8.34 (m, 1H), 8.09 (br s, 1H), 7.04-6.44 (m, 2H), 5.24-4.63 (m, 1H), 2.25-2.14 (m, 1H), 2.03 (br d, J = 4.5 Hz, 3H), 1.76-1.63 (m, 1H), 1.21 (tdd, J = 6.2, 9.1, 12.4 Hz, 1H); LCMS (electrospray) m/z 429.3 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
96	 <p>(1S,2S)-N-(6-(5-chloro-7-(ethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.41 (s, 1H), 11.37 (s, 1H), 9.02 (d, J = 0.6 Hz, 1H), 8.89 (d, J = 1.3 Hz, 1H), 8.49-8.44 (m, 1H), 8.35 (s, 1H), 8.02-7.92 (m, 1H), 5.80-5.58 (m, 1H), 5.08-4.84 (m, 1H), 3.65-3.53 (m, 2H), 2.26-2.13 (m, 1H), 1.79 (s, 1H), 1.25-1.20 (m, 3H), 1.20 (s, 1H); LCMS (electrospray) m/z 432.2 (M + H) ⁺ .	D
97	 <p>(3R,4S)-4-methyltetrahydrofuran-3-yl (6-(5-chloro-7-(dimethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)carbamate</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.47 (s, 1 H) 10.74 (s, 1 H) 9.01 (s, 1 H) 8.92 (s, 1 H) 8.18 (s, 1 H) 8.00 (br s, 1 H) 4.87-4.92 (m, 1 H) 3.91-4.04 (m, 2 H) 3.78 (br d, J = 9.76 Hz, 1 H) 3.02 (s, 6 H) 1.07 (d, J = 7.13 Hz, 3 H); LCMS (electrospray) m/z 474.1 (M + H) ⁺ .	D
98	 <p>(1S,2S)-N-(6-(5-chloro-7-(2-(dimethylamino)-2-oxoethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.45 (s, 1H), 11.39 (s, 1H), 9.08 (s, 1H), 9.02 (d, J = 1.5 Hz, 1H), 8.40 (s, 1H), 8.03 (s, 1H), 5.07-4.86 (m, 1H), 4.12 (s, 2H), 3.20 (s, 3H), 2.90 (s, 3H), 2.23-2.17 (m, 1H), 1.74-1.65 (m, 1H), 1.24-1.17 (m, 1H); LCMS (electrospray) m/z 474.2 (M + H) ⁺ .	D
99	 <p>(1S,2S)-N-(6-(5-chloro-7-((2-(dimethylamino)-2-oxoethyl)thio)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.80 (s, 1H), 11.43 (s, 1H), 9.08 (s, 1H), 9.03 (d, J = 1.3 Hz, 1H), 8.47 (s, 1H), 8.40 (s, 1H), 8.12 (s, 1H), 5.20-4.75 (m, 1H), 4.05 (s, 2H), 3.02 (s, 3H), 2.81 (s, 3H), 2.26-2.08 (m, 1H), 1.76-1.61 (m, 1H), 1.29-1.15 (m, 2H); LCMS (electrospray) m/z 506.0 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
100	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-fluoroethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.47 (s, 1H), 11.47-11.38 (m, 1H), 9.07 (s, 1H), 9.03-8.98 (m, 1H), 8.39 (s, 1H), 8.05 (s, 1H), 5.08-5.05 (m, 1H), 5.04-4.84 (m, 1H), 3.24 (s, 3H), 2.19 (td, J = 7.0, 13.8 Hz, 1H), 1.76-1.63 (m, 1H), 1.59 (d, J = 6.6 Hz, 3H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 447.1 (M + H) ⁺ .	D
101	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3,3,3-trifluoroprop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.83 (s, 1H), 11.42 (s, 1H), 9.11-9.03 (m, 2H), 8.48 (s, 1H), 8.40 (s, 1H), 8.15 (s, 1H), 6.65 (s, 1H), 6.34 (s, 1H), 5.11-4.84 (m, 1H), 2.25-2.14 (m, 1H), 1.78-1.62 (m, 1H), 1.27-1.13 (m, 1H); LCMS (electrospray) m/z 483.0 (M + H) ⁺ .	D
102	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.06 (s, 1H), 11.34 (s, 1H), 9.01 (s, 1H), 8.76 (d, J = 1.1 Hz, 1H), 8.48 (s, 1H), 8.32 (s, 1H), 7.88 (br s, 1H), 5.08-4.85 (m, 1H), 4.77 (br d, J = 8.8 Hz, 1H), 4.07-3.91 (m, 1H), 2.27 (d, J = 3.3 Hz, 3H), 2.23-2.15 (m, 1H), 1.75-1.63 (m, 1H), 1.25-1.24 (m, 1H), 1.21-1.20 (m, 7H); LCMS (electrospray) m/z 426.1 (M + H) ⁺ .	D
103	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((methylamino)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.41 (s, 1H), 9.07 (s, 1H), 9.00 (dd, J = 8.2, 1.1 Hz, 1H), 8.39 (s, 1H), 8.05-8.03 (m, 1H), 5.07-4.86 (m, 1H), 4.17-4.02 (m, 2H), 2.37-2.15 (m, 4H), 1.74-1.64 (m, 1H), 1.27-1.20 (m, 1H); LCMS (electrospray) m/z 432.10 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
104	 <p>(1S,2S)-N-(6-(5-chloro-7-((dimethylamino)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.44 (s, 1H), 11.41 (d, J = 11.5 Hz, 1H), 9.08 (s, 1H), 9.02 (d, J = 1.6 Hz, 1H), 8.39 (s, 1H), 8.04 (s, 1H), 5.07-4.86 (m, 1H), 3.79 (d, J = 24.2 Hz, 2H), 2.27-2.15 (m, 8H), 1.69 (dtd, J = 23.3, 6.9, 3.8 Hz, 1H), 1.25-1.09 (m, 1H); LCMS (electrospray) m/z 446.10 (M + H) ⁺ .	D
105	 <p>(1S,2S)-N-(6-(5-ethyl-6-fluoro-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.14 (s, 1H), 11.39 (s, 1H), 9.04 (s, 1H), 8.82 (d, J = 1.1 Hz, 1H), 8.36 (s, 1H), 7.94-7.85 (m, 1H), 5.57 (s, 1H), 5.32 (s, 1H), 5.10-4.83 (m, 1H), 2.77-2.60 (m, 2H), 2.28-2.11 (m, 4H), 1.82-1.58 (m, 1H), 1.22-1.16 (m, 1H), 1.13 (t, J = 7.6 Hz, 3H); LCMS (electrospray) m/z 423.15 (M + H) ⁺ .	D
106	 <p>(1S,2S)-N-(6-(5-ethyl-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.20 (s, 1H), 11.38 (s, 1H), 9.03 (d, J = 1.1 Hz, 1H), 8.80 (s, 1H), 8.35 (s, 1H), 7.87 (d, J = 6.0 Hz, 1H), 5.09-4.84 (m, 1H), 3.67-3.53 (m, 1H), 2.74-2.59 (m, 2H), 2.25-2.13 (m, 1H), 1.78-1.61 (m, 1H), 1.44 (d, J = 7.1 Hz, 6H), 1.22-1.15 (m, 1H), 1.15-1.06 (m, 3H); LCMS (electrospray) m/z 425.20 (M + H) ⁺ .	D
107	 <p>(1S,2S)-N-(6-(5-ethyl-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.93 (s, 1H), 11.35 (s, 1H), 8.99 (s, 1H), 8.73 (d, J = 1.6 Hz, 1H), 8.33 (s, 1H), 7.80 (d, J = 1.1 Hz, 1H), 5.12-4.83 (m, 1H), 4.74 (dd, J = 9.9, 2.2 Hz, 1H), 4.10-3.90 (m, 1H), 2.72-2.60 (m, 2H), 2.24-2.14 (m, 1H), 1.75-1.61 (m, 1H), 1.32-1.16 (m, 7H), 1.13 (t, J = 7.1 Hz, 3H); LCMS (electrospray) m/z 440.20 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
108	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-methyl-1H-pyrrol-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.31 (s, 1H), 11.42 (s, 1H), 9.08 (s, 1H), 9.01 (d, J = 1.6 Hz, 1H), 8.39 (s, 1H), 8.07 (s, 1H), 7.48 (s, 1H), 7.01-6.96 (m, 1H), 6.65 (d, J = 2.2 Hz, 1H), 5.07-4.86 (m, 1H), 3.76 (s, 3H), 2.23-2.16 (m, 1H), 1.74-1.64 (m, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 469.1 (M + H) ⁺ .	D
109	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1H-pyrrol-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.31 (s, 1H), 11.45 (s, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.01 (d, J = 1.1 Hz, 1H), 8.39 (s, 1H), 8.07 (d, J = 1.1 Hz, 1H), 7.50 (s, 1H), 7.02 (q, J = 2.4 Hz, 1H), 6.69 (s, 1H), 5.07-4.86 (m, 1H), 2.23-2.16 (m, 1H), 1.69 (dtd, J = 23.5, 6.9, 3.7 Hz, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 455.1 (M + H) ⁺ .	D
110	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-methyl-1H-pyrazol-5-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.54 (s, 1H), 11.44 (s, 1H), 9.12 (s, 1H), 9.09 (d, J = 1.6 Hz, 1H), 8.43 (d, J = 7.7 Hz, 1H), 8.18 (d, J = 1.1 Hz, 1H), 7.71-7.68 (m, 1H), 6.67 (d, J = 1.9 Hz, 1H), 5.08-4.88 (m, 1H), 3.77 (t, J = 11.0 Hz, 3H), 2.24-2.17 (m, 1H), 1.70 (dtd, J = 23.4, 6.8, 3.8 Hz, 1H), 1.26-1.18 (m, 2H); LCMS (electrospray) m/z 470.1 (M + H) ⁺ .	D
111	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((1-hydroxy-2-methylpropan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.82 (s, 1H), 11.39 (s, 1H), 9.04 (s, 1H), 8.96 (d, J = 1.3 Hz, 1H), 8.48 (br s, 1H), 8.36 (s, 1H), 7.98 (s, 1H), 5.54-4.80 (m, 2H), 4.61 (br s, 1H), 3.44-3.40 (m, 3H), 2.27-2.08 (m, 1H), 1.75-1.62 (m, 1H), 1.23 (s, 1H), 1.19 (s, 6H); LCMS (electrospray) m/z 476.2 (M + H) ⁺ .	D

TABLE 1-continued





Ex #	Structure/Name	1H NMR/MS (M + 1)	Method
112	 <p data-bbox="375 716 678 800">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-pivaloyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="816 401 1073 569">¹H NMR (400 MHz, DMSO-d₆) δ 13.79 (s, 1H), 11.42 (s, 1H), 9.12-9.05 (m, 2H), 8.41 (s, 1H), 8.18 (s, 1H), 5.10-4.85 (m, 2H), 2.23-2.16 (m, 1H), 1.75-1.64 (m, 1H), 1.30 (d, J = 1.1 Hz, 9H), 1.25 (br s, 1H); LCMS (electrospray) m/z 473.3 (M + H)⁺.</p>	D
113	 <p data-bbox="375 1115 678 1192">(1S,2S)-N-(6-(5-chloro-7-cyclopropoxy-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="816 835 1073 1024">¹H NMR (400 MHz, DMSO-d₆) δ 13.63 (s, 1H) 11.40 (s, 1H) 9.04-9.10 (m, 1 H) 8.98 (s, 1 H) 8.38 (s, 1 H) 8.07 (br s, 1 H) 4.81-5.12 (m, 1 H) 4.55 (m, 1 H) 2.15-2.25 (m, 1 H) 1.63-1.77 (m, 1 H) 1.15-1.28 (m, 1 H) 0.86-0.96 (m, 2 H) 0.69-0.78 (m, 2 H); LCMS (electrospray) m/z 445.0 (M + H)⁺.</p>	D
114	 <p data-bbox="375 1486 678 1570">4-methyltetrahydrofuran-3-yl (6-(5-chloro-6-fluoro-7-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)carbamate</p>	<p data-bbox="816 1228 1073 1444">¹H NMR (400 MHz, DMSO-d₆) δ 13.98 (s, 1H), 10.95-10.53 (m, 1H), 9.03 (s, 1H), 9.00 (d, J = 1.3 Hz, 1H), 8.50 (s, 1H), 8.19 (br s, 1H), 8.12 (s, 1H), 4.92-4.81 (m, 1H), 4.04-3.91 (m, 2H), 3.81-3.71 (m, 1H), 2.59 (s, 3H), 1.23 (br s, 1H), 1.07 (d, J = 7.1 Hz, 3H); LCMS (electrospray) m/z 477.3 (M + H)⁺.</p>	D
115	 <p data-bbox="375 1850 678 1934">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((2-hydroxyethyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="816 1606 1073 1864">¹H NMR (400 MHz, DMSO-d₆) δ 13.50 (s, 1H), 11.35 (s, 1H), 9.02 (d, J = 0.6 Hz, 1H), 8.88 (d, J = 1.3 Hz, 1H), 8.49 (s, 1H), 8.35 (s, 1H), 8.01-7.88 (m, 1H), 8.09-7.79 (m, 1H), 5.67 (br d, J = 2.6 Hz, 1H), 5.07-4.83 (m, 2H), 3.66-3.53 (m, 4H), 2.24-2.10 (m, 1H), 1.76-1.59 (m, 1H), 1.20 (tdd, J = 6.3, 9.0, 12.4 Hz, 1H), 1.05 (t, J = 7.0 Hz, 1H); LCMS (electrospray) m/z 448.3 (M + H)⁺.</p>	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
116	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyclobutylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.12 (s, 1H), 11.35 (s, 1H), 9.02 (s, 1H), 8.88 (d, J = 1.1 Hz, 1H), 8.35 (s, 1H), 7.94 (br s, 1H), 5.79 (br d, J = 6.4 Hz, 1H), 5.10-4.80 (m, 1H), 4.35 (br d, J = 5.3 Hz, 1H), 2.36-2.30 (m, 2H), 2.22-2.15 (m, 1H), 2.06-2.01 (m, 1H), 2.06-1.99 (m, 1H), 1.71 (td, J = 3.2, 6.8 Hz, 2H), 1.68-1.63 (m, 1H), 1.25-1.15 (m, 2H); LCMS (electrospray) m/z 458.1 (M + H) ⁺ .	D
117	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyclopentylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.53 (s, 1H), 11.36 (s, 1H), 9.02 (s, 1H), 8.89 (d, J = 1.2 Hz, 1H), 8.47 (s, 1H), 8.35 (s, 1H), 7.96 (br s, 1H), 5.52-5.39 (m, 1H), 5.11-4.82 (m, 1H), 4.43-4.23 (m, 1H), 2.23-2.15 (m, 1H), 1.94 (br d, J = 5.4 Hz, 2H), 1.82-1.69 (m, 3H), 1.63-1.55 (m, 4H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 472.1 (M + H) ⁺ .	D
118	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-methoxyethyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.31 (s, 1H), 11.36 (s, 1H), 9.02 (s, 1H), 8.89 (d, J = 1.3 Hz, 1H), 8.35 (s, 1H), 8.08-7.86 (m, 1H), 5.67 (br s, 1H), 5.15-4.76 (m, 1H), 3.74-3.61 (m, 2H), 3.58-3.49 (m, 2H), 3.29 (s, 3H), 2.25-2.11 (m, 1H), 1.80-1.54 (m, 1H), 1.26-1.12 (m, 1H); LCMS (electrospray) m/z 426.0 (M + H) ⁺ .	D
119	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1,1,1-trifluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.94 (s, 1H), 11.42 (s, 1H), 9.11-9.01 (m, 2H), 8.47 (s, 1H), 8.38 (s, 1H), 8.13 (s, 1H), 5.12-4.82 (m, 1H), 4.60-4.46 (m, 1H), 2.25-2.15 (m, 1H), 1.75 (br d, J = 6.7 Hz, 3H), 1.66 (dt, J = 3.8, 6.7 Hz, 1H), 1.29-1.13 (m, 1H); LCMS (electrospray) m/z 485.0 (M + H) ⁺ .	D

TABLE 1-continued





Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
120	 <p data-bbox="378 604 678 716">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((1-hydroxypropan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.65 (s, 1H), 11.38 (s, 1H), 9.03 (s, 1H), 8.90 (s, 1H), 8.44 (s, 1H), 8.36 (s, 1H), 7.98 (s, 1H), 7.23 (s, 1H), 6.96-6.84 (m, 1H), 5.31 (d, J = 7.9 Hz, 1H), 5.14-5.00 (m, 1H), 4.98-4.82 (m, 1H), 4.14-3.85 (m, 1H), 2.25-2.14 (m, 1H), 2.08 (s, 2H), 1.79-1.57 (m, 1H), 1.30-1.12 (m, 5H); LCMS (electrospray) m/z 462.0 (M + H) ⁺ .	D
121	 <p data-bbox="378 940 678 1031">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((1-methoxypropan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.20 (s, 1H), 11.36 (s, 1H), 9.02 (s, 1H), 8.90 (s, 1H), 8.35 (s, 1H), 7.95 (s, 1H), 5.32-5.20 (m, 1H), 5.05 (dd, J = 6.2, 3.7 Hz, 1H), 4.95-4.81 (m, 1H), 4.42-4.29 (m, 1H), 4.16-3.99 (m, 1H), 3.27 (m, 3H), 2.24-2.12 (m, 1H), 1.77-1.61 (m, 1H), 1.29-1.13 (m, 1H), 1.05 (t, J = 7.0 Hz, 1H); LCMS (electrospray) m/z 476.1 (M + H) ⁺ .	D
122	 <p data-bbox="378 1367 678 1486">(1S,2R,3S)-N-(6-(5-chloro-7-(dimethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-methyl-3-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.80 (s, 1H), 11.27 (s, 1H), 9.04 (s, 1H), 8.93 (d, J = 1.3 Hz, 1H), 8.37 (s, 1H), 8.00 (s, 1H), 7.54 (s, 1H), 7.29 (s, 1H), 3.80 (s, 3H), 3.02 (d, J = 2.3 Hz, 6H), 2.37-2.30 (m, 1H), 2.02 (t, J = 4.7 Hz, 1H), 1.62 (ddd, J = 9.1, 6.1, 4.8 Hz, 1H), 0.97 (d, J = 6.2 Hz, 3H); LCMS (electrospray) m/z 508.1 (M + H) ⁺ .	D
123	 <p data-bbox="378 1822 678 1932">(1S,2S,3S)-N-(6-(5-chloro-7-(dimethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-methyl-3-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.27 (s, 1H), 9.04 (d, J = 0.6 Hz, 1H), 8.92 (d, J = 1.4 Hz, 1H), 8.41 (s, 1H), 8.00 (s, 1H), 7.53 (s, 1H), 7.26 (s, 1H), 3.76 (s, 3H), 3.01 (d, J = 2.4 Hz, 7H), 2.23-2.16 (m, 1H), 2.12 (dd, J = 8.9, 4.8 Hz, 1H), 1.60 (dt, J = 8.9, 6.3 Hz, 1H), 1.25 (d, J = 6.1 Hz, 3H); LCMS (electrospray) m/z 508.1 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
124	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-fluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.19 (br s, 1H), 11.40 (s, 1H), 9.08 (s, 1H), 8.99 (s, 1H), 8.39 (s, 1H), 8.06 (s, 1H), 5.12-4.84 (m, 1H), 2.28-2.15 (m, 1H), 1.96-1.86 (m, 6H), 1.74-1.64 (m, 1H), 1.26-1.16 (m, 1H); LCMS (electrospray) m/z 449.2 (M + H) ⁺ .	D
125	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyclopent-1-en-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.37 (s, 1H), 11.42 (s, 1H), 9.08 (s, 1H), 9.01 (d, J = 1.1 Hz, 1H), 8.39 (s, 1H), 8.08 (d, J = 1.1 Hz, 1H), 6.42 (t, J = 1.9 Hz, 1H), 5.07-4.86 (m, 1H), 3.01-2.85 (m, 2H), 2.67-2.59 (m, 2H), 2.33-2.16 (m, 1H), 2.09-1.91 (m, 2H), 1.69 (dtd, J = 23.4, 3.6 Hz, 1H), 1.31-1.16 (m, 1H); LCMS (electrospray) m/z 455.10 (M + H) ⁺ .	D
126	 <p>(1S,2S)-N-(6-(7-((1H-imidazol-1-yl)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.97 (s, 1H), 11.42 (s, 1H), 9.07 (s, 1H), 9.02 (d, J = 1.1 Hz, 1H), 8.38 (s, 1H), 8.15 (s, 1H), 7.86 (s, 1H), 7.22 (s, 1H), 6.89 (t, 1H), 5.62 (s, 2H), 5.07-4.86 (m, 1H), 2.22-2.15 (m, 1H), 1.72-1.63 (m, 1H), 1.22-1.16 (m, 1H); LCMS (electrospray) m/z 469.10 (M + H) ⁺ .	D
127	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(morpholinoamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.73 (s, 1H), 11.39 (s, 1H), 9.03 (s, 1H), 8.94-8.86 (m, 1H), 8.37 (d, J = 7.7 Hz, 1H), 7.96 (d, J = 2.2 Hz, 1H), 7.32 (d, J = 2.7 Hz, 1H), 5.13-4.81 (m, 1H), 3.95-3.72 (m, 4H), 2.97-2.78 (m, 4H), 2.24-2.13 (m, 1H), 1.75-1.62 (m, 1H), 1.27-1.18 (m, 1H); LCMS (electrospray) m/z 489.10 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
128	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-isopropoxy-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.26 (s, 1H), 11.39 (s, 1H), 9.05 (s, 1H), 8.98 (d, J = 1.4 Hz, 1H), 8.37 (s, 1H), 8.06 (s, 1H), 5.09-4.83 (m, 1H), 4.75 (br s, 1H), 4.68-4.66 (m, 1H), 2.24-2.13 (m, 1H), 2.07 (s, 1H), 1.79-1.59 (m, 1H), 1.37 (d, J = 6.1 Hz, 6H), 1.26-1.12 (m, 1H); LCMS (electrospray) m/z 447.0 (M + H) ⁺ .	D
129	 <p>(1S,2S)-N-(6-(7-(2-amino-2-oxoethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.55 (s, 1H), 11.39 (s, 1H), 9.08 (s, 1H), 9.00 (d, J = 1.4 Hz, 1H), 8.40 (s, 1H), 8.04 (s, 1H), 7.66 (br s, 1H), 7.15 (br s, 1H), 5.07-4.84 (m, 1H), 3.89 (s, 2H), 2.24-2.15 (m, 1H), 1.78-1.63 (m, 1H), 1.24-1.17 (m, 1H); LCMS (electrospray) m/z 446.2 (M + H) ⁺ .	D
130	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-methylprop-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.41 (s, 1H), 11.41 (s, 1H), 9.08 (d, J = 0.6 Hz, 1H), 9.03 (d, J = 1.5 Hz, 1H), 8.39 (s, 1H), 8.06 (s, 1H), 6.31 (d, J = 1.1 Hz, 1H), 5.12-4.80 (m, 1H), 2.24-2.15 (m, 1H), 2.04 (s, 3H), 1.74-1.65 (m, 4H), 1.26-1.17 (m, 2H); LCMS (electrospray) m/z 443.2 (M + H) ⁺ .	D
131	 <p>(1S,2S)-N-(6-(5-chloro-7-((2,2-difluoroethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.09 (s, 1H), 11.36 (s, 1H), 9.02 (s, 1H), 8.90 (d, J = 1.2 Hz, 1H), 8.45 (br s, 1H), 8.35 (s, 1H), 8.05 (br s, 1H), 6.44-6.00 (m, 2H), 5.10-4.80 (m, 1H), 4.12-3.79 (m, 2H), 2.23-2.14 (m, 1H), 2.07 (s, 1H), 1.75-1.62 (m, 1H), 1.26-1.14 (m, 1H); LCMS (electrospray) m/z 468.3 (M + H) ⁺ .	D

TABLE 1-continued





Ex #	Structure/Name	1H NMR/MS (M + 1)	Method
132	 <p data-bbox="370 705 683 789">(1S,2S)-N-(6-(7-(2-bromo-2-fluorocyclopropyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 411 1081 621">¹H NMR (400 MHz, DMSO-d₆) δ 14.08 (s, 1H), 11.44-11.37 (m, 1H), 9.34 (s, 1H), 9.07 (s, 1H), 9.05-9.00 (m, 1H), 8.73 (s, 1H), 8.45 (s, 1H), 8.41-8.36 (m, 1H), 8.13 (s, 1H), 7.59 (d, J = 12.1 Hz, 1H), 5.16-4.71 (m, 1H), 2.27-2.04 (m, 3H), 1.77-1.60 (m, 1H), 1.29-1.13 (m, 2H); LCMS (electrospray) m/z 527.3 (M + H)⁺.</p>	D
133	 <p data-bbox="370 1073 683 1157">(1S,2S)-N-(6-(7-(allylamino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 831 1081 1062">¹H NMR (400 MHz, DMSO-d₆) δ 13.01 (s, 1 H) 11.24-11.49 (m, 1 H) 8.97-9.11 (m, 1 H) 8.90 (s, 1 H) 8.29-8.43 (m, 1 H) 7.90-8.06 (m, 1 H) 5.88-6.08 (m, 2 H) 5.21 (br d, J = 16.94 Hz, 1 H) 5.07-5.14 (m, 1 H) 4.85-5.07 (m, 1 H) 4.02-4.28 (m, 2 H) 2.11-2.26 (m, 1 H) 1.54-1.79 (m, 1 H) 1.13-1.25 (m, 1 H); LCMS (electrospray) m/z 444.0 (M + H)⁺.</p>	D
134	 <p data-bbox="370 1472 683 1556">(1S,2S)-N-(6-(5-chloro-7-cyclopentyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 1199 1081 1409">¹H NMR (400 MHz, DMSO-d₆) δ 13.48 (s, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 8.99 (dd, J = 13.5, 1.4 Hz, 1H), 8.45-8.38 (m, 1H), 8.07-8.03 (m, 1H), 5.07-4.86 (m, 1H), 3.62 (t, J = 8.2 Hz, 1H), 2.23-2.16 (m, 1H), 2.07-1.91 (m, 6H), 1.73-1.64 (m, 3H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 455.10 (M + H)⁺.</p>	D
135	 <p data-bbox="370 1850 683 1932">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((4-methylpiperazin-1-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="813 1598 1081 1808">¹H MR (400 MHz, DMSO-d₆) δ 12.54 (s, 1H), 11.38 (s, 1H), 9.02 (s, 1H), 8.89 (d, J = 1.6 Hz, 1H), 8.35 (s, 1H), 7.94 (d, J = 1.6 Hz, 1H), 7.20 (s, 1H), 5.09-4.83 (m, 1H), 2.88 (m, 4H), 2.57 (m, 4H), 2.29-2.11 (m, 4H), 1.76-1.60 (m, 1H), 1.21-1.18 (m, 1H); LCMS (electrospray) m/z 502.20 (M + H)⁺.</p>	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
136	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((2-fluoroethyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.49 (s, 1H), 11.36 (s, 1H), 9.02 (d, J = 0.6 Hz, 1H), 8.90 (d, J = 1.4 Hz, 1H), 8.35 (s, 1H), 8.01 (br d, J = 2.5 Hz, 1H), 5.93 (br s, 1H), 5.10-4.80 (m, 1H), 4.68 (t, J = 4.8 Hz, 1H), 4.56 (t, J = 4.9 Hz, 1H), 4.01-3.66 (m, 2H), 2.25-2.13 (m, 1H), 1.75-1.61 (m, 1H), 1.20 (tdd, J = 6.3, 9.1, 12.4 Hz, 1H); LCMS (electrospray) m/z 450.3 (M + H) ⁺ .	D
137	 <p>(1S,2S)-N-(6-(5-chloro-7-((1,3-dihydroxy-2-methylpropan-2-yl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.98 (s, 1H), 11.38 (s, 1H), 9.11-9.02 (m, 1H), 8.96 (d, J = 1.5 Hz, 1H), 8.36 (s, 1H), 8.00 (br s, 1H), 5.28-4.82 (m, 3H), 4.51 (br s, 1H), 3.56-3.45 (m, 4H), 2.19 (td, J = 7.0, 13.9 Hz, 1H), 1.74-1.62 (m, 1H), 1.30-1.11 (m, 2H), 1.06 (br s, 3H); LCMS (electrospray) m/z 492.2 (M + H) ⁺ .	D
138	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.34 (br s, 1H), 11.36 (s, 1H), 9.28 (d, J = 1.3 Hz, 1H), 9.05 (s, 1H), 8.66 (s, 1H), 8.38 (s, 1H), 7.51 (d, J = 12.7 Hz, 1H), 5.08-4.85 (m, 1H), 3.64-3.53 (m, 1H), 2.19 (td, J = 6.9, 13.8 Hz, 1H), 1.77-1.63 (m, 1H), 1.43 (d, J = 7.0 Hz, 6H), 1.23-1.14 (m, 1H); LCMS (electrospray) m/z 397.2 (M + H) ⁺ .	D
139	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((1-methyl-1H-pyrazol-5-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.19 (br s, 1H), 11.39 (s, 1H), 9.06 (s, 1H), 8.99 (d, J = 1.1 Hz, 1H), 8.49 (s, 1H), 8.38 (s, 1H), 8.28 (br s, 1H), 8.04 (br s, 1H), 7.24 (d, J = 1.9 Hz, 1H), 5.45 (br s, 1H), 5.10-4.83 (m, 1H), 3.79 (s, 3H), 2.19 (td, J = 6.9, 13.8 Hz, 1H), 1.77-1.61 (m, 1H), 1.21 (tdd, J = 6.2, 9.0, 12.3 Hz, 1H); LCMS (electrospray) m/z 484.1 (M + H) ⁺ .	D

TABLE 1-continued




Ex #	Structure/Name	1H NMR/MS (M + 1)	Method
140	 <p data-bbox="375 789 683 869">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((4-hydroxybutan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.30 (s, 1H), 11.35 (s, 1H), 9.02 (s, 1H), 8.90 (s, 1H), 8.35 (s, 1H), 7.95 (s, 1H), 5.26-5.18 (m, 1H), 5.10-5.00 (m, 1H), 4.90-4.84 (m, 1H), 4.78-4.71 (m, 1H), 4.04-3.94 (m, 1H), 3.66-3.54 (m, 3H), 2.23-2.15 (m, 2H), 1.85-1.75 (m, 1H), 1.73-1.63 (m, 3H), 1.22 (d, J = 6.2 Hz, 4H); LCMS (electrospray) m/z 476.1 (M + H) ⁺ .	D
141	 <p data-bbox="375 1192 683 1297">(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide. 2 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.33-13.64 (m, 1H), 11.33-11.43 (m, 1H), 9.00-9.07 (m, 1H), 8.81-8.89 (m, 1H), 8.43-8.43 (m, 1H), 8.40-8.46 (m, 3H), 8.34-8.38 (m, 1H), 7.91-8.00 (m, 1H), 5.13-4.97 (m, 1H), 4.91-4.84 (m, 1H), 2.28-2.25 (m, 3H), 2.23-2.14 (m, 1H), 1.77-1.62 (m, 1H), 1.50-1.41 (m, 6H), 1.12-1.00 (m, 1H); LCMS (electrospray) m/z 443.1 (M + H) ⁺ .	D
142	 <p data-bbox="375 1839 683 1927">(1S,2R,3S)-N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-methyl-3-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.80 (s, 1H), 11.28 (s, 1H), 9.06 (s, 1H), 8.97 (d, J = 1.3 Hz, 1H), 8.37 (s, 1H), 8.04 (s, 1H), 7.54 (s, 1H), 7.29 (s, 1H), 3.80 (s, 3H), 2.33 (dd, J = 5.3, 3.8 Hz, 1H), 2.02 (t, J = 4.7 Hz, 1H), 1.72-1.57 (m, 2H), 1.45 (d, J = 6.9 Hz, 7H), 0.97 (d, J = 6.2 Hz, 3H); LCMS (electrospray) m/z 507.1 (M + H) ⁺ .	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
143	 <p>(1S,2S,3S)-N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-methyl-3-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.74 (s, 1H), 11.26 (s, 1H), 9.05 (s, 1H), 8.95 (d, J = 1.3 Hz, 1H), 8.40 (s, 1H), 8.04 (s, 1H), 7.53 (s, 1H), 7.26 (s, 1H), 3.76 (s, 3H), 3.67-3.62 (m, 1H), 2.23-2.16 (m, 1H), 2.13 (dd, J = 8.9, 4.7 Hz, 1H), 1.60 (dt, J = 8.9, 6.2 Hz, 1H), 1.45 (d, J = 7.0 Hz, 6H), 1.30-1.21 (m, 3H); LCMS (electrospray) m/z 507.1 (M + H) ⁺ .	D
144	 <p>(1S,2S)-N-(6-(7-((1H-pyrrol-1-yl)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.86 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.02 (d, J = 1.6 Hz, 1H), 8.37 (s, 1H), 8.11 (s, 1H), 6.93 (t, 2H), 6.00 (t, J = 2.2 Hz, 2H), 5.51 (s, 2H), 5.05-4.88 (m, 1H), 2.21-2.21 (m, 1H), 1.72-1.66 (m, 1H), 1.18-1.18 (m, 1H); LCMS (electrospray) m/z 468.10 (M + H) ⁺ .	D
145	 <p>(1S,2S)-N-(6-(7-((1H-pyrazol-1-yl)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.79 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.02 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.09 (s, 1H), 7.97 (s, 1H), 7.43 (s, 1H), 6.26 (t, J = 1.9 Hz, 1H), 5.75 (s, 2H), 5.05-4.86 (m, 1H), 2.21-2.15 (m, 1H), 1.74-1.65 (m, 1H), 1.21-1.16 (m, 1H); LCMS (electrospray) m/z 469.10 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
146	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2,2,2-trifluoro-1-hydroxyethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.31 (s, 1H), 11.37 (s, 1H), 9.07-8.99 (m, 2H), 8.34 (s, 1H), 8.04 (s, 1H), 7.60 (d, J = 5.5 Hz, 1H), 5.75 (q, J = 6.6 Hz, 1H), 5.03-4.82 (m, 1H), 2.19-2.12 (m, 1H), 1.70-1.62 (m, 1H), 1.18-1.13 (m, 1H); LCMS (electrospray) m/z 488.1 (M + H) ⁺ .	D
147	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(pyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.87 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.1 Hz, 1H), 8.38 (s, 1H), 8.12 (s, 1H), 6.83 (t, J = 2.5 Hz, 1H), 6.64 (s, 1H), 5.81 (t, 1H), 5.41 (s, 2H), 5.06-4.86 (m, 1H), 2.22-2.15 (m, 1H), 1.94 (s, 3H), 1.74-1.64 (m, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 482.10 (M + H) ⁺ .	D
148	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-hydroxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.12 (s, 1H), 11.35 (s, 1H), 9.02 (s, 1H), 8.88 (s, 1H), 8.36 (s, 1H), 7.95 (s, 1H), 5.11-4.80 (m, 2H), 4.50-4.32 (m, 1H), 4.23-3.88 (m, 2H), 3.81-3.61 (m, 1H), 3.53-3.40 (m, 1H), 2.26-2.13 (m, 1H), 2.13-1.95 (m, 1H), 1.95-1.82 (m, 1H), 1.78-1.58 (m, 1H), 1.22-1.11 (m, 1H); LCMS (electrospray) m/z 474.10 (M + H) ⁺ .	D
149	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((R)-3-hydroxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.12 (s, 1H), 11.36 (s, 1H), 9.03 (s, 1H), 8.87 (d, J = 11.5 Hz, 1H), 8.36 (s, 1H), 7.95 (s, 1H), 5.12-4.82 (m, 2H), 4.50-4.34 (m, 1H), 4.22-3.88 (m, 2H), 3.82-3.63 (m, 1H), 3.53-3.38 (m, 1H), 2.26-2.12 (m, 1H), 2.12-1.96 (m, 1H), 1.95-1.82 (m, 1H), 1.77-1.60 (m, 1H), 1.28-1.13 (m, 1H); LCMS (electrospray) m/z 474.10 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
150	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-oxocyclopent-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.58 (s, 1H), 11.41 (s, 1H), 9.10-9.06 (m, 2H), 8.41 (d, J = 6.0 Hz, 1H), 8.19 (d, J = 1.1 Hz, 1H), 6.79 (s, 1H), 5.07-4.86 (m, 1H), 3.40-3.36 (m, 1H), 3.29-3.27 (m, 2H), 2.58-2.56 (m, 2H), 2.23-2.16 (m, 1H), 1.75-1.64 (m, 1H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 469.10 (M + H) ⁺ .	D
151	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-methoxyethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.47 (s, 1H), 11.47-11.38 (m, 1H), 9.07 (s, 1H), 9.03-8.98 (m, 1H), 8.39 (s, 1H), 8.05 (s, 1H), 5.08-5.05 (m, 1H), 5.04-4.84 (m, 1H), 3.24 (s, 3H), 2.19 (td, J = 7.0, 13.8 Hz, 1H), 1.76-1.63 (m, 1H), 1.59 (d, J = 6.6 Hz, 3H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 447.1 (M + H) ⁺ .	D
152	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(N-methylacetamido)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.44 (s, 1H), 11.40 (s, 1H), 9.36-9.30 (m, 1H), 9.07 (s, 1H), 8.99 (s, 1H), 8.69 (br s, 1H), 8.38 (s, 1H), 8.25-8.16 (m, 1H), 8.08 (s, 1H), 7.60-7.51 (m, 1H), 6.17-5.99 (m, 1H), 5.80-5.68 (m, 1H), 5.11-4.84 (m, 1H), 3.03 (s, 2H), 2.96 (s, 1H), 2.78 (br s, 1H), 2.21-2.17 (m, 1H), 2.04 (s, 3H), 1.86-1.72 (m, 1H), 1.68 (br d, J = 7.3 Hz, 3H), 1.24-1.16 (m, 1H); LCMS (electrospray) m/z 488.1 (M + H) ⁺ .	D
153	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyclopropyl(hydroxy)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.26 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.01 (s, 1H), 5.88 (d, J = 1.5 Hz, 1H), 5.08-5.01 (m, 1H), 4.92-4.84 (m, 1H), 4.62 (d, J = 6.0 Hz, 1H), 2.25-2.12 (m, 1H), 1.78-1.60 (m, 1H), 1.52-1.39 (m, 1H), 1.35-1.13 (m, 3H), 0.65-0.52 (m, 2H), 0.48-0.28 (m, 2H); LCMS (electrospray) m/z 459.1 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
154	 <p>(1S,2S)-N-(6-(7-((1H-pyrazol-5-yl)amino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.26 (br s, 1H), 12.14 (br s, 1H), 11.37 (s, 1H), 9.05 (s, 1H), 8.96 (d, J = 1.5 Hz, 1H), 8.44 (br s, 1H), 8.38 (s, 1H), 8.00 (s, 1H), 7.63 (s, 1H), 5.90 (s, 1H), 5.08-4.84 (m, 1H), 2.19 (td, J = 6.9, 13.8 Hz, 1H), 1.75-1.63 (m, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 470.1 (M + H) ⁺ .	D
155	 <p>(1R,2R)-N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.51 (br s, 1H), 11.39 (s, 1H), 9.06 (s, 1H), 8.97 (d, J = 1.4 Hz, 1H), 8.38 (s, 1H), 8.04 (s, 1H), 5.08-4.85 (m, 1H), 3.69-3.56 (m, 1H), 2.19 (td, J = 7.0, 13.9 Hz, 1H), 1.75-1.63 (m, 1H), 1.46 (d, J = 7.0 Hz, 6H), 1.26-1.16 (m, 1H); LCMS (electrospray) m/z 431.1 (M + H) ⁺ .	D
156	 <p>(1S,2R)-N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.52 (br s, 1H), 11.51 (br s, 1H), 9.08 (s, 1H), 8.98 (d, J = 1.3 Hz, 1H), 8.34 (s, 1H), 8.04 (s, 1H), 5.06-4.82 (m, 1H), 3.63 (td, J = 7.0, 14.0 Hz, 1H), 1.64-1.51 (m, 1H), 1.46 (d, J = 7.0 Hz, 6H), 1.28 (td, J = 6.4, 13.1 Hz, 1H); LCMS (electrospray) m/z 431.2 (M + H) ⁺ .	D
157	 <p>(1R,2S)-N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.52 (br s, 1H), 11.50 (s, 1H), 9.07 (d, J = 0.6 Hz, 1H), 8.97 (d, J = 1.3 Hz, 1H), 8.33 (s, 1H), 8.04 (br s, 1H), 5.05-4.82 (m, 1H), 3.63 (td, J = 7.0, 14.2 Hz, 1H), 1.65-1.51 (m, 1H), 1.45 (d, J = 7.1 Hz, 6H), 1.34-1.21 (m, 1H); LCMS (electrospray) m/z 431.2 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
158	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methyl(1H-pyrazol-5-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.47 (br s, 1H), 11.88 (br s, 1H), 11.40 (s, 1H), 9.08 (s, 1H), 9.02 (d, J = 1.2 Hz, 1H), 8.40 (s, 1H), 8.07 (s, 1H), 7.52 (s, 1H), 5.51 (s, 1H), 5.09-4.85 (m, 1H), 3.38 (s, 3H), 2.20 (td, J = 6.9, 14.0 Hz, 1H), 1.76-1.63 (m, 1H), 1.27-1.15 (m, 1H); LCMS (electrospray) m/z 484.1 (M + H) ⁺ .	D
159	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methyl(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.55 (br s, 1H), 11.40 (s, 1H), 9.08 (d, J = 0.6 Hz, 1H), 9.01 (d, J = 1.5 Hz, 1H), 8.40 (s, 1H), 8.08 (s, 1H), 7.68 (d, J = 2.4 Hz, 1H), 5.59 (d, J = 2.3 Hz, 1H), 5.21 (s, 2H), 5.08-4.86 (m, 1H), 3.55-3.47 (m, 2H), 3.37 (br s, 3H), 2.19 (td, J = 6.9, 13.9 Hz, 1H), 1.76-1.63 (m, 1H), 1.26-1.16 (m, 1H), 0.85-0.80 (m, 2H), -0.03 (s, 9H); LCMS (electrospray) m/z 614.2 (M + H) ⁺ .	D
160	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methyl(1-methyl-1H-pyrazol-5-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.76 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.3 Hz, 1H), 8.39 (s, 1H), 8.13 (d, J = 1.2 Hz, 1H), 7.34 (d, J = 2.0 Hz, 1H), 6.07 (d, J = 2.0 Hz, 1H), 5.07-4.85 (m, 1H), 3.32 (br s, 3H), 3.28 (s, 3H), 2.19 (td, J = 7.0, 13.9 Hz, 1H), 1.76-1.62 (m, 1H), 1.21 (tdd, J = 6.2, 9.0, 12.4 Hz, 1H); LCMS (electrospray) m/z 498.2 (M + H) ⁺ .	D
161	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-isobutyryl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.78 (s, 1H), 11.43 (s, 1H), 9.10 (s, 2H), 8.43 (s, 1H), 8.18 (s, 1H), 5.14-4.79 (m, 1H), 3.62-3.53 (m, 1H), 2.20 (td, J = 6.9, 13.8 Hz, 1H), 1.79-1.67 (m, 1H), 1.24 (d, J = 6.6 Hz, 7H); LCMS (electrospray) m/z 459.3 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
162	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-hydroxy-2-methylpropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.18 (br s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.5 Hz, 1H), 8.39 (s, 1H), 8.00 (s, 1H), 5.87 (br d, J = 3.1 Hz, 1H), 5.10- 4.83 (m, 2H), 2.24-2.14 (m, 2H), 1.75-1.63 (m, 1H), 1.21 (tdd, J = 6.1, 9.0, 12.3 Hz, 1H), 1.08 (d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.7 Hz, 3H); LCMS (electrospray) m/z 461.4 (M + H) ⁺	D
163	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(((1S,3R)-3-hydroxycyclopentyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.21 (s, 1H), 11.35 (s, 1H), 9.02 (s, 1H), 8.89 (d, J = 1.1 Hz, 1H), 8.34 (d, J = 6.0 Hz, 1H), 7.95 (s, 1H), 5.56-5.39 (m, 1H), 5.09-4.84 (m, 1H), 4.84-4.73 (m, 1H), 4.48- 4.13 (m, 2H), 2.26-2.11 (m, 2H), 2.03-1.87 (m, 1H), 1.81-1.53 (m, 5H), 1.22-1.13 (m, 1H); LCMS (electrospray) m/z 488.10 (M + H) ⁺	D
164	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((2-methyl-1H-imidazol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.92 (s, 1H), 11.41 (d, J = 7.4 Hz, 1H), 9.08 (d, J = 7.1 Hz, 1H), 9.04-9.02 (m, 1H), 8.39 (d, J = 7.1 Hz, 1H), 8.18 (d, J = 6.6 Hz, 1H), 7.03 (d, J = 7.1 Hz, 1H), 6.73-6.71 (m, 1H), 5.53 (d, J = 7.1 Hz, 2H), 5.06-4.88 (m, 1H), 2.39 (d, J = 7.7 Hz, 3H), 2.22-2.17 (m, 1H), 1.72-1.67 (m, 1H), 1.19- 1.19 (m, 1H); LCMS (electro- spray) m/z 483.10 (M + H) ⁺	D
165	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-hydroxycyclopentyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.91 (s, 1H), 11.39 (s, 1H), 9.07 (d, J = 1.6 Hz, 1H), 8.97 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 7.98 (d, J = 1.1 Hz, 1H), 5.76 (d, J = 5.5 Hz, 1H), 5.07-4.86 (m, 1H), 2.20 (d, J = 17.6 Hz, 6H), 1.95 (dd, J = 18.7, 13.2 Hz, 3H), 1.83 (d, J = 6.6 Hz, 2H), 1.74-1.64 (m, 1H), 1.25-1.19 (m, 1H); LCMS (electrospray) m/z 473.10 (M + H) ⁺	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
166	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.39 (s, 1 H) 11.32-11.50 (m, 1 H) 8.96-9.04 (m, 1 H) 8.81-8.91 (m, 1 H) 8.27-8.40 (m, 1 H) 7.95-8.11 (m, 1 H) 5.11-4.83 (m, 1 H) 3.59-3.74 (m, 1 H) 2.14-2.26 (m, 1 H) 1.63-1.77 (m, 1 H) 1.40-1.52 (m, 6 H) 1.13-1.26 (m, 1 H); LCMS (electrospray) m/z 465.1 (M + H) ⁺ .	D
167	 <p>(1S,2S)-N-(6-(5-chloro-7-(1,1-difluoropropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.40 (s, 1H), 9.07 (s, 1H), 9.02 (d, J = 1.5 Hz, 1H), 9.04-8.99 (m, 1H), 8.39 (s, 1H), 8.12 (s, 1H), 6.70-6.31 (m, 1H), 5.12-4.82 (m, 1H), 4.10-3.89 (m, 1H), 2.25-2.15 (m, 2H), 1.78-1.62 (m, 1H), 1.56 (d, J = 7.2 Hz, 3H), 1.29-1.13 (m, 2H); LCMS (electrospray) m/z 467.0 (M + H) ⁺ .	D
168	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-isobutyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.60 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.04 (s, 1H), 5.06-4.86 (m, 1H), 2.89 (br d, J = 7.2 Hz, 2H), 2.23-2.17 (m, 1H), 2.09-2.03 (m, 1H), 1.74-1.66 (m, 1H), 1.26-1.18 (m, 1H), 0.97 (d, J = 6.5 Hz, 6H); LCMS (electrospray) m/z 445.4 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
169	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-methoxy-2-methylpropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.35 (s, 1H), 11.40 (br s, 1H), 9.07 (s, 1H), 9.03 (d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.04 (s, 1H), 5.07-4.85 (m, 1H), 4.55 (d, J = 7.9 Hz, 1H), 3.21 (s, 3H), 2.27 (br dd, J = 7.0, 13.5 Hz, 1H), 2.22-2.16 (m, 1H), 1.74-1.63 (m, 1H), 1.24- 1.16 (m, 1H), 1.10 (d, J = 6.6 Hz, 3H), 0.79 (d, J = 6.7 Hz, 3H); LCMS (electrospray) m/z 475.4 (M + H) ⁺ .	D
170	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-fluoro-2-methylpropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.60 (s, 1H), 11.42 (s, 1H), 9.09 (d, J = 0.6 Hz, 1H), 9.05 (d, J = 1.5 Hz, 1H), 8.46 (s, 1H), 8.40 (s, 1H), 8.11 (s, 1H), 5.92-5.76 (m, 1H), 5.58 (br d, J = 8.2 Hz, 1H), 5.10-4.85 (m, 1H), 2.21 (br dd, J = 2.1, 6.8 Hz, 1H), 1.64-1.60 (m, 1H), 1.56-1.47 (m, 1H), 1.18 (br d, J = 6.5 Hz, 3H), 0.85 (d, J = 6.7 Hz, 3H); LCMS (electro- spray) m/z 463.4 (M + H) ⁺ .	D
171	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((4-methoxybutan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.10 (s, 1H), 11.35 (s, 1H), 9.02 (s, 1H), 8.90 (s, 1H), 8.35 (s, 1H), 7.98-7.92 (m, 1H), 5.29-4.84, (m, 2H), 3.47 (t, J = 6.17 Hz, 2H), 3.21 (s, 4H), 2.23-2.14 (m, 2H), 1.22 (d, J = 6.2 Hz, 4H), 1.16 (d, J = 6.9 Hz, 2H); LCMS (electro- spray) m/z 443.1 (M + H) ⁺ .	D
172	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-fluorocyclobutyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.70 (s, 1H), 11.35 (s, 1H), 9.02 (s, 1H), 8.89 (s, 1H), 8.35 (s, 1H), 7.96 (br s, 1H), 5.46-5.20 (m, 1H), 5.11-4.82 (m, 1H), 4.75-4.44 (m, 1H), 2.70-2.64 (m, 1H), 2.35-2.30 (m, 1H), 2.26-2.10 (m, 2H), 1.74- 1.60 (m, 1H), 1.20 (br dd, J = 9.0, 12.2 Hz, 2H); LCMS (electrospray) m/z 476.2 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
173	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyclopropyl(methoxy)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.40 (s, 1H), 11.44 (s, 1H), 9.08 (s, 1H), 9.03 (s, 1H), 8.38 (s, 1H), 8.05 (s, 1H), 5.10-4.82 (m, 1H), 4.26 (d, J = 8.6 Hz, 1H), 3.26 (s, 3H), 2.19 (dt, J = 13.2, 6.6 Hz, 1H), 1.79-1.62 (m, 1H), 1.35-1.11 (m, 2H), 0.77-0.53 (m, 2H), 0.51-0.21 (m, 2H); LCMS (electrospray) m/z 473.0 (M + H) ⁺ .	D
174	 <p>(1S,2S)-N-(6-(7-((E)-but-2-en-2-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.40 (s, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.03 (s, 1H), 8.39 (s, 1H), 8.06 (s, 1H), 6.95-5.97 (m, 1H), 5.07-4.86 (m, 1H), 2.18-2.21 (m, 1H), 2.14 (m, 3H), 1.63-1.73 (m, 1H), 1.47 (m, 3H), 1.23 (m, 1H); LCMS (electrospray) m/z 443.1 (M + H) ⁺ .	D
175	 <p>(1S,2S)-N-(6-(7-(but-3-en-2-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.52 (s, 1H), 11.41 (s, 1H), 9.07 (s, 1H), 9.00 (s, 1H), 8.39 (s, 1H), 8.06 (s, 1H), 6.20-6.28 (m, 1H), 5.19 (d, J = 8 Hz, 1H), 5.12 (d, J = 8 Hz, 1H), 4.87-5.07 (m, 1H), 4.20-4.24 (m, 1H), 2.16-2.23 (m, 1H), 1.53-1.74 (m, 1H), 1.56 (d, J = 6.8 Hz, 3H), 0.84-0.88 (m, 1H); LCMS (electrospray) m/z 443.1 (M + H) ⁺ .	D
176	 <p>(1S,2S)-N-(6-(7-(sec-butylamino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.03-13.28 (m, 1H), 11.26-11.42 (m, 1H), 8.99-9.07 (m, 1H), 8.86-8.95 (m, 1H), 8.32-8.39 (m, 1H), 7.89-8.04 (m, 1H), 5.25-4.85 (m, 1H), 3.73-3.99 (m, 1H), 2.14-2.24 (m, 1H), 1.59-1.74 (m, 2H), 1.45-1.56 (m, 1H), 1.16-1.25 (m, 4H), 0.91-0.98 (m, 3H); LCMS (electrospray) m/z 460.2 (M + H) ⁺ .	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
177	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((2-methyl-1H-pyrrol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.65 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.03 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.12 (s, 1H), 6.68 (s, 1H), 5.87 (t, J = 3.0 Hz, 1H), 5.77 (s, 1H), 5.44 (s, 2H), 5.05-4.88 (m, 1H), 2.23-2.17 (m, 4H), 1.71-1.66 (m, 1H), 1.17-1.15 (m, 1H); LCMS (electrospray) m/z 482.10 (M + H) ⁺ .	D
178	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((4-methyl-1H-imidazol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.92 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.14 (s, 1H), 7.72 (s, 1H), 6.87 (s, 1H), 5.53 (s, 2H), 5.07-4.86 (m, 1H), 2.22-2.15 (m, 1H), 2.02 (s, 3H), 1.74-1.64 (m, 1H), 1.22-1.16 (m, 1H); LCMS (electrospray) m/z 483.10 (M + H) ⁺ .	D
179	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((4-methyl-1H-pyrazol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.79 (s, 1H), 11.40 (s, 1H), 9.07 (d, J = 1.6 Hz, 1H), 9.02 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.10 (s, 1H), 7.65 (s, 1H), 7.22 (s, 1H), 5.64 (s, 2H), 5.07-4.86 (m, 1H), 2.23-2.15 (m, 1H), 1.98 (s, 3H), 1.74-1.64 (m, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 483.10 (M + H) ⁺ .	D

TABLE 1-continued





Ex #	Structure/Name	1H NMR/MS (M + 1)	Method
180	 <p data-bbox="370 678 686 764">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((S)-3-hydroxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="816 432 1081 663">¹H NMR (400 MHz, DMSO-d₆) δ 13.12 (s, 1H), 11.36 (s, 1H), 9.02 (s, 1H), 8.88 (s, 1H), 8.36 (s, 1H), 7.95 (s, 1H), 5.11-4.82 (m, 2H), 4.51-4.33 (m, 1H), 4.22-3.89 (m, 2H), 3.70 (s, 1H), 3.54-3.41 (m, 1H), 2.26-2.14 (m, 1H), 2.11-1.95 (m, 1H), 1.95-1.81 (m, 1H), 1.77-1.62 (m, 1H), 1.25-1.18 (m, 1H); LCMS (electrospray) m/z 474.10 (M + H)⁺.</p>	D
181	 <p data-bbox="370 1073 686 1163">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-hydroxycyclopentyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="816 806 1081 1058">¹H NMR (400 MHz, DMSO-d₆) δ 13.47 (s, 1H), 11.37 (d, J = 13.2 Hz, 1H), 9.07 (s, 1H), 8.97 (d, J = 1.6 Hz, 1H), 8.39 (d, J = 4.4 Hz, 1H), 8.02 (d, J = 1.1 Hz, 1H), 7.53 (d, J = 12.6 Hz, 0H), 5.07-4.86 (m, 2H), 4.53-4.42 (m, 1H), 3.48 (dd, J = 18.7, 8.2 Hz, 1H), 2.33-2.01 (m, 4H), 1.99-1.61 (m, 6H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 473.10 (M + H)⁺.</p>	D
182	 <p data-bbox="370 1451 686 1541">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((tetrahydrofuran-3-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="816 1205 1081 1457">¹H NMR (400 MHz, DMSO-d₆) δ 13.12 (s, 1H), 11.32 (s, 1H), 8.98 (d, J = 8.2 Hz, 1H), 8.85 (d, J = 10.4 Hz, 1H), 8.31 (d, J = 6.6 Hz, 1H), 7.92 (s, 1H), 5.60 (d, J = 8.2 Hz, 1H), 5.01-4.82 (m, 1H), 4.53 (s, 1H), 3.93-3.81 (m, 2H), 3.75-3.67 (m, 2H), 2.24-2.11 (m, 2H), 1.88 (d, J = 9.3 Hz, 1H), 1.67-1.61 (m, 1H), 1.19-1.12 (m, 1H); LCMS (electrospray) m/z 475.1 (M + H)⁺.</p>	D
183	 <p data-bbox="370 1850 686 1927">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-methoxycyclopentyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="816 1583 1081 1814">¹H NMR (400 MHz, DMSO-d₆) δ 13.58 (s, 1H), 11.38 (d, J = 13.2 Hz, 1H), 9.07 (s, 1H), 8.99 (t, J = 1.9 Hz, 1H), 8.38 (s, 1H), 8.04 (d, J = 1.1 Hz, 1H), 5.07-4.86 (m, 1H), 4.20 (q, J = 5.9 Hz, 1H), 3.61 (q, J = 8.2 Hz, 1H), 3.15-3.10 (m, 3H), 2.23-2.08 (m, 4H), 1.97-1.64 (m, 6H), 1.27-1.16 (m, 2H); LCMS (electrospray) m/z 486.90 (M + H)⁺.</p>	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
184	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(((1S,3S)-3-hydroxycyclopentyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.12 (s, 1H), 11.35 (s, 1H), 9.02 (s, 1H), 8.90 (s, 1H), 8.34 (s, 1H), 7.94 (s, 1H), 5.34 (d, J = 7.7 Hz, 1H), 5.09-4.82 (m, 1H), 4.55 (d, J = 3.3 Hz, 1H), 4.50-4.38 (m, 1H), 4.35-4.21 (m, 1H), 2.26-2.08 (m, 2H), 2.04-1.87 (m, 2H), 1.81-1.62 (m, 2H), 1.59-1.44 (m, 2H), 1.22-1.11 (m, 1H); LCMS (electrospray) m/z 488.10 (M + H) ⁺ .	D
185	 <p>(1S,2S)-N-(6-(5-chloro-7-(1-(dimethylamino)-1-oxopropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.24 (br s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.00 (s, 1H), 8.38 (s, 1H), 8.08 (br s, 1H), 5.09-4.84 (m, 1H), 4.61 (q, J = 7.0 Hz, 1H), 2.87 (d, J = 3.2 Hz, 6H), 2.24-2.12 (m, 1H), 1.77-1.62 (m, 1H), 1.50 (d, J = 7.0 Hz, 3H), 1.27-1.15 (m, 1H); LCMS (electrospray) m/z 488.1 (M + H) ⁺ .	D
186	 <p>(1S,2S)-N-(6-(7-((R)-1-(2H-tetrazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.04-13.53 (m, 1H), 11.40 (s, 1H), 9.08 (s, 1H), 9.06-8.96 (m, 2H), 8.39 (s, 1H), 8.18 (br s, 1H), 6.79 (q, J = 6.9 Hz, 1H), 5.11-4.77 (m, 1H), 2.28 (br d, J = 6.9 Hz, 3H), 2.22-2.16 (m, 1H), 1.77-1.63 (m, 1H), 1.22-1.15 (m, 1H); LCMS (electrospray) m/z 485.1 (M + H) ⁺ .	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
187	 <p>(1S,2S)-N-(6-(7-((S)-1-(2H-tetrazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.72 (s, 1H), 11.40 (s, 1H), 9.08 (s, 1H), 9.03 (s, 2H), 8.39 (s, 1H), 8.15 (s, 1H), 6.79 (br d, J = 7.0 Hz, 1H), 5.08-4.81 (m, 1H), 2.28 (br d, J = 7.0 Hz, 3H), 2.22-2.16 (m, 1H), 1.73-1.64 (m, 1H), 1.23-1.17 (m, 1H); LCMS (electrospray) m/z 485.1 (M + H) ⁺ .	D
188	 <p>(1S,2S)-N-(6-(5-chloro-7-(1-cyanoethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.11-13.66 (m, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.03 (s, 1H), 8.52 (br s, 1H), 8.40 (s, 1H), 8.18 (s, 1H), 5.11-4.79 (m, 2H), 2.20 (br s, 1H), 1.75 (br d, J = 7.1 Hz, 3H), 1.67 (br s, 1H), 1.27-1.16 (m, 1H); LCMS (electrospray) m/z 442.3 (M + H) ⁺ .	D
189	 <p>(1S,2S)-N-(6-(7-((R)-1-(1H-tetrazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.97-13.60 (m, 1H), 11.40 (s, 1H), 9.76 (s, 1H), 9.08 (s, 1H), 9.02 (d, J = 1.1 Hz, 1H), 8.39 (s, 1H), 8.20 (br s, 1H), 6.60 (q, J = 7.0 Hz, 1H), 5.08-4.83 (m, 1H), 2.24-2.13 (m, 4H), 1.74-1.63 (m, 1H), 1.23-1.16 (m, 1H); LCMS (electrospray) m/z 485.4 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
190	 <p>(1S,2S)-N-(6-(7-((S)-1-(1H-tetrazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.15-13.21 (m, 1H), 11.40 (s, 1H), 11.33 (s, 1H), 9.76 (s, 1H), 9.38 (s, 1H), 9.08 (s, 1H), 9.02 (s, 1H), 8.98 (s, 1H), 8.45 (s, 1H), 8.39 (s, 1H), 8.20 (br s, 1H), 7.77 (s, 1H), 6.59 (q, J = 7.0 Hz, 1H), 5.08-4.83 (m, 1H), 2.19-2.14 (m, 1H), 1.74-1.63 (m, 1H), 1.19 (br d, J = 8.5 Hz, 1H); LCMS (electrospray) m/z 485.4 (M + H) ⁺ .	D
191	 <p>(1S,2S)-N-(6-(7-(1-amino-1-oxopropan-2-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.29 (br s, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 8.98 (s, 1H), 8.40 (s, 1H), 8.05 (br s, 1H), 7.48 (br s, 1H), 7.16 (br s, 1H), 5.11-4.78 (m, 1H), 4.25 (br d, J = 7.4 Hz, 1H), 2.19 (br s, 1H), 1.78-1.62 (m, 1H), 1.55 (br d, J = 7.0 Hz, 3H), 1.20 (br s, 1H); LCMS (electrospray) m/z 460.0 (M + H) ⁺ .	D
192	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((1-fluoropropan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.68 (s, 1H), 11.52 (s, 1H), 9.07 (s, 1H), 8.96 (s, 1H), 8.51 (s, 1H), 8.39 (s, 1H), 6.08 (s, 1H), 5.33-4.68 (m, 1H), 4.13-3.96 (m, 1H), 2.23-2.14 (m, 1H), 1.77-1.60 (m, 1H), 1.42-1.28 (m, 1H), 1.26-1.10 (m, 1H); LCMS (electrospray) m/z 464.1 (M + H) ⁺ .	D
193	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(furan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.70 (br s, 1H), 11.41 (s, 1H), 9.09 (s, 1H), 9.06 (s, 1H), 8.40 (s, 1H), 8.16 (s, 1H), 7.97 (s, 1H), 7.18 (br s, 1H), 6.82 (dd, J = 1.7, 3.2 Hz, 1H), 5.10-4.82 (m, 1H), 2.20 (td, J = 6.8, 13.7 Hz, 1H), 1.76-1.63 (m, 1H), 1.21 (tdd, J = 6.2, 8.9, 12.3 Hz, 1H); LCMS (electrospray) m/z 455.0 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
194	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(isoxazol-4-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.60 (br s, 1H), 11.41 (s, 1H), 9.70 (s, 1H), 9.29 (s, 1H), 9.09 (s, 1H), 9.06 (d, J = 0.9 Hz, 1H), 8.41 (s, 1H), 8.28 (br s, 1H), 5.08-4.85 (m, 1H), 2.25-2.12 (m, 1H), 1.75- 1.62 (m, 1H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 455.9 (M + H) ⁺ .	D
195	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(((1R,3S)-3-hydroxycyclopentyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.21 (s, 1H), 11.35 (s, 1H), 9.02 (s, 1H), 8.89 (d, J = 0.8 Hz, 1H), 8.35 (s, 1H), 7.95 (s, 1H), 5.46 (d, J = 6.6 Hz, 1H), 5.11-4.83 (m, 1H), 4.77 (d, J = 2.7 Hz, 1H), 4.29 (s, 1H), 4.19 (s, 1H), 2.28- 2.09 (m, 2H), 2.04-1.87 (m, 1H), 1.83-1.51 (m, 6H), 1.22-1.11 (m, 1H); LCMS (electrospray) m/z 488.70 (M + H) ⁺ .	D
196	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-hydroxycyclopent-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.32 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.02 (d, J = 1.6 Hz, 1H), 8.39 (s, 1H), 8.09 (s, 1H), 6.37 (s, 1H), 4.99 (d, J = 52.2 Hz, 2H), 2.92-3.09 (1H), 2.67 (s, 1H), 2.33 (s, 1H), 2.19 (d, J = 4.9 Hz, 1H), 1.72 (s, 3H), 1.35-1.18 (m, 4H); LCMS (electrospray) m/z 471.1 (M + H) ⁺ .	D
197	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((3-methyl-1H-pyrazol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.61-13.94 (1H), 11.39 (s, 1H), 9.07 (s, 1H), 9.02 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.10 (s, 1H), 7.84 (d, J = 2.2 Hz, 1H), 6.02 (d, J = 1.6 Hz, 1H), 5.65 (s, 2H), 5.06-4.86 (m, 1H), 2.22-2.15 (m, 1H), 2.09 (d, J = 3.3 Hz, 3H), 1.72-1.64 (m, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 483.70 (M + H) ⁺ .	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
198	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2,2,2-trifluoro-1-methoxyethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.46 (s, 1H), 11.42 (s, 1H), 9.08-9.06 (m, 2H), 8.40 (d, J = 11.0 Hz, 1H), 8.14 (d, J = 20.9 Hz, 1H), 5.82-5.75 (m, 1H), 5.07-4.86 (m, 1H), 3.50 (s, 3H), 2.23-2.16 (m, 1H), 1.74-1.64 (m, 1H), 1.21-1.16 (m, 1H); LCMS (electrospray) m/z 501.7 (M + H) ⁺ .	D
199	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methyl(tetrahydrofuran-3-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.51 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 8.98 (d, J = 1.6 Hz, 1H), 8.39 (s, 1H), 8.03 (d, J = 1.1 Hz, 1H), 5.07-4.87 (m, 1H), 4.12 (t, J = 5.5 Hz, 1H), 3.92-3.80 (m, 2H), 3.75-3.65 (m, 2H), 2.90-2.86 (m, 3H), 2.23-2.16 (m, 1H), 2.06 (td, J = 13.1, 7.3 Hz, 1H), 1.91 (td, J = 12.6, 7.1 Hz, 1H), 1.75-1.65 (m, 1H), 1.23-1.17 (m, 1H); LCMS (electrospray) m/z 488.7 (M + H) ⁺ .	D
200	 <p>(1S,2S)-N-(6-(7-(1-(2H-1,2,3-triazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.63 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.02 (d, J = 1.1 Hz, 1H), 8.38 (s, 1H), 8.11 (s, 1H), 7.84 (s, 2H), 6.50 (q, J = 7.1 Hz, 1H), 5.07-4.86 (m, 1H), 2.23-2.14 (m, 4H), 1.74-1.65 (m, 1H), 1.22-1.16 (m, 1H); LCMS (electrospray) m/z 484.70 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
201	 <p>(1S,2S)-N-(6-(7-(1-(1H-1,2,4-triazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.61 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.1 Hz, 1H), 8.86 (s, 1H), 8.38 (s, 1H), 8.11 (s, 1H), 7.98 (s, 1H), 6.29 (q, J = 7.0 Hz, 1H), 5.06-4.86 (m, 1H), 2.22-2.09 (m, 4H), 1.74-1.65 (m, 1H), 1.22-1.16 (m, 1H); LCMS (electrospray) m/z 484.70 (M + H) ⁺ .	D
202	 <p>(1S,2S)-N-(6-(5-chloro-7-((3S,4S)-3,4-dihydropyrrolidin-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.02 (s, 1H), 11.24 (s, 1H), 9.00 (s, 1H), 8.85 (s, 1H), 8.35 (s, 1H), 7.93 (s, 1H), 5.11-4.84 (m, 3H), 4.17 (d, J = 9.9 Hz, 2H), 4.08 (s, 2H), 3.49 (d, J = 8.8 Hz, 1H), 3.41 (t, J = 2.7 Hz, 1H), 2.19 (q, J = 7.1 Hz, 1H), 1.70 (ddd, J = 23.4, 10.7, 6.9 Hz, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 490.10 (M + H) ⁺ .	D
203	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-methoxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.10 (s, 1H), 11.24 (s, 1H), 9.01 (s, 1H), 8.87 (s, 1H), 8.36 (s, 1H), 7.95 (s, 1H), 5.12-4.79 (m, 1H), 4.37-3.78 (m, 4H), 3.78-3.51 (m, 1H), 3.31 (s, 3H), 2.27-2.14 (m, 1H), 2.13-1.97 (m, 2H), 1.70 (m, 1H), 1.24-1.14 (m, 1H); LCMS (electrospray) m/z 488.70 (M + H) ⁺ .	D
204	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((R)-3-methoxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.09 (s, 1H), 11.24 (s, 1H), 9.00 (s, 1H), 8.86 (s, 1H), 8.35 (s, 1H), 7.94 (s, 1H), 5.05-4.82 (m, 1H), 4.42-3.75 (m, 4H), 3.74-3.52 (m, 1H), 3.31 (s, 3H), 2.27-1.99 (m, 3H), 1.79-1.63 (m, 1H), 1.24-1.14 (m, 1H); LCMS (electrospray) m/z 488.70 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
205	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((S)-3-methoxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.09 (s, 1H), 11.24 (s, 1H), 9.01 (s, 1H), 8.86 (s, 1H), 8.36 (s, 1H), 7.94 (s, 1H), 5.05-4.83 (m, 1H), 4.37-3.80 (m, 4H), 3.76-3.50 (m, 1H), 3.31 (s, 3H), 2.27-1.99 (m, 3H), 1.76-1.64 (m, 1H), 1.23-1.08 (m, 1H); LCMS (electrospray) m/z 488.70 (M + H) ⁺ .	D
206	 <p>(1S,2S)-N-(6-(5-chloro-7-((1-cyclopropylethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.17 (s, 1H), 11.36 (s, 1H), 9.10-8.97 (m, 1H), 8.91 (s, 1H), 8.35 (s, 1H), 7.95 (s, 1H), 5.33 (br d, J = 7.9 Hz, 1H), 5.10-4.81 (m, 1H), 2.56-2.52 (m, 3H), 2.26-2.12 (m, 1H), 1.76-1.55 (m, 1H), 1.27 (d, J = 6.4 Hz, 3H), 1.23 (br s, 1H), 1.21-1.15 (m, 1H), 1.05-0.92 (m, 1H), 0.49-0.33 (m, 2H), 0.24 (dt, J = 4.8, 9.7 Hz, 2H); LCMS (electrospray) m/z 472.1 (M + H) ⁺ .	D
207	 <p>(1S,2S)-N-(6-(5-chloro-7-((3,3-difluorocyclobutyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.83-12.67 (m, 1H), 11.36 (s, 1H), 9.02 (s, 1H), 8.90 (d, J = 1.2 Hz, 1H), 8.36 (s, 1H), 8.03 (br s, 1H), 6.16 (br s, 1H), 5.08-4.85 (m, 1H), 4.66-4.14 (m, 1H), 3.31-3.25 (m, 1H), 3.01 (br s, 2H), 2.83-2.70 (m, 2H), 2.23-2.14 (m, 1H), 1.75-1.61 (m, 1H), 1.23 (br s, 2H), 1.21-1.15 (m, 1H); LCMS (electrospray) m/z 494.1 (M + H) ⁺ .	D
208	 <p>(1R,2S)-N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.60-13.15 (m, 1H), 11.51 (br s, 1H), 9.07 (s, 1H), 8.96 (s, 1H), 8.33 (s, 1H), 8.00 (br s, 1H), 5.09-4.81 (m, 1H), 3.02 (br s, 4H), 2.61-2.59 (m, 1H), 1.68-1.50 (m, 1H), 1.38-1.21 (m, 1H), 0.70-0.56 (m, 2H), 0.48 (br s, 2H); LCMS (electrospray) m/z 458.1 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
209	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-hydroxyprop-2-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.38 (br s, 1H), 11.41 (s, 1H), 9.09 (s, 1H), 9.03 (d, J = 1.3 Hz, 1H), 8.40 (s, 1H), 8.07 (s, 1H), 6.59 (br d, J = 4.3 Hz, 1H), 6.03 (br d, J = 1.8 Hz, 1H), 5.11-4.84 (m, 1H), 3.60 (d, J = 2.0 Hz, 1H), 2.27-2.16 (m, 1H), 1.78-1.63 (m, 1H), 1.22-1.15 (m, 1H); LCMS (electrospray) m/z 443.1 (M + H) ⁺ .	D
210	 <p>(1S,2S)-N-(6-(7-(1-acetamidoethyl)-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.44 (s, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 8.99 (d, J = 1.2 Hz, 1H), 8.45 (br d, J = 7.0 Hz, 1H), 8.38 (s, 1H), 8.05 (s, 1H), 5.50-5.43 (m, 1H), 5.11-4.84 (m, 1H), 2.23- 2.16 (m, 1H), 1.86 (s, 3H), 1.74- 1.64 (m, 1H), 1.57 (br d, J = 7.2 Hz, 3H), 1.23-1.17 (m, 1H); LCMS (electrospray) m/z 474.1 (M + H) ⁺ .	D
211	 <p>(1S,2S)-N-(6-(5-chloro-7-(2-cyanopropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.84-13.64 (m, 1H), 11.41 (s, 1H), 9.19 (d, J = 1.3 Hz, 1H), 9.08 (s, 1H), 9.01 (d, J = 1.3 Hz, 1H), 8.73 (d, J = 1.3 Hz, 1H), 8.46 (s, 1H), 8.39 (s, 1H), 8.25 (m, 1H), 5.08-4.86 (m, 1H), 4.43-4.29 (m, 1H), 2.24-2.15 (m, 1H), 2.06 (s, 1H), 1.75-1.63 (m, 1H), 1.25-1.15 (m, 1H); LCMS (electrospray) m/z 456.0 (M + H) ⁺ .	D
212	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(5-methylfuran-2-yl)-2H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.66-13.56 (m, 1H), 11.42 (s, 1H), 9.08 (s, 1H), 9.06 (s, 1H), 8.40 (s, 1H), 8.16 (s, 1H), 7.05 (s, 1H), 6.44 (s, 1H), 4.50-4.88 (m, 1H), 4.1 (d, J = 4.8 Hz, 2H), 3.39 (d, J = 4.4 Hz, 3H), 2.21-2.19 (m, 1H), 1.75-1.66 (m, 1H), 1.23-1.16 (m, 1H); LCMS (electrospray) m/z 469.0 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
213	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-(methylthio)-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.24-13.41 (m, 1H), 11.29-11.47 (m, 1H), 9.01-9.07 (m, 1H), 8.84-8.91 (m, 1H), 8.33-8.43 (m, 1H), 7.90-8.03 (m, 1H), 5.55-5.67 (m, 1H), 5.31-5.42 (m, 1H), 5.00-5.08 (m, 1H), 4.83-4.93 (m, 1H), 2.26-2.31 (m, 3H), 2.14-2.25 (m, 4H), 1.62-1.76 (m, 1H), 1.13-1.27 (m, 1H); LCMS (electrospray) m/z 441.1 (M + H) ⁺ .	D
214	 <p>(1S,2S)-N-(6-(7-((E)-buta-1,3-dien-1-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.95-13.52 (m, 1H), 11.49-11.31 (m, 1H), 9.07 (d, J = 0.6 Hz, 1H), 9.02 (d, J = 1.4 Hz, 1H), 8.42-8.37 (m, 1H), 8.17-8.12 (m, 1H), 7.59-7.40 (m, 1H), 7.04 (d, J = 15.8 Hz, 1H), 6.76-6.59 (m, 1H), 5.58 (d, J = 16.7 Hz, 1H), 5.38 (d, J = 10.2 Hz, 1H), 5.11-4.83 (m, 1H), 2.28-2.10 (m, 1H), 1.80-1.58 (m, 1H), 1.30-1.10 (m, 1H); LCMS (electrospray) m/z 441.1 (M + H) ⁺ .	D
215	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((S)-1,1,1-trifluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.65 (s, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.04 (d, J = 1.3 Hz, 1H), 8.39 (s, 1H), 8.12 (s, 1H), 4.96 (m, 1H), 4.50 (m, 1H), 2.19 (m, 1H), 1.75 (br d, J = 6.6 Hz, 3H), 1.66 (m, 1H), 1.21 (m, 1H); LCMS (electrospray) m/z 485.0 (M + H) ⁺ .	D
216	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((R)-1,1,1-trifluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.65 (s, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.04 (d, J = 1.3 Hz, 1H), 8.39 (s, 1H), 8.12 (s, 1H), 4.96 (m, 1H), 4.50 (m, 1H), 2.19 (m, 1H), 1.75 (br d, J = 6.6 Hz, 3H), 1.66 (m, 1H), 1.21 (m, 1H); LCMS (electrospray) m/z 485.0 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
217	 <p>(1S,2S)-N-(6-(5-chloro-7-((cyclopropylmethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.19 (br s, 1H), 11.36 (s, 1H), 9.03 (s, 1H), 8.90 (s, 1H), 8.36 (s, 1H), 7.96 (br s, 1H), 5.76-5.58 (m, 1H), 5.13-4.81 (m, 1H), 3.36 (br d, J = 5.5 Hz, 2H), 2.19 (td, J = 6.9, 13.8 Hz, 1H), 1.76-1.61 (m, 1H), 1.23-1.15 (m, 1H), 1.07 (br d, J = 9.9 Hz, 1H), 0.48 (br d, J = 7.4 Hz, 2H), 0.33-0.23 (m, 2H); LCMS (electrospray) m/z 458.1 (M + H) ⁺ .	D
218	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((R)-1-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.51 (br s, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 8.99 (s, 1H), 8.38 (s, 1H), 8.04 (br s, 1H), 5.09-4.85 (m, 1H), 3.79 (br s, 2H), 3.71-3.62 (m, 1H), 3.25 (s, 3H), 2.23-2.15 (m, 1H), 1.75-1.63 (m, 1H), 1.41 (br d, J = 6.0 Hz, 3H), 1.26-1.20 (m, 1H); LCMS (electrospray) m/z 461.2 (M + H) ⁺ .	D
219	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((S)-1-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.52 (br s, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 8.99 (s, 1H), 8.38 (s, 1H), 8.04 (br s, 1H), 5.09-4.84 (m, 1H), 3.79 (br s, 2H), 3.68 (br s, 1H), 3.25 (s, 3H), 2.25-2.14 (m, 1H), 1.76-1.62 (m, 1H), 1.41 (br d, J = 5.9 Hz, 3H), 1.26-1.20 (m, 2H); LCMS (electrospray) m/z 461.1 (M + H) ⁺ .	D
220	 <p>(1S,2S)-N-(6-(5-chloro-7-(1-ethoxy-2,2,2-trifluoroethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.38 (s, 1H), 11.42 (s, 1H), 9.09-9.07 (m, 2H), 8.39 (s, 1H), 8.12 (d, J = 1.6 Hz, 1H), 5.83 (q, J = 7.0 Hz, 1H), 5.08-4.87 (m, 1H), 3.80-3.60 (m, 2H), 2.24-2.17 (m, 1H), 1.75-1.65 (m, 1H), 1.25-1.18 (m, 4H); LCMS (electrospray) m/z 515.7 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
221	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1,2,2,2-tetrafluoroethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.74 (s, 1H), 11.42 (s, 1H), 9.09 (d, J = 1.1 Hz, 2H), 8.40 (s, 1H), 8.19 (s, 1H), 7.12-7.00 (m, 1H), 5.07-4.86 (m, 1H), 2.23-2.16 (m, 1H), 1.69 (dtd, J = 23.4, 6.9, 3.6 Hz, 1H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 489.8 (M + H) ⁺ .	D
222	 <p>(1S,2S)-N-(6-(5-chloro-7-((3S,4S)-3,4-dimethoxypyrrolidin-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.11 (s, 1H), 11.24 (s, 1H), 9.01 (s, 1H), 8.86 (s, 1H), 8.36 (s, 1H), 7.95 (s, 1H), 4.94 (dd, J = 66.2, 4.1 Hz, 1H), 4.08-3.99 (m, 5H), 3.60 (d, J = 9.9 Hz, 1H), 3.37 (s, 7H), 2.20 (d, J = 6.6 Hz, 1H), 1.73-1.65 (m, 1H), 1.22-1.10 (m, 1H); LCMS (electrospray) m/z 518.9 (M + H) ⁺ .	D
223	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(furan-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.41 (s, 1H), 9.09 (s, 1H), 9.04 (s, 1H), 8.49 (s, 1H), 8.41 (s, 1H), 8.18 (s, 1H), 7.96 (s, 1H), 7.18 (d, J = 1.2 Hz, 1H), 5.14-4.83 (m, 1H), 2.23-2.17 (m, 1H), 1.77-1.64 (m, 1H), 1.24-1.18 (m, 1H); LCMS (electrospray) m/z 455.1 (M + H) ⁺ .	D
224	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(propa-1,2-dien-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.66-13.30 (m, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.03 (d, J = 1.2 Hz, 1H), 8.49 (s, 1H), 8.40 (s, 1H), 8.11 (s, 1H), 6.78 (t, J = 6.7 Hz, 1H), 5.51 (d, J = 7.0 Hz, 2H), 5.17-4.68 (m, 1H), 2.25-2.14 (m, 1H), 1.77-1.62 (m, 1H), 1.24-1.17 (m, 1H); LCMS (electrospray) m/z 427.1 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
225	 <p>(1S,2R)-N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.35 (br s, 1H), 11.50 (s, 1H), 9.07 (d, J = 0.6 Hz, 1H), 8.96 (d, J = 1.5 Hz, 1H), 8.33 (s, 1H), 8.00 (s, 1H), 5.06-4.79 (m, 1H), 3.06- 2.99 (m, 4H), 2.60-2.53 (m, 2H), 1.66-1.50 (m, 1H), 1.29 (qd, J = 6.6, 13.2 Hz, 1H), 0.68-0.59 (m, 2H), 0.53-0.41 (m, 2H); LCMS (electrospray) m/z 458.1 (M + H) ⁺ .	D
226	 <p>(1R,2R)-N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.34-13.32 (m, 1H), 11.38 (s, 1H), 9.05 (d, J = 0.4 Hz, 1H), 8.95 (d, J = 1.6 Hz, 1H), 8.36 (s, 1H), 7.99 (s, 1H), 5.06-4.86 (m, 1H), 3.01 (m, 4H), 2.20-2.17 (m, 1H), 1.73-1.64 (m, 1H), 1.20-1.16 (m, 1H), 0.65-0.61 (m, 2H), 0.49-0.45 (m, 2H); LCMS (electrospray) m/z 458.1 (M + H) ⁺ .	D
227	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(hydroxy(tetrahydro-2H-pyran-3-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.28 (br s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.02 (s, 1H), 5.88 (br d, J = 3.5 Hz, 1H), 5.08- 4.85 (m, 2H), 4.16 (br dd, J = 3.4, 10.6 Hz, 1H), 3.74 (br d, J = 11.5 Hz, 1H), 3.42 (t, J = 10.0 Hz, 1H), 3.30 (s, 1H), 2.23-2.17 (m, 2H), 1.76-1.63 (m, 1H), 1.56-1.49 (m, 1H), 1.38-1.29 (m, 2H), 1.23-1.17 (m, 2H); LCMS (electrospray) m/z 503.4 (M + H) ⁺ .	D
228	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.02-13.21 (m, 1H), 11.30-11.40 (m, 1H), 8.95-9.06 (m, 1H), 8.75- 8.82 (m, 1H), 8.29-8.41 (m, 1H), 7.81-7.95 (m, 1H), 5.01-5.08 (m, 1H), 4.84-4.95 (m, 2H), 3.92-4.13 (m, 1H), 2.24-2.30 (m, 3H), 2.12- 2.23 (m, 2H), 1.61-1.76 (m, 1H), 1.20-1.27 (m, 1H), 1.16-1.20 (m, 1H); LCMS (electrospray) m/z 458.1 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
229	 <p>(1S,2S)-N-(6-(5-chloro-7-(5,6-dihydro-1,4-dioxin-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.28 (br s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.3 Hz, 1H), 8.39 (s, 1H), 8.04 (s, 1H), 6.94 (s, 1H), 5.12-4.82 (m, 1H), 4.36 (dd, J = 2.8, 4.8 Hz, 2H), 4.27-4.22 (m, 2H), 2.24-2.15 (m, 1H), 1.76-1.58 (m, 1H), 1.26-1.14 (m, 1H); LCMS (electrospray) m/z 473.1 (M + H) ⁺ .	D
230	 <p>(1S,2S)-N-(6-(7-(1-(1H-pyrazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.51 (s, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.1 Hz, 1H), 8.38 (s, 1H), 8.09 (s, 1H), 8.05 (s, 1H), 7.48 (s, 1H), 6.30 (s, 1H), 6.25 (q, J = 6.8 Hz, 1H), 5.06- 4.86 (m, 1H), 2.21-2.15 (m, 1H), 2.09 (d, J = 7.1 Hz, 3H), 1.72- 1.65 (m, 1H), 1.21-1.16 (m, 1H); LCMS (electrospray) m/z 483.85 (M + H) ⁺ .	D
231	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(((1R,3S)-3-hydroxycyclopentyl)(methyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.41 (s, 1H), 11.39 (s, 1H), 9.05 (s, 1H), 8.97 (d, J = 1.1 Hz, 1H), 8.37 (s, 1H), 8.00 (d, J = 1.1 Hz, 1H), 5.10-4.82 (m, 1H), 4.57 (d, J = 3.8 Hz, 1H), 4.48-4.39 (m, 1H), 4.16-4.04 (m, 1H), 3.70 (t, J = 7.1 Hz, 1H), 2.89 (d, J = 1.1 Hz, 3H), 2.28-2.14 (m, 1H), 2.14- 2.03 (m, 1H), 1.78-1.63 (m, 4H), 1.61-1.39 (m, 2H), 1.33-1.20 (m, 1H); LCMS (electrospray) m/z 502.90 (M + H) ⁺	D
232	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(prop-1-en-2-yl)-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.52-13.91 (m, 1H), 11.38-11.44 (m, 1H), 8.99 (s, 1H), 8.87-8.93 (m, 1H), 8.32-8.38 (m, 1H), 8.06- 8.12 (m, 1H), 5.64-5.71 (m, 1H), 5.38-5.44 (m, 1H), 5.00-5.09 (m, 1H), 4.85-4.92 (m, 1H), 2.15-2.27 (m, 5H), 1.63-1.76 (m, 1H), 1.15- 1.27 (m, 1H); LCMS (electro- spray) m/z 463.2 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
233	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(5-methylfuran-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.99-13.14 (m, 1H), 11.40 (s, 1H), 9.26-8.79 (m, 2H), 8.40 (s, 1H), 8.29 (s, 1H), 8.17 (s, 1H), 6.78 (br s, 1H), 5.13-4.68 (m, 1H), 2.40 (s, 3H), 2.22-2.15 (m, 1H), 1.74-1.64 (m, 1H), 1.22-1.15 (m, 1H); LCMS (electrospray) m/z 469.1 (M + H) ⁺ .	D
234	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-hydroxyprop-1-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 14.48-13.25 (m, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.06 (d, J = 1.5 Hz, 1H), 8.40 (s, 1H), 8.16 (s, 1H), 5.55 (br d, J = 1.8 Hz, 1H), 5.13-4.77 (m, 1H), 4.50 (s, 2H), 2.89 (s, 1H), 2.73 (s, 1H), 2.28-2.06 (m, 1H), 1.84-1.55 (m, 1H), 1.21 (tdd, J = 6.3, 9.0, 12.4 Hz, 1H); LCMS (electrospray) m/z 443.0 (M + H) ⁺ .	D
235	 <p>HCOOH (1S,2S)-N-(6-(5-chloro-6-fluoro-7-(prop-2-yn-1-ylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.83-13.38 (m, 1H), 11.37 (s, 1H), 9.03 (s, 1H), 8.93 (s, 1H), 8.48 (s, 1H), 8.35 (s, 1H), 8.01 (br s, 1H), 6.29 (br dd, J = 1.3, 3.0 Hz, 1H), 5.13-4.80 (m, 1H), 4.30 (br s, 2H), 3.09 (s, 1H), 2.19 (td, J = 7.0, 13.7 Hz, 1H), 1.78-1.60 (m, 1H), 1.20 (tdd, J = 6.1, 9.1, 12.5 Hz, 1H); LCMS (electrospray) m/z 442.1 (M + H) ⁺ .	D
236	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.09 (m, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.01 (d, J = 1.3 Hz, 1H), 8.40 (s, 1H), 8.06 (s, 1H), 5.39-5.30 (m, 1H), 5.10-4.83 (m, 1H), 4.32 (q, J = 7.3 Hz, 1H), 3.91-3.79 (m, 1H), 2.46-2.38 (m, 1H), 2.26-2.16 (m, 1H), 2.16-2.00 (m, 3H), 1.99-1.82 (m, 1H), 1.77-1.61 (m, 1H), 1.28-1.14 (m, 1H); LCMS (electrospray) m/z 459.1 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
237	 <p>(1S,2S)-N-(6-(5-chloro-7-((1,1-difluoropropan-2-yl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.83-13.06 (m, 1H), 11.36 (s, 1H), 9.03 (d, J = 0.6 Hz, 1H), 8.91 (d, J = 1.3 Hz, 1H), 8.36 (s, 1H), 8.06 (s, 1H), 8.05 (br d, J = 1.2 Hz, 1H), 6.32-5.92 (m, 1H), 5.75-5.54 (m, 1H), 5.11-4.81 (m, 1H), 4.74-4.15 (m, 1H), 2.25-2.12 (m, 1H), 1.78-1.60 (m, 1H), 1.33 (d, J = 6.6 Hz, 3H), 1.20 (ddt, J = 12.33, 9.00, 6.15, 6.15 Hz, 1H); LCMS (electrospray) m/z 459.1 (M + H) ⁺ .	D
238	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(4-hydroxytetrahydrofuran-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.40 (s, 1H), 9.39 (d, J = 1.2 Hz, 1H), 9.07 (s, 1H), 8.995-8.992 (m, 1H), 8.39 (s, 1H), 8.04 (s, 1H), 5.59 (dd, J = 5.7, 10.6 Hz, 1H), 5.18-5.17 (m, 1H), 5.08-4.85 (m, 1H), 4.55 (br s, 1H), 4.47 (dd, J = 4.6, 9.1 Hz, 1H), 3.73-3.70 (m, 1H), 2.28-2.23 (m, 1H), 2.21-2.16 (m, 1H), 2.12-2.05 (m, 1H), 1.74-1.64 (m, 1H), 1.22-1.16 (m, 1H); LCMS (electrospray) m/z 475.1 (M + H) ⁺ .	D
239	 <p>(1S,2S)-N-(6-(5-chloro-7-(3,3-dimethylazetidin-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 12.97 (s, 1H), 11.35 (s, 1H), 9.02 (s, 1H), 8.87 (d, J = 6.0 Hz, 1H), 8.36 (s, 1H), 7.96 (s, 1H), 5.06-4.85 (m, 1H), 4.14 (d, J = 11.5 Hz, 4H), 2.22-2.15 (m, 1H), 1.72-1.65 (m, 1H), 1.32 (d, J = 12.1 Hz, 6H), 1.24-1.16 (m, 1H); LCMS (electrospray) m/z 472.10 (M + H) ⁺ .	D
240	 <p>(1S,2S)-N-(6-(5-chloro-7-(3-chloro-2,2-dimethylpropyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.28 (s, 1H), 11.36 (s, 1H), 9.02 (d, J = 9.3 Hz, 1H), 8.91-8.88 (m, 1H), 8.36 (s, 1H), 7.96 (s, 1H), 5.25 (d, J = 6.0 Hz, 1H), 5.07-4.86 (m, 1H), 3.64 (d, J = 17.6 Hz, 2H), 3.49-3.39 (m, 2H), 2.23-2.16 (m, 1H), 1.73-1.66 (m, 1H), 1.24-1.16 (m, 1H), 1.05 (t, J = 12.9 Hz, 6H); LCMS (electrospray) m/z 472.10 (M + H) ⁺ .	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
241	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(4-methyl-1H-pyrazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.53 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.6 Hz, 1H), 8.39 (s, 1H), 8.10 (s, 1H), 7.79 (s, 1H), 7.28 (s, 1H), 6.16 (q, J = 7.0 Hz, 1H), 5.07-4.86 (m, 1H), 2.21-2.16 (m, 1H), 2.06-2.00 (m, 6H), 1.73-1.66 (m, 1H), 1.22-1.18 (m, 1H); LCMS (electrospray) m/z 497.90 (M + H) ⁺ .	D
242	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(5-methyl-1H-pyrazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.05 (s, 1H), 11.39 (s, 1H), 9.06 (s, 1H), 9.00 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.09 (s, 1H), 7.48 (s, 1H), 6.22 (q, 1H), 6.09 (s, 1H), 5.05-4.86 (m, 1H), 2.29 (s, 3H), 2.21-2.17 (m, 1H), 2.03 (d, J = 7.1 Hz, 3H), 1.72-1.66 (m, 1H), 1.14-1.22 (m, 1H); LCMS (electrospray) m/z 497.90 (M + H) ⁺ .	D
243	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(3-methyl-1H-pyrazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.56 (s, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.10 (s, 1H), 7.91 (d, J = 2.2 Hz, 1H), 6.14 (q, J = 7.0 Hz, 1H), 6.06 (d, J = 2.7 Hz, 1H), 5.07-4.86 (m, 1H), 2.23-2.15 (m, 1H), 2.12 (s, 3H), 2.04 (d, J = 7.7 Hz, 3H), 1.72-1.64 (m, 1H), 1.22-1.16 (m, 1H); LCMS (electrospray) m/z 497.90 (M + H) ⁺ .	D

TABLE 1-continued





Ex #	Structure/Name	1H NMR/MS (M + 1)	Method
244	 <p data-bbox="375 722 686 810">(1S,2S)-N-(6-(5-chloro-7-(3,3-difluoroazetidino-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.10 (s, 1H), 11.25 (s, 1H), 9.01 (s, 1H), 8.87 (s, 1H), 8.32 (d, J = 36.8 Hz, 1H), 8.01 (s, 1H), 5.05-4.82 (m, 5H), 2.23-2.16 (m, 1H), 1.75-1.65 (m, 1H), 1.24-1.16 (m, 1H); LCMS (electrospray) m/z 480.10 (M + H) ⁺ .	D
245	 <p data-bbox="375 1129 686 1213">(1S,2S)-N-(6-(5-chloro-7-(cyanomethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.78 (s, 1H), 11.40 (s, 1H), 9.08 (s, 1H), 9.05 (d, J = 1.6 Hz, 1H), 8.40 (s, 1H), 8.18-8.10 (1H), 5.09-4.83 (m, 1H), 4.47-4.32 (m, 2H), 2.25-2.14 (m, 1H), 1.75-1.62 (m, 1H), 1.26-1.15 (m, 1H); LCMS (electrospray) m/z 428.80 (M + H) ⁺ .	D
246	 <p data-bbox="375 1446 686 1539">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-methoxyprop-1-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.98 (br s, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.06 (d, J = 1.3 Hz, 1H), 8.40 (s, 1H), 8.17 (s, 1H), 5.12-4.77 (m, 1H), 4.52 (s, 2H), 3.43 (s, 3H), 2.27-2.11 (m, 1H), 1.79-1.61 (m, 1H), 1.35-1.13 (m, 1H); LCMS (electrospray) m/z 457.1 (M + H) ⁺ .	D
247	 <p data-bbox="375 1808 686 1913">(1S,2S)-N-(6-(5-chloro-7-(2,5-dihydrofuran-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.33-13.04 (m, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.3 Hz, 1H), 8.49 (s, 1H), 8.39 (s, 1H), 8.07 (s, 1H), 6.40 (br d, J = 2.0 Hz, 1H), 6.33-6.21 (m, 1H), 6.09 (br d, J = 6.48 Hz, 1H), 5.15-4.99 (m, 1H), 4.88 (td, J = 6.14, 3.6 Hz, 1H), 4.80-4.68 (m, 1H), 2.27-2.13 (m, 1H), 1.79-1.59 (m, 1H), 1.31-1.12 (m, 1H); LCMS (electrospray) m/z 457.1 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
248	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-propionamidoethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.48 (br d, J = 5.4 Hz, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 8.98 (d, J = 1.5 Hz, 1H), 8.40-8.33 (m, 2H), 8.05 (s, 1H), 5.46 (s, 1H), 5.09-4.85 (m, 1H), 2.22-2.10 (m, 3H), 1.76-1.63 (m, 1H), 1.56 (d, J = 7.1 Hz, 3H), 1.26-1.16 (m, 1H), 0.94 (t, J = 7.6 Hz, 3H); LCMS (electrospray) m/z 488.1 (M + H) ⁺ .	D
249	 <p>(1R,2S)-N-(6-(5-chloro-6-fluoro-7-(3-hydroxypropanamido)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.34 (m, 1H), 11.52 (s, 1H), 10.33 (s, 1H), 9.08 (s, 1H), 9.03 (d, J = 1.4 Hz, 1H), 8.34 (s, 1H), 8.04 (s, 1H), 4.92 (m, 1H), 4.76 (br d, J = 7.8 Hz, 1H), 3.79 (br t, J = 6.30 Hz, 2H), 2.65 (br t, J = 6.6 Hz, 3H), 1.57 (m, 1H), 1.29 (dq, J = 13.16, 6.62 Hz, 1H); LCMS (electrospray) m/z 476.1 (M + H) ⁺ .	D
250	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-formamidoethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.78-13.27 (m, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 8.99 (s, 1H), 8.68 (br d, J = 7.1 Hz, 1H), 8.38 (s, 1H), 8.06 (br s, 2H), 5.56 (br t, J = 7.2 Hz, 1H), 5.12-4.79 (m, 1H), 2.25-2.12 (m, 1H), 1.73-1.63 (m, 1H), 1.58 (d, J = 7.1 Hz, 3H), 1.20 (ddd, J = 2.9, 6.3, 9.5 Hz, 1H); LCMS (electrospray) m/z 460.1 (M + H) ⁺ .	D
251	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(E)-4-hydroxybut-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.41 (s, 1H), 9.08 (d, J = 0.6 Hz, 1H), 9.02 (d, J = 1.3 Hz, 1H), 8.43 (s, 1H), 8.40-8.36 (m, 1H), 8.28 (s, 1H), 8.18-8.09 (m, 1H), 6.94-6.73 (m, 1H), 5.11-4.83 (m, 1H), 4.76-4.65 (m, 1H), 4.35 (t, J = 6.5 Hz, 1H), 3.68-3.60 (m, 1H), 2.76-2.69 (m, 1H), 2.26-2.15 (m, 1H), 2.06-1.9 (m, 1H), 2.06-1.91 (m, 1H), 1.80-1.59 (m, 1H), 1.33-1.14 (m, 1H); LCMS (electrospray) m/z 487.1 (M + H) ⁺ .	D

TABLE 1-continued





Ex #	Structure/Name	1H NMR/MS (M + 1)	Method
252	 <p data-bbox="483 642 548 659">ratio 1;1</p> <p data-bbox="375 678 1084 852">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-methylbut-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide or (1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-methylbut-2-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="816 449 1084 743">¹H NMR (400 MHz, DMSO-d₆) δ 13.49-13.39 (m, 1H), 13.38-13.27 (m, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.02 (t, J = 1.6 Hz, 1H), 8.43 (s, 1H), 8.38 (d, J = 2.0 Hz, 1H), 8.05 (d, J = 6.9 Hz, 1H), 5.57 (s, 1H), 5.28 (s, 1H), 5.10-4.82 (m, 1H), 2.80 (dt, J = 13.2, 6.6 Hz, 1H), 2.25-2.15 (m, 1H), 2.01 (s, 2H), 1.92 (s, 2H), 1.76-1.63 (m, 1H), 1.52 (s, 2H), 1.27-1.16 (m, 2H), 1.11 (d, J = 6.7 Hz, 4H), 0.84 (t, J = 7.4 Hz, 1H); LCMS (electrospray) m/z 457.2 (M + H)⁺.</p>	D
253	 <p data-bbox="407 1052 472 1068">HCOOH</p> <p data-bbox="375 1087 683 1192">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-(trimethylsilyl)prop-2-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	<p data-bbox="816 905 1084 1073">¹H NMR (400 MHz, DMSO-d₆) δ 11.41 (s, 1H), 9.05 (br d, J = 18.0 Hz, 2H), 8.46 (s, 1H), 8.39 (s, 1H), 8.09 (s, 1H), 5.19-4.71 (m, 1H), 4.16-3.92 (m, 2H), 2.26-2.12 (m, 1H), 1.77-1.57 (m, 1H), 1.21-1.10 (m, 1H), 0.11 (s, 9H); LCMS (electrospray) m/z 499.2 (M + H)⁺.</p>	D
254	 <p data-bbox="407 1392 472 1409">HCOOH</p> <p data-bbox="375 1428 683 1533">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-hydroxy-3-(trimethylsilyl)prop-2-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	<p data-bbox="816 1245 1084 1434">¹H NMR (400 MHz, DMSO-d₆) δ 13.98-12.92 (m, 1H), 11.41 (s, 1H), 9.05 (br d, J = 18.2 Hz, 2H), 8.45 (s, 1H), 8.39 (s, 1H), 8.06 (s, 1H), 6.04 (s, 1H), 5.15-4.74 (m, 1H), 2.28-2.12 (m, 1H), 1.78-1.60 (m, 1H), 1.24-1.13 (m, 2H), 0.13 (s, 9H); LCMS (electrospray) m/z 515.3 (M + H)⁺.</p>	D
255	 <p data-bbox="375 1833 683 1915">(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-hydroxybutan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	<p data-bbox="816 1585 1084 1795">¹H NMR (400 MHz, DMSO-d₆) δ 12.98-13.58 (m, 1H), 11.30-11.43 (m, 1H), 9.01-9.06 (m, 1H), 8.87-8.93 (m, 1H), 8.33-8.38 (m, 1H), 7.92-8.10 (m, 1H), 5.09-5.23 (m, 1H), 5.00-5.08 (m, 1H), 4.79-4.92 (m, 1H), 3.71-4.06 (m, 2H), 2.14-2.23 (m, 1H), 1.63-1.75 (m, 1H), 1.11-1.24 (m, 8H); LCMS (electrospray) m/z 476.2 (M + H)⁺.</p>	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
256	 <p>(1S,2S)-N-(6-(5-chloro-7-(5,5-dimethyltetrahydrofuran-3-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.64-13.48 (m, 1H), 11.49-11.34 (m, 1H), 9.10-9.03 (m, 1H), 8.98 (d, J = 1.3 Hz, 1H), 8.43-8.35 (m, 1H), 8.11-8.02 (m, 1H), 5.11-4.81 (m, 1H), 4.21-4.12 (m, 2H), 4.10-3.98 (m, 1H), 2.28-2.15 (m, 3H), 1.77-1.63 (m, 1H), 1.40 (s, 3H), 1.32 (s, 3H), 1.22-1.17 (m, 1H); LCMS (electrospray) m/z 487.1 (M + H) ⁺ .	D
257	 <p>(1S,2S)-N-(6-(7-(1-(1H-imidazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.81 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.16 (s, 1H), 7.91 (s, 1H), 7.31 (s, 1H), 6.91 (s, 1H), 6.15 (q, J = 7.3 Hz, 1H), 5.04-4.87 (m, 1H), 2.23-2.15 (m, 1H), 2.09 (d, J = 7.1 Hz, 3H), 1.72-1.65 (m, 1H), 1.18-1.18 (m, 1H); LCMS (electrospray) m/z 483.90 (M + H) ⁺ .	D
258	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(2-methyl-1H-imidazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.73 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (s, 1H), 8.37 (s, 1H), 8.16 (s, 1H), 7.51 (s, 1H), 6.79 (s, 1H), 6.07-6.05 (m, 1H), 5.05-4.87 (m, 1H), 2.18 (s, 3H), 2.01 (d, 3H), 1.72-1.66 (m, 1H), 1.18-1.16 (m, 1H); LCMS (electrospray) m/z 497.90 (M + H) ⁺ .	D
259	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((E)-3-(triethylsilyl)prop-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.60 (br s, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 8.99 (s, 1H), 8.39 (s, 1H), 8.14 (s, 1H), 8.06 (s, 1H), 6.86-6.73 (m, 1H), 6.67-6.60 (m, 1H), 5.17-4.77 (m, 1H), 2.26-2.12 (m, 1H), 1.92 (br d, J = 8.3 Hz, 2H), 1.80-1.60 (m, 1H), 1.30-1.13 (m, 1H), 1.06-0.91 (m, 9H), 0.61 (q, J = 7.9 Hz, 6H); LCMS (electrospray) m/z 543.3 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
260	 <p>(1S,2S)-N-(6-(5-chloro-7-((1,1-difluoropropan-2-yl)(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.42 (s, 1H), 11.40 (s, 1H), 9.06 (d, J = 0.7 Hz, 1H), 8.97 (d, J = 1.3 Hz, 1H), 8.39 (s, 1H), 8.04 (d, J = 1.2 Hz, 1H), 6.46-6.06 (m, 1H), 5.12-4.82 (m, 1H), 3.77-3.53 (m, 1H), 3.02 (d, J = 1.2 Hz, 3H), 2.25-2.14 (m, 1H), 1.77-1.62 (m, 1H), 1.34 (br d, J = 6.8 Hz, 3H), 1.26-1.15 (m, 2H); LCMS (electrospray) m/z 496.2 (M + H) ⁺ .	D
261	 <p>(1S,2S)-N-(6-(7-(sec-butyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.51 (br d, J = 1.5 Hz, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.05 (s, 1H), 5.11-4.85 (m, 1H), 3.42 (s, 1H), 2.27-2.15 (m, 1H), 1.86 (td, J = 13.7, 6.4 Hz, 2H), 1.77-1.64 (m, 1H), 1.45 (br d, J = 7.0 Hz, 3H), 1.35-1.16 (m, 1H), 1.10-1.02 (m, 1H), 0.85 (q, J = 7.5 Hz, 4H); LCMS (electrospray) m/z 445.3 (M + H) ⁺ .	D
262	 <p>(1S,2S)-N-(6-(5-chloro-7-(1,4-dioxan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.31 (br s, 1H), 11.41 (s, 1H), 9.07 (s, 1H), 9.00 (d, J = 1.4 Hz, 1H), 8.39 (s, 1H), 8.06 (s, 1H), 5.25 (dd, J = 2.7, 10.3 Hz, 1H), 5.09-4.85 (m, 1H), 4.01 (d, J = 9.4 Hz, 1H), 3.95-3.84 (m, 3H), 3.79 (d, J = 9.0 Hz, 1H), 3.72-3.64 (m, 1H), 2.26-2.09 (m, 1H), 1.78-1.62 (m, 1H), 1.28-1.13 (m, 1H); LCMS (electrospray) m/z 475.1 (M + H) ⁺ .	D
263	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(tetrahydro-2H-pyran-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.82-13.50 (m, 1H), 11.44-11.34 (m, 1H), 9.06 (s, 1H), 8.97 (d, J = 1.3 Hz, 1H), 8.45 (s, 1H), 8.38 (s, 1H), 8.06 (s, 1H), 5.13-4.83 (m, 1H), 3.99-3.87 (m, 1H), 3.61-3.52 (m, 1H), 2.25-2.14 (m, 1H), 2.04-1.95 (m, 1H), 1.82-1.72 (m, 2H), 1.71-1.62 (m, 1H), 1.29-1.13 (m, 1H); LCMS (electrospray) m/z 473.1 (M + H) ⁺ .	D

TABLE 1-continued




Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
264	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(4-methyl-1H-imidazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.75 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.00 (s, 1H), 8.38 (s, 1H), 8.15 (s, 1H), 7.77 (s, 1H), 6.96 (s, 1H), 6.06-6.04 (m, 1H), 5.05-4.88 (m, 1H), 2.19-2.19 (m, 1H), 2.05 (d, J = 8.2 Hz, 6H), 1.72-1.66 (m, 1H), 1.21-1.21 (m, 1H); LCMS (electrospray) m/z 497.90 (M + H) ⁺ .	D
265	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyanofluoromethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.94 (s, 1H), 11.42 (s, 1H), 9.10 (s, 2H), 8.42 (s, 1H), 8.24 (s, 1H), 7.37 (d, J = 43.4 Hz, 1H), 5.06-4.86 (m, 1H), 2.21-2.16 (m, 1H), 1.73-1.66 (m, 1H), 1.30-1.21 (m, 1H); LCMS (electrospray) m/z 446.85 (M + H) ⁺ .	D
266	 <p>(1S,2S)-N-(6-(7-(acetamido(cyano)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.79 (s, 1H), 11.41 (s, 1H), 9.30 (s, 1H), 9.07 (d, J = 18.1 Hz, 2H), 8.41 (s, 1H), 8.21 (s, 1H), 6.56 (s, 1H), 5.07-4.81 (m, 1H), 2.19 (s, 1H), 1.95 (s, 3H), 1.72 (s, 1H), 1.21-1.12 (m, 1H); LCMS (electrospray) m/z 485.85 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
267	 <p>(1S,2S)-N-(6-(5-chloro-7-(6,6-difluoro-2-azaspiro[3.3]heptan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ ¹ H-NMR (400 MHz, DMSO-D ₆) δ 12.96 (s, 1H), 11.24 (s, 1H), 8.99 (d, J = 8.8 Hz, 1H), 8.87 (d, J = 12.6 Hz, 1H), 8.35 (s, 1H), 7.95 (s, 1H), 5.04-4.85 (m, 1H), 4.53 (d, J = 11.0 Hz, 4H), 2.90 (t, J = 12.6 Hz, 4H), 2.19 (t, J = 7.1 Hz, 1H), 1.73-1.66 (m, 1H), 1.22- 1.17 (m, 1H); LCMS (electro- spray) m/z 519.8 (M + H) ⁺ .	D
268	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(methylsulfonamido)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ ¹ H-NMR (400 MHz, DMSO-D ₆) δ 13.43 (s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.1 Hz, 1H), 8.38 (s, 1H), 8.08 (d, J = 1.6 Hz, 1H), 7.68 (d, J = 6.6 Hz, 1H), 5.21 (t, J = 6.6 Hz, 1H), 5.07-4.86 (m, 1H), 2.86 (s, 3H), 2.23-2.16 (m, 1H), 1.74-1.60 (m, 4H), 1.21- 1.16 (m, 1H); LCMS (electro- spray) m/z 475.9 (M + H) ⁺ .	D
269	 <p>(1S,2S)-N-(6-(5-chloro-7-(1,1-difluoroprop-1-en-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.77 (s, 1H), 11.42 (s, 1H), 9.08 (d, J = 1.6 Hz, 1H), 9.03 (d, J = 1.6 Hz, 1H), 8.39 (s, 1H), 8.11 (s, 1H), 5.07-4.86 (m, 1H), 2.23-2.16 (m, 1H), 2.05 (t, J = 3.0 Hz, 3H), 1.74-1.65 (m, 1H), 1.22-1.16 (m, 1H); LCMS (electrospray) m/z 465.90 (M + H) ⁺ .	D
270	 <p>(1S,2S)-N-(6-(5-chloro-7-((1S,2R)-1,2-dihydroxypropyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.05 (s, 1H), 11.39 (s, 1H), 9.07 (s, 1H), 8.99 (d, J = 1.1 Hz, 1H), 8.38 (s, 1H), 7.99 (s, 1H), 5.89 (s, 1H), 5.07-5.00 (m, 2H), 4.88 (td, J = 6.3, 3.8 Hz, 0H), 4.80 (s, 1H), 4.09-4.01 (m, 1H), 2.23-2.16 (m, 1H), 1.77-1.64 (m, 1H), 1.25-1.16 (m, 1H), 1.04 (d, J = 6.6 Hz, 3H); LCMS (electrospray) m/z 463.10 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
271	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(prop-2-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.70 (s, 1H), 11.41 (s, 1H), 9.08 (s, 1H), 9.03 (d, J = 1.5 Hz, 1H), 8.40 (s, 1H), 8.09 (s, 1H), 5.11-4.82 (m, 1H), 3.98 (d, J = 1.8 Hz, 2H), 3.05 (s, 1H), 2.26-2.16 (m, 1H), 1.82-1.64 (m, 1H), 1.30-1.13 (m, 1H); LCMS (electrospray) m/z 427.2 (M + H) ⁺ .	D
272	 <p>HCOOH HCOOH</p> <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-methylbutan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 2 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.58-13.46 (m, 1H), 11.46-11.37 (m, 1H), 9.07 (s, 1H), 9.01 (s, 1H), 8.46 (s, 2H), 8.38 (s, 1H), 8.05 (s, 1H), 5.13-4.82 (m, 1H), 3.13-3.04 (m, 1H), 2.20 (dd, J = 7.1, 5.4 Hz, 2H), 2.08 (s, 3H), 1.77-1.63 (m, 1H), 1.47-1.39 (m, 3H), 1.24 (t, J = 7.2 Hz, 1H), 1.11 (d, J = 6.5 Hz, 3H), 0.78-0.68 (m, 3H); LCMS (electrospray) m/z 459.3 (M + H) ⁺ .	D
273	 <p>HCOOH</p> <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(3-methylbut-2-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.39-13.30 (m, 1H), 11.42 (s, 1H), 9.08 (s, 1H), 9.03 (d, J = 1.0 Hz, 1H), 8.47 (s, 2H), 8.39 (s, 1H), 8.05 (s, 1H), 5.12-4.83 (m, 1H), 2.20 (dd, J = 7.6, 6.1 Hz, 1H), 2.08 (s, 9H), 2.02 (s, 3H), 1.93 (s, 3H), 1.79-1.63 (m, 1H), 1.52 (s, 3H), 1.32-1.25 (m, 1H); LCMS (electrospray) m/z 457.2 (M + H) ⁺ .	D
274	 <p>(1S,2S)-N-(6-(7-(acetamidomethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.33 (s, 1H), 11.37 (d, J = 9.9 Hz, 1H), 9.06 (s, 1H), 8.98 (d, J = 1.6 Hz, 1H), 8.45 (t, J = 5.5 Hz, 1H), 8.41-8.38 (m, 1H), 8.05 (d, J = 1.6 Hz, 1H), 5.06-4.85 (m, 1H), 4.61 (dd, J = 17.9, 5.2 Hz, 2H), 2.32-2.15 (m, 1H), 2.01-1.80 (m, 3H), 1.68 (dtd, J = 23.2, 6.9, 3.8 Hz, 1H), 1.27-1.15 (m, 1H); LCMS (electrospray) m/z 425.90 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
275	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-formyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.94 (s, 1H), 11.43 (s, 1H), 10.49 (s, 1H), 9.13 (d, J = 1.6 Hz, 1H), 9.11 (s, 1H), 8.43 (s, 1H), 8.22 (d, J = 1.6 Hz, 1H), 5.07-4.87 (m, 1H), 2.22-2.16 (m, 1H), 1.75-1.66 (m, 1H), 1.25-1.18 (m, 1H); LCMS (electrospray) m/z 417.85 (M + H) ⁺ .	D
276	 <p>ethyl 5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazole-7-carboxylate</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.54 (s, 1H), 11.42 (s, 1H), 9.10 (s, 2H), 8.42 (s, 1H), 8.20 (d, J = 1.1 Hz, 1H), 5.07-4.86 (m, 1H), 4.51 (q, J = 7.0 Hz, 2H), 2.21-2.16 (m, 1H), 1.75-1.64 (m, 1H), 1.41 (t, J = 6.9 Hz, 3H), 1.22-1.17 (m, 1H); LCMS (electrospray) m/z 461.80 (M + H) ⁺ .	D
277	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(((2R,3R)-3-methoxybutan-2-yl)(methyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 2 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.11-13.51 (m, 1H), 11.31-11.43 (m, 1H), 9.02-9.06 (m, 1H), 8.91-8.96 (m, 1H), 8.40-8.47 (m, 2H), 8.31-8.38 (m, 1H), 7.97-8.08 (m, 1H), 4.98-5.12 (m, 1H), 4.83-4.92 (m, 1H), 3.48-3.49 (m, 1H), 3.47-3.54 (m, 8H), 3.24-3.26 (m, 3H), 2.96-3.05 (m, 4H), 2.11-2.24 (m, 1H), 1.62-1.78 (m, 2H), 1.47-1.58 (m, 2H), 1.27 (br d, J = 6.6 Hz, 3H), 1.06-1.13 (m, 3H); LCMS (electrospray) m/z 504.2 (M + H) ⁺ .	D
278	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(((2R,3S)-3-methoxybutan-2-yl)(methyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 2 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.11-13.50 (m, 1H), 11.31-11.43 (m, 1H), 9.02-9.06 (m, 1H), 8.91-8.96 (m, 1H), 8.40-8.47 (m, 2H), 8.31-8.38 (m, 1H), 7.97-8.08 (m, 1H), 4.98-5.12 (m, 1H), 4.83-4.92 (m, 1H), 3.48-3.49 (m, 1H), 3.47-3.54 (m, 8H), 3.24-3.26 (m, 3H), 2.96-3.05 (m, 4H), 2.11-2.24 (m, 1H), 1.62-1.78 (m, 2H), 1.47-1.58 (m, 2H), 1.28 (br d, J = 6.6 Hz, 3H), 1.05-1.12 (m, 3H); LCMS (electrospray) m/z 504.2 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
279	 <p>(1S,2S)-N-(6-(5-chloro-7-(1-(1-cyanocyclopropyl)amino)ethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.28-13.03 (m, 1H), 11.52-11.34 (m, 1H), 9.07 (s, 1H), 9.03-8.98 (m, 1H), 8.46 (s, 1H), 8.39 (s, 1H), 8.08-8.01 (m, 1H), 5.10-4.84 (m, 1H), 4.81-4.70 (m, 1H), 4.04 (d, J = 3.3 Hz, 1H), 2.24-2.15 (m, 1H), 1.75-1.63 (m, 1H), 1.52 (d, J = 6.7 Hz, 3H), 1.29-1.23 (m, 1H), 1.22-1.14 (m, 1H), 0.97 (ddd, J = 9.9, 7.6, 4.6 Hz, 1H), 0.66-0.56 (m, 1H); LCMS (electrospray) m/z 497.2 (M + H) ⁺ .	D
280	 <p>2-(5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)ethyl acetate</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.67 (s, 1H), 11.42 (s, 1H), 9.07 (s, 1H), 9.02 (d, J = 1.1 Hz, 1H), 8.39 (s, 1H), 8.07 (s, 1H), 5.05-4.86 (m, 1H), 4.36 (t, J = 6.3 Hz, 2H), 3.38 (d, J = 3.8 Hz, 2H), 2.18 (q, J = 7.0 Hz, 1H), 1.94 (s, 3H), 1.69 (dd, J = 23.6, 3.8 Hz, 1H), 1.19 (d, J = 8.8 Hz, 1H); LCMS (electrospray) m/z 475.10 (M + H) ⁺ .	D
281	 <p>(9H-fluoren-9-yl)methyl (5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)carbamate</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.35-13.57 (m, 1H), 11.43 (s, 1H), 9.80-10.03 (m, 1H), 9.09 (s, 1H), 9.05 (s, 1H), 8.40 (s, 1H), 8.07 (s, 1H), 7.89 (d, J = 30.2 Hz, 4H), 7.44-7.34 (m, 4H), 4.83-5.13 (m, 1H), 4.21-4.66 (m, 3H), 2.14-2.27 (m, 1H), 1.71-1.71 (m, 1H), 1.14-1.21 (m, 1H); LCMS (electrospray) m/z 627.80 (M + H) ⁺ .	D
282	 <p>(1S,2S)-N-(6-(5-chloro-7-(difluoromethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.84 (s, 1H), 11.45 (d, J = 4.4 Hz, 1H), 9.14-9.08 (m, 2H), 8.42 (s, 1H), 8.21 (d, J = 8.5 Hz, 1H), 7.65 (t, J = 53.3 Hz, 1H), 5.08-4.87 (m, 1H), 2.22-2.16 (m, 1H), 1.74-1.64 (m, 1H), 1.21-1.17 (m, 1H); LCMS (electrospray) m/z 439.80 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
283	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyano(hydroxy)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide. 1 HCl</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 11.43 (s, 1H), 9.10 (d, J = 2.0 Hz, 1H), 9.06 (d, J = 1.6 Hz, 1H), 8.40 (d, J = 5.5 Hz, 1H), 8.16 (s, 1H), 6.37 (s, 1H), 5.17-4.87 (m, 1H), 2.23-2.16 (m, 1H), 1.74-1.64 (m, 1H), 1.24-1.17 (m, 1H); LCMS (electrospray) m/z 444.00 (M + H) ⁺ .	D
284	 <p>N-(1-(5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)ethyl)cyclobutanecarboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.78-13.32 (m, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 8.99 (d, J = 1.0 Hz, 1H), 8.50 (s, 1H), 8.37 (s, 1H), 8.33 (br d, J = 6.8 Hz, 1H), 8.04 (s, 1H), 5.45 (br t, J = 7.0 Hz, 1H), 5.10-4.81 (m, 1H), 3.08 (br t, J = 8.1 Hz, 1H), 2.24-2.17 (m, 1H), 2.15-2.01 (m, 2H), 1.98-1.91 (m, 2H), 1.90-1.82 (m, 1H), 1.76-1.63 (m, 2H), 1.56 (br d, J = 7.2 Hz, 3H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 514.2 (M + H) ⁺ .	D
285	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-fluorocyclopropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.95-13.62 (1H), 11.41 (s, 1H), 9.06 (s, 1H), 8.96 (d, J = 1.2 Hz, 1H), 8.39 (s, 1H), 8.08 (s, 1H), 5.46-5.22 (m, 1H), 5.08-4.85 (m, 1H), 2.82-2.69 (m, 1H), 2.25-2.13 (m, 1H), 1.80-1.72 (m, 1H), 1.71-1.62 (m, 1H), 1.48-1.36 (m, 1H), 1.22-1.15 (m, 1H); LCMS (electrospray) m/z 447.1 (M + H) ⁺ .	D
286	 <p>(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide. 2 formic acid</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.02-13.21 (m, 1H), 11.30-11.40 (m, 1H), 8.95-9.06 (m, 1H), 8.75-8.82 (m, 1H), 8.29-8.41 (m, 1H), 7.81-7.95 (m, 1H), 5.01-5.08 (m, 1H), 4.84-4.95 (m, 2H), 3.92-4.13 (m, 1H), 2.24-2.30 (m, 3H), 2.12-2.23 (m, 2H), 1.61-1.76 (m, 1H), 1.20-1.27 (m, 1H), 1.16-1.20 (m, 1H); LCMS (electrospray) m/z 564.3 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
287	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(tetrahydrofuran-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.43-13.59 (m, 1H), 13.34 (br d, J = 1.2 Hz, 1H), 11.35-11.48 (m, 1H), 9.28-9.33 (m, 1H), 9.28-9.33 (m, 1H), 9.04-9.10 (m, 1H), 8.97-9.02 (m, 1H), 8.63-8.72 (m, 1H), 8.63-8.65 (m, 1H), 8.36-8.42 (m, 1H), 8.00-8.11 (m, 1H), 7.53-7.60 (m, 1H), 5.00-5.11 (m, 1H), 4.82-4.94 (m, 1H), 4.06-4.16 (m, 2H), 3.96-4.04 (m, 1H), 3.82-3.96 (m, 2H), 2.35-2.44 (m, 1H), 2.11-2.30 (m, 2H), 1.62-1.75 (m, 1H), 1.15-1.29 (m, 1H); LCMS (electrospray) m/z 458.8 (M + H) ⁺ .	D
288	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(2,2,2-trifluoroacetamido)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.66 (m, 1H), 11.40 (s, 1H), 10.13 (m, 1H), 9.07 (s, 1H), 9.01 (d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.10 (s, 1H), 5.56 (q, J = 7.2 Hz, 1H), 4.96 (m, 1H), 2.19 (m, 1H), 1.70 (m, 4H), 1.21 (ddt, J = 12.3, 9.0, 6.2, 6.2 Hz, 1H); LCMS (electrospray) m/z 528.1 (M + H) ⁺ .	D
289	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((methylthio)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.65 (s, 1H), 11.42 (s, 1H), 9.08 (s, 1H), 9.03 (d, J = 1.6 Hz, 1H), 8.39 (s, 1H), 8.07 (d, J = 1.1 Hz, 1H), 5.07-4.86 (m, 1H), 4.11 (s, 2H), 2.23-2.15 (m, 1H), 2.10-2.03 (m, 3H), 1.69 (dtd, J = 23.3, 6.9, 3.8 Hz, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 450.00 (M + H) ⁺ .	D
290	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(methylthio)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.53 (s, 1H), 11.42 (s, 1H), 9.08 (s, 1H), 9.02 (d, J = 1.6 Hz, 1H), 8.38 (s, 1H), 8.08 (s, 1H), 5.76 (s, 0H), 5.07-4.86 (m, 1H), 4.65 (q, J = 7.1 Hz, 1H), 2.23-2.16 (m, 1H), 1.97 (d, J = 11.0 Hz, 3H), 1.78 (d, J = 7.1 Hz, 3H), 1.69 (dtd, J = 23.4, 6.9, 3.6 Hz, 1H), 1.25-1.16 (m, 1H); LCMS (electrospray) m/z 464.10 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
291	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methylsulfonyl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.67 (s, 1H), 11.41 (d, J = 9.9 Hz, 1H), 9.09-9.05 (m, 2H), 8.39 (d, J = 3.3 Hz, 1H), 8.10 (d, J = 1.6 Hz, 1H), 5.07-4.87 (m, 1H), 4.56-4.44 (m, 2H), 2.74-2.67 (m, 3H), 2.23-2.16 (m, 1H), 1.69 (dtd, J = 23.5, 6.9, 3.7 Hz, 1H), 1.25-1.15 (m, 1H); LCMS (electrospray) m/z 466.00 (M + H) ⁺ .	D
292	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(methylsulfonyl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.67 (s, 1H), 11.43 (s, 1H), 9.09-9.06 (m, 2H), 8.40 (s, 1H), 8.12 (s, 1H), 5.07-4.87 (m, 3H), 3.13 (d, J = 14.3 Hz, 3H), 2.23-2.16 (m, 1H), 1.69 (dtd, J = 23.1, 6.9, 3.8 Hz, 1H), 1.25-1.17 (m, 1H); LCMS (electrospray) m/z 482.00 (M + H) ⁺ .	D
293	 <p>(1S,2S)-N-(6-(5-chloro-7-(1,3-dimethylureido)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.67 (s, 1H), 11.42 (s, 1H), 9.09 (s, 1H), 8.99 (d, J = 1.6 Hz, 1H), 8.44 (s, 1H), 8.10 (s, 1H), 6.46 (s, 1H), 5.07-4.87 (m, 1H), 3.21 (s, 3H), 2.58 (d, J = 4.4 Hz, 3H), 2.23-2.16 (m, 1H), 1.72-1.66 (m, 1H), 1.25-1.15 (m, 1H); LCMS (electrospray) m/z 475.10 (M + H) ⁺ .	D
294	 <p>(1S,2S)-N-(6-(5-chloro-7-((1S,2R)-1,2-dimethoxypropyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.28 (s, 1H), 11.42 (s, 1H), 9.07 (s, 1H), 9.03 (d, J = 1.1 Hz, 1H), 8.38 (s, 1H), 8.04 (s, 1H), 5.07-4.87 (m, 2H), 3.90 (t, J = 6.3 Hz, 1H), 3.37 (s, 3H), 3.25 (s, 3H), 2.23-2.15 (m, 1H), 1.69 (dtd, J = 23.3, 7.1, 3.6 Hz, 1H), 1.25-1.15 (m, 1H), 0.96-0.91 (m, 3H); LCMS (electrospray) m/z 491.1 (M + H) ⁺ .	D

TABLE 1-continued





Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
295	 <p>(1S,2S)-N-(6-(5-chloro-7-(1-(2,2-difluoroacetamido)ethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.96-12.70 (m, 1H), 11.39 (br s, 1H), 9.07 (s, 1H), 8.99 (br d, J = 1.3 Hz, 1H), 8.38 (s, 1H), 8.09 (s, 1H), 6.49-6.10 (m, 1H), 5.56 (br d, J = 7.2 Hz, 1H), 5.10-4.83 (m, 1H), 2.28-2.13 (m, 1H), 1.71 (br s, 1H), 1.66 (br d, J = 7.2 Hz, 3H), 1.26-1.16 (m, 1H); LCMS (electrospray) m/z 510.2 (M + H) ⁺ .	D
296	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(2-methyl-1H-imidazol-5-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.18 (s, 1H), 12.55-12.26 (m, 1H), 11.41 (s, 1H), 9.09 (s, 1H), 9.05 (d, J = 1.3 Hz, 1H), 8.40 (s, 1H), 8.08 (s, 1H), 7.70 (d, J = 3.7 Hz, 1H), 5.10-4.84 (m, 1H), 2.49 (s, 3H), 2.27-2.16 (m, 1H), 1.78-1.64 (m, 1H), 1.26-1.16 (m, 1H); LCMS (electrospray) m/z 468.9 (M + H) ⁺ .	D
297	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(methylsulfonyl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.34-13.85 (OH), 11.42 (s, 1H), 9.09 (s, 1H), 9.03 (d, J = 1.6 Hz, 1H), 8.40 (s, 1H), 8.11 (s, 1H), 5.18 (q, J = 7.3 Hz, 1H), 5.07-4.86 (m, 1H), 3.06 (s, 3H), 2.23-2.16 (m, 1H), 1.99-1.96 (m, 3H), 1.74-1.64 (m, 2H), 1.22-1.15 (m, 1H); LCMS (electrospray) m/z 496.00 (M + H) ⁺ .	D
298	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-(1-(methylsulfinyl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.57-13.99 (1H), 11.43 (s, 1H), 9.10 (d, J = 11.5 Hz, 1H), 9.02 (d, J = 1.6 Hz, 1H), 8.40 (s, 1H), 8.13 (s, 1H), 5.08-4.87 (m, 1H), 4.65 (q, J = 7.1 Hz, 1H), 2.49 (s, 3H), 2.23-2.16 (m, 1H), 1.84-1.83 (m, 3H), 1.75-1.64 (m, 2H), 1.23-1.16 (m, 1H); LCMS (electrospray) m/z 480.05 (M + H) ⁺ .	D

TABLE 1-continued





Ex #	Structure/Name	1H NMR/MS (M + 1)	Method
299	 <p data-bbox="370 667 685 751">(1S,2S)-N-(6-(5-chloro-7-(1-(ethylamino)-1-oxopropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.24 (s, 1H), 11.38 (d, J = 24.2 Hz, 1H), 9.07 (s, 1H), 8.99-8.89 (m, 1H), 8.43 (d, J = 24.2 Hz, 1H), 8.04 (dd, J = 6.0, 4.9 Hz, 2H), 5.07-4.86 (m, 1H), 4.25 (q, J = 7.1 Hz, 1H), 3.14-3.08 (m, 2H), 2.33-2.15 (m, 1H), 1.77-1.65 (m, 1H), 1.64-1.49 (m, 3H), 1.35-1.16 (m, 1H), 1.01 (t, J = 7.1 Hz, 3H), 0.86 (q, J = 7.5 Hz, 1H); LCMS (electrospray) m/z 488.1 (M + H) ⁺ .	D
300	 <p data-bbox="370 1033 685 1117">(1S,2S)-N-(6-(5-chloro-7-(cyano(2,2,2-trifluoroacetamido)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.72 (s, 1H), 11.43 (d, J = 8.2 Hz, 1H), 10.96 (s, 1H), 9.13-9.05 (m, 2H), 8.40 (d, J = 10.4 Hz, 1H), 8.20 (d, J = 11.5 Hz, 1H), 6.63 (s, 1H), 5.06-4.86 (m, 1H), 2.32-2.15 (m, 1H), 1.73-1.65 (m, 1H), 1.24-1.16 (m, 1H); LCMS (electrospray) m/z 539.1 (M + H) ⁺ .	D
301	 <p data-bbox="381 1440 673 1558">methyl 2-(5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)-3-(cyclobutylamino)-3-oxopropanoate</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.54 (s, 1H), 11.38 (s, 1H), 9.02 (dd, J = 19.2, 1.6 Hz, 2H), 8.62 (d, J = 5.5 Hz, 1H), 8.35 (s, 1H), 8.06 (s, 1H), 6.19 (d, J = 7.1 Hz, 1H), 4.93 (ddd, J = 66.0, 9.9, 6.0 Hz, 1H), 3.64 (d, J = 12.1 Hz, 4H), 2.29-1.62 (m, 11H), 1.34-1.13 (m, 1H); LCMS (electrospray) m/z 558.1 (M + H) ⁺ .	D
302	 <p data-bbox="381 1812 673 1929">(1S,2S)-N-((5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)(cyano)methyl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.76 (s, 1H), 11.43 (s, 1H), 9.62-9.58 (m, 1H), 9.10-9.06 (m, 2H), 8.41 (s, 1H), 8.18 (d, J = 13.7 Hz, 1H), 6.62 (t, J = 5.8 Hz, 1H), 5.07-4.77 (m, 2H), 2.23-2.16 (m, 1H), 1.93-1.86 (m, 1H), 1.73-1.55 (m, 2H), 1.27-1.15 (m, 3H); LCMS (electrospray) m/z 529.1 (M + H) ⁺ .	D

TABLE 1-continued






Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
303	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyano(cyclopropanecarboxamido)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.25 (s, 1H), 11.43 (s, 1H), 9.54 (d, J = 4.9 Hz, 1H), 9.10-9.06 (m, 2H), 8.42 (s, 1H), 8.05-8.31 (1H), 6.58 (d, J = 4.9 Hz, 1H), 4.97 (d, J = 69.8 Hz, 1H), 2.20 (d, J = 7.1 Hz, 1H), 1.94 (d, J = 30.8 Hz, 1H), 1.71 (d, J = 5.5 Hz, 1H), 1.34 (s, 7H); LCMS (electrospray) m/z 511.1 (M + H) ⁺ .	D
304	 <p>(1S,2S)-N-(6-(5-chloro-7-(cyano(2,2-difluoroacetamido)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.72 (s, 1H), 11.43 (s, 1H), 10.37-10.32 (m, 1H), 9.10-9.06 (m, 2H), 8.41 (t, J = 5.5 Hz, 1H), 8.19 (d, J = 1.6 Hz, 1H), 6.65 (d, J = 4.9 Hz, 1H), 6.50-6.23 (m, 1H), 5.07-4.87 (m, 1H), 2.19 (q, J = 7.0 Hz, 1H), 1.72-1.66 (m, 1H), 1.24-1.17 (m, 1H); LCMS (electrospray) m/z 521.1 (M + H) ⁺ .	D
305	 <p>(1S,2S)-N-(6-(5-chloro-6-fluoro-7-((propan-2-yl-1,1,1,3,3,3-d6)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.16 (s, 1H), 11.36 (s, 1H), 9.01 (s, 1H), 8.90 (s, 1H), 8.34 (s, 1H), 7.94 (s, 1H), 5.28-5.18 (m, 1H), 5.06-4.85 (m, 1H), 4.00 (d, J = 9.3 Hz, 1H), 2.21-2.14 (m, 1H), 1.67 (dtd, J = 23.3, 6.8, 3.7 Hz, 1H), 1.23-1.15 (m, 1H); LCMS (electrospray) m/z 452.9 (M + H) ⁺ .	D
306	 <p>(1S,2S)-N-(6-(7-ethoxy-6-fluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.68 (s, 1H), 11.39 (s, 1H), 9.02 (s, 1H), 8.84 (d, J = 1.4 Hz, 1H), 8.36 (s, 1H), 7.97 (s, 1H), 5.05-4.89 (m, 1H), 4.36 (q, J = 7.0 Hz, 2H), 2.29 (s, 3H), 2.20-2.16 (m, 1H), 1.72-1.66 (m, 1H), 1.40 (t, J = 7.1 Hz, 3H), 1.20 (s, 1H); LCMS (electrospray) m/z 445.10 (M + H) ⁺ .	D

TABLE 1-continued

Compounds of Examples			
Ex #	Structure/Name	¹ H NMR/MS (M + 1)	Method
307	 <p>(1S,2S)-N-(6-(5-ethoxy-6-fluoro-7-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide</p>	¹ H NMR (400 MHz, DMSO-d ₆) δ 13.48 (s, 1H), 11.40 (s, 1H), 9.13 (d, J = 1.6 Hz, 1H), 9.08 (s, 1H), 8.44 (s, 1H), 8.31 (s, 1H), 5.07-4.86 (m, 1H), 3.96 (q, J = 7.0 Hz, 2H), 2.55 (s, 3H), 2.22-2.15 (m, 1H), 1.72-1.65 (m, 1H), 1.21-1.16 (m, 4H); LCMS (electrospray) m/z 445.10 (M + H) ⁺	D

Evaluation of Compounds

HPK1 Kinase Assay

HPK1 kinase activity was measured by Promega's ADP-Glo™ kinase assay. In this assay, 5 ng of recombinant human HPK1 (signalchem) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μL) and 5 μL of ATP (25 μM) in buffer (40 mM Tris, 7.5; 20 mM MgCl₂; 0.1 mg/ml BSA; 50 μM DTT). The assay was started by incubating the reaction mixture in a 96-well plate at 30° C. for 40 minutes. After the incubation, 25 uL ADP-Glo reagent was added and the reaction was incubated at room temperature for 40-min to stop the reaction and degrade residual ATP. The ADP product was then converted to ATP by adding 50 uL per well of detection reagent. Luminescence was detected after 30-min room temperature incubation with the Molecular device I3X plate reader. The IC₅₀ values were calculated from a series of percent inhibition values determined at a range of inhibitor concentration using software routines as implemented in the GraphPad Prism 7 software and SigmaPlot13.0.

TABLE 2

In vitro activity against HPK1 data	
Example	HPK1 IC ₅₀ (nM)
1	+
2	++++
3	+++
4	++++
5	++++
6	++++
7	++++
8	+++
9	++++
10	++++
11	+
12	++++
13	++++
14	++++
15	++++
16	++++
17	++++
18	++++
19	++++
20	++++
21	++++
22	+++

TABLE 2-continued

In vitro activity against HPK1 data	
Example	HPK1 IC ₅₀ (nM)
23	++++
24	+
25	++++
26	++++
27	++++
28	++++
29	++++
30	++++
31	+++
32	++++
33	++++
34	++++
35	+++
36	++++
37	++++
38	++++
39	++++
40	++++
41	++++
42	++++
43	++++
44	++++
45	++++
46	++++
47	++++
48	++++
49	++++
50	++++
51	++++
52	++++
53	++++
54	++++
55	++++
56	++++
57	++++
58	++++
59	+++
60	++++
61	++++
62	++++
63	++++
64	++++
65	++++
66	++++
67	++++
68	++++
69	++++
70	++++

207

TABLE 2-continued

In vitro activity against HPK1 data	
Example	HPK1 IC ₅₀ (nM)
71	++++
72	+++
73	++++
74	+++
75	++++
76	++++
77	++++
78	++++
79	++++
80	++++
81	++++
82	++++
83	++++
84	++++
85	++++
86	++++
87	++++
88	++++
89	++++
90	++++
91	++++
92	++++
93	++++
94	++++
95	++++
96	++++
97	++++
98	+++
99	+++
100	++++
101	++++
102	++++
103	+++
104	+++
105	++++
106	++++
107	++++
108	++++
109	++++
110	++++
111	+++
112	+++
113	++++
114	++++
115	++++
116	++++
117	++++
118	++++
119	++++
120	++++
121	++++
122	++++
123	++++
124	++++
125	++++
126	++++
127	+++
128	++++
129	+++
130	++++
131	++++
132	++++
133	++++
134	++++
135	+
136	++++
137	+
138	+++
139	++++
140	++++
141	++++
142	++++
143	++++
144	++++
145	++++
146	++++

208

TABLE 2-continued

In vitro activity against HPK1 data	
Example	HPK1 IC ₅₀ (nM)
147	++++
148	++++
149	+++
150	++++
151	++++
152	+++
153	++++
154	+++
155	++++
156	++++
157	++++
158	++++
159	+++
160	++++
161	+++
162	++++
163	+++
164	+++
165	++++
166	++++
167	++++
168	++++
169	++++
170	++++
171	++++
172	++++
173	++++
174	++++
175	++++
176	++++
177	++++
178	+++
179	++++
180	++++
181	++++
182	++++
183	++++
184	+++
185	++++
186	++++
187	++++
188	++++
189	+++
190	++++
191	++++
192	++++
193	++++
194	++++
195	++++
196	++++
197	++++
198	++++
199	++++
200	++++
201	++++
202	+++
203	+++
204	+++
205	+++
206	++++
207	++++
208	++++
209	++++
210	++++
211	++++
212	++++
213	++++
214	++++
215	++++
216	++++
217	++++
218	++++
219	++++
220	++++
221	++++
222	++++

209

TABLE 2-continued

In vitro activity against HPK1 data	
Example	HPK1 IC ₅₀ (nM)
223	++++
224	++++
225	++++
226	++++
227	+++
228	++++
229	++++
230	++++
231	++++
232	++++
233	++++
234	++++
235	++++
236	++++
237	++++
238	+++
239	+++
240	+++
241	++++
242	++++
243	++++
244	++++
245	++++
246	++++
247	++++
248	++++
249	+++
250	++++
251	++++
252	++++
253	++++
254	++++
255	++++
256	++++
257	++++
258	++++
259	+++
260	++++
261	++++
262	++++
263	++++
264	++++
265	++++
266	++++
267	+++
268	++++
269	++++
270	+++
271	++++
272	++++
273	++++
274	++++
275	+++
276	+++
277	+++
278	+
279	++++
280	++++
281	+
282	++++
283	+++
284	++++
285	++++
286	++++
287	++++
288	++++
289	++++
290	++++
291	+++
292	+++
293	++++
294	+++
295	++++
296	++++
297	++++
298	++++

210

TABLE 2-continued

In vitro activity against HPK1 data	
Example	HPK1 IC ₅₀ (nM)
299	++++
300	++++
301	++++
302	++++
303	++++
304	++++
305	++++
306	++++
307	++++

15 IFN γ and IL-2 Analysis of Human Peripheral Pan T Cells
Human peripheral blood pan T cells were purchased from STEMCELL™ Technologies Inc. Human peripheral blood pan T cells were thawed and suspended in DMEM media (10% FBS and 100 Penicillin/Streptomycin). 8×10⁴ T cells were seeded in 96-well plate and incubated with various concentration of compounds and 100 nM Prostaglandin E2 for 1 hr. T cells were stimulated with Dynabeads Human T-Activator CD3/CD28 (Life Technologies) at a 1:3 cells: beads ratio. Cytokine secretion was measured after 24 hr post stimulation using MSD V-PLEX human cytokine kit as suggested by the manufacturer. Data were analyzed with an MESO Quickplex SQ120 (Mesoscale Discovery).


20 In Table 3, the values represent + for >1000 nM, ++ 200-1,000 nM, +++ for <200 nM and – for not determined.
25 Table 3. IFN γ and IL-2 secretion of the invented compounds in human peripheral blood pan T cells

TABLE 3

IFN γ and IL-2 secretion of the invented compounds in human peripheral blood pan T cells			
Example	IFN γ (EC ₅₀)	IL-2 (EC ₅₀)	
4	+++	++	
7	++	++	
13	++	++	
26	+++	++	40
27	+++	–	
33	+++	++	
34	+++	++	
38	++	++	
38	+++	++	45
40	+++	++	
41	+++	++	
42	+++	++	
44	+++	++	
58	+++	++	
61	+++	++	50
62	+++	++	
64	+++	+++	

What is claimed is:

1. A compound of Formula (I):



or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof,
wherein:


R¹ is alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;
wherein the alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, NR⁶NR¹⁰R¹¹, NR⁶OR⁹, NR⁶S(O)₂R⁹, NR⁶S(O)₂NR¹⁰R¹¹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, =O, P(O)R¹²R¹³, SR⁹, S(O)R⁹, S(O)(NH)R¹⁰, S(O)₂R⁹, S(O)₂NR¹⁰R¹¹, cycloalkyl, heterocyclyl, aryl, and heteroaryl; and
wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more independently selected R⁷ substituents;

each R⁷ is independently halo, CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, NR⁶NR¹⁰R¹¹, NR⁶OR⁹, NR⁶S(O)₂R⁹, NR⁶S(O)₂NR¹⁰R¹¹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, =O, P(O)R¹²R¹³, SR⁹, S(O)R⁹, S(O)(NH)R¹⁰, S(O)₂R⁹, S(O)₂NR¹⁰R¹¹, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

L is a bond, —NR⁶—, —O—, or —S—;

X is O or S;

Het is:



R^a is H, D, halo, CN, CH₂F, CHF₂, CF₃, NR¹⁰R¹¹, or OR⁹;

R^b is H, D, halo, CN, CH₂F, CHF₂, CF₃, NR¹⁰R¹¹, or OR⁹;

R^c is H, D, halo, CN, CH₂F, CHF₂, CF₃, NR¹⁰R¹¹, or OR⁹;

R² is H, D, halo, CN, NO₂, CD₃, CD₂OH, CH₂OCH[Si(CH₃)₃]CH₃, CH₂OCH₂CH₂Si(CH₃)₃, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, NR⁶NR¹⁰R¹¹, NR⁶OR⁹, NR⁶S(O)₂R⁹, NR⁶S(O)₂NR¹⁰R¹¹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, P(O)R¹²R¹³, SR⁹, S(O)R⁹, S(O)(NH)R¹⁰, S(O)₂R⁹, S(O)₂NR¹⁰R¹¹, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, NO₂, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, and OC(O)OR⁹; and

wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, NO₂, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, and OC(O)OR⁹;

R³ is H, D, halo, CN, NO₂, CD₃, CH₂OH, CD₂OH, C₁₋₆ alkyl, haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, NR⁶NR¹⁰R¹¹, NR⁶OR⁹, NR⁶S(O)₂R⁹, NR⁶S(O)₂NR¹⁰R¹¹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, P(O)R¹²R¹³, SR⁹, S(O)R⁹, S(O)(NH)R¹⁰, S(O)₂R⁹, S(O)₂NR¹⁰R¹¹, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R⁵ is H, D, halo, CN, CD₃, CH₂OH, CD₂OH, C₁₋₆ alkyl, haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, OH, or cycloalkyl;

M is a bond, —NR⁶—, —O—, or —S—;

each R⁶ is independently H or C₁₋₆ alkyl;

R⁴ is H, D, halo, CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, OH, P(O)R¹²R¹³, S(O)(NH)R¹⁰, S(O)₂R⁹, S(O)₂NR¹⁰R¹¹, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, CN, NO₂, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, NR⁶S(O)₂R⁹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, and OC(O)OR⁹; and

wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, NO₂, CD₃, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, NR⁶S(O)₂R⁹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, and OC(O)OR⁹;

each R¹⁰ is independently H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

each R¹¹ is independently H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; or each R¹⁰ and R¹¹, taken together with the nitrogen atom to which they are attached, independently form a 4- to 12-membered heterocyclyl, wherein the 4- to 12-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, NO₂, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, NR⁶S(O)₂R⁹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, and OC(O)OR⁹;

each R¹² is independently C₁₋₆ alkyl, OC₁₋₆ alkyl, C₃₋₈ cycloalkyl, heterocyclyl, aryl, or heteroaryl;

each R¹³ is independently C₁₋₆ alkyl, OC₁₋₆ alkyl, C₃₋₈ cycloalkyl, heterocyclyl, aryl, or heteroaryl; or each R¹² and R¹³, taken together with the phosphorus atom to which they are attached, independently form a

213

4- to 8-membered heterocyclyl, wherein the 4- to 8-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, NO₂, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR¹⁰C(O)R⁹, NR¹⁰C(O)NR¹⁰R¹¹, NR¹⁰C(O)OR⁹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, and OC(O)OR⁹; and

each R⁹ is independently H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.

2. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R¹ is cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more independently selected R⁷ substituents;

each R⁷ is independently halo, CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, NR⁶NR¹⁰R¹¹, NR⁶OR⁹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, or cycloalkyl; and

L is a bond.

3. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R² is H, halo, C₁₋₆ alkyl, or SR⁹, wherein the C₁₋₆ alkyl is optionally substituted with one or more independently selected halo substituents;

R³ is H, halo, C₁₋₆ alkyl, haloalkyl, or SR⁹; and each R⁹ is independently C₁₋₆ alkyl.

4. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:


M is a bond, —NR⁶—, or —O—; and

R⁴ is H, D, halo, CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, OH, S(O)(NH)R¹⁰, S(O)₂R⁹, S(O)₂NR¹⁰R¹¹, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

wherein the C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, CN, NR¹⁰R¹¹, NR¹⁰C(O)R⁹, NR¹⁰S(O)₂R⁹, and OH; and

wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, CD₃, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, NR¹⁰R¹¹, NR¹⁰C(O)R⁹, NR¹⁰S(O)₂R⁹, and OH.


5. The compound of claim 1, wherein the compound is of Formula (II):



or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.


214

6. The compound of claim 1, wherein the compound is of Formula (III):



or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

7. The compound of claim 1, wherein the compound is of Formula (IV):



or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

8. The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R¹ is cyclopropyl, wherein the cyclopropyl is optionally substituted with one or more independently selected R⁷ substituents;

each R⁷ is independently halo or C₁₋₆ alkyl; and

L is a bond, —NR⁶—, —O—, or —S—;

R² is H, halo, C₁₋₆ alkyl, or SR⁹, wherein the C₁₋₆ alkyl is optionally substituted with one or more independently selected halo substituents;

R³ is H, halo, or C₁₋₆ alkyl;

R⁵ is H, halo, or C₁₋₆ alkyl;

M is a bond, —NR⁶—, —O—, or —S—;

R⁴ is H, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, cycloalkyl, tetrahydrofuranyl, dioxanyl, pyrrolyl, furanyl, pyrazolyl, or isoxazolyl;

wherein the C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, C(O)NH₂, NHC(O)H, NHC(O)CH₃, NHC(O)CH₂CH₃, NHS(O)₂CH₃, OH, and OC₁₋₆ alkyl;

wherein the C₂₋₆ alkenyl is optionally substituted with one or more independently selected halo substituents;

wherein the cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of OH and OCH₃; and

wherein the pyrrolyl or pyrazolyl is optionally substituted with one or more CH₃ substituents;

R⁹ is C₁₋₆ alkyl.

9. The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R¹ is cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more independently selected R⁷ substituents;

each R⁷ is independently halo, CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C(O)R⁹, C(O)NR¹⁰R¹¹, C(O)OR⁹, NR¹⁰R¹¹, NR⁶C(O)R⁹, NR⁶C(O)NR¹⁰R¹¹, NR⁶C(O)OR⁹, NR⁶NR¹⁰R¹¹, NR⁶OR⁹, OR⁹, OC(O)R⁹, OC(O)NR¹⁰R¹¹, or cycloalkyl; and

L is a bond.

10. The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R¹ is cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more independently selected R⁷ substituents;

each R⁷ is independently halo or C₁₋₃ alkyl; and

L is a bond.

11. The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R¹ is cyclopropyl, wherein the cyclopropyl is optionally substituted with one or more independently selected R⁷ substituents;

each R⁷ is independently halo or C₁₋₃ alkyl;

L is a bond;

R² is H, halo, C₁₋₆ alkyl, or SR⁹, wherein the C₁₋₆ alkyl is optionally substituted with one or more independently selected halo substituents;

R³ is H, halo, or C₁₋₆ alkyl;

R⁵ is H, halo, or C₁₋₆ alkyl;

M is a bond, —NR⁶—, —O—, or —S—;

R⁴ is H, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, or cycloalkyl; wherein the C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo and OH; and

wherein the C₂₋₆ alkenyl is substituted with one or more independently selected halo substituents; and

R⁹ is C₁₋₆ alkyl.

12. The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R¹ is cyclopropyl, wherein the cyclopropyl is optionally substituted with one or more independently selected R⁷ substituents;

each R⁷ is independently halo or C₁₋₃ alkyl;

L is a bond;

R² is H, halo, or C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with one or more independently selected halo substituents;

R³ is H, halo, or C₁₋₆ alkyl;

R⁵ is H, halo, or C₁₋₆ alkyl;

M is a bond, —NR⁶—, or —O—; and

R⁴ is H, halo, or C₁₋₆ alkyl.

13. The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R¹ is cyclopropyl, wherein the cyclopropyl is substituted with one or more independently selected R⁷ substituents;

each R⁷ is independently F, Cl, or C₁₋₃ alkyl;

L is a bond;

R^a is H;

R^b is H;

R² is H, F, Cl, or C₁₋₆ alkyl;

R³ is H, F, Cl, or C₁₋₆ alkyl;

R⁵ is H or C₁₋₆ alkyl;

M is a bond or —NR⁶—;

R⁶ is H; and

R⁴ is H, F, Cl, CH₃, CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂, or CH₂CH₂CH₂CH₃.

14. The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R¹ is cyclopropyl, wherein the cyclopropyl is substituted with one or more independently selected R⁷ substituents;

each R⁷ is independently F or Cl;

L is a bond;

R^a is H;

R^b is H;

R² is H, F, or Cl;

R³ is H, F, or Cl;

R⁵ is H;

M is a bond or —NR⁶—;

R⁶ is H; and

R⁴ is H, F, Cl, CH₃, CH₂CH₃, CH₂CH₂CH₃, or CH(CH₃)₂.

15. The compound of claim 8, or a stereoisomer thereof, wherein the compound, or stereoisomer thereof, is selected from the group consisting of:

(1S,2S)—N-(6-(7-(dimethylamino)-5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-5,7-bis(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-ethoxy-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(ethyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(ethyl(methyl)amino)-6-fluoro-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-ethyl-7-(ethyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-ethoxy-5-ethyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(ethyl(methyl)amino)-6-fluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(isopropyl(methyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1H-pyrrol-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((cyanomethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

217

(1S,2S)—N-(6-(5-chloro-7-cyclopropyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyclopropylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 5

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-methyl-1H-pyrrol-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(1-(2H-tetrazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 10

(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-methyl-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide; 15

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-propyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-methyl-1H-pyrrol-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-hydroxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-fluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 30

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(propylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(ethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 35

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3,3,3-trifluoroprop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-ethyl-6-fluoro-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-ethyl-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 45

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-methyl-1H-pyrazol-5-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-cyclopropoxy-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 50

(1S,2S)—N-(6-(5-chloro-7-(cyclobutylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-methoxyethylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 55

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1,1,1-trifluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-hydroxypropan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-isopropoxy-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 65

218

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-methylprop-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((2,2-difluoroethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(allylamino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-cyclopentyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-fluoroethylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyclopropyl(hydroxy)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(methyl(1-methyl-1H-pyrazol-5-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 25

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-hydroxy-2-methylpropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide; 30

(1S,2S)—N-(6-(5-chloro-7-(1,1-difluoropropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-isobutyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-fluoro-2-methylpropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 40

(1S,2S)—N-(6-(5-chloro-7-(cyclopropyl(methoxymethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((E)-but-2-en-2-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(but-3-en-2-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 50

(1S,2S)—N-(6-(7-(sec-butylamino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(4-methyl-1H-pyrazol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-hydroxycyclopentyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-methoxycyclopentyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 60

(1S,2S)—N-(6-(7-((R)-1-(2H-tetrazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1-cyanoethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((S)-1-(1H-tetrazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(7-(1-amino-1-oxopropan-2-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(isoxazol-4-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1R,2S)—N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(7-(1-acetamidoethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)-2-fluoro-N-(6-(6-fluoro-5-(methylthio)-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-((S)-1,1,1-trifluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-((R)-1,1,1-trifluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-7-((cyclopropylmethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-((R)-1-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-((S)-1-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1,2,2,2-tetrafluoroethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(furan-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1R,2R)—N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;
 (1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(prop-1-en-2-yl)-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(prop-2-yn-1-ylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-7-((1,1-difluoropropan-2-yl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-propionamidoethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-formamidoethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methylbut-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methylbut-2-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(1-(1H-imidazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(7-(sec-butyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-7-(1,4-dioxan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(4-methyl-1H-imidazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(7-(acetamido(cyano)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(methylsulfonylamido)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-7-(1,1-difluoroprop-1-en-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methylbutan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methylbut-2-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 N-(1-(5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)ethyl)cyclobutanecarboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-fluorocyclopropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(tetrahydrofuran-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(2,2,2-trifluoroacetamido)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-7-(1-(2,2-difluoroacetamido)ethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-7-(cyano(2,2,2-trifluoroacetamido)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-((5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)(cyano)methyl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-7-(cyano(cyclopropanecarboxamido)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 (1S,2S)—N-(6-(5-chloro-7-(cyano(2,2-difluoroacetamido)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
 and
 (1S,2S)—N-(6-(5-chloro-6-fluoro-7-((propan-2-yl-1,1,1,3,3,3-d6)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide,
 or a pharmaceutically acceptable salt or tautomer thereof.
 16. The compound of claim 7, or a stereoisomer thereof, wherein the compound, or stereoisomer thereof, is selected from the group consisting of:

(1S,2S)—N-(6-(5-chloro-7-((cyanomethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-hydroxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-vinyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-acetyl-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-cyclopropyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(2-ethoxypropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(tert-butylamino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyclopropylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-fluoropyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-methyl-1H-pyrrol-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(prop-1-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-methyl-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1R,2S)—N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2R)—N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1R,2R)—N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-propyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-methyl-1H-pyrrol-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-hydroxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-fluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(isobutylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(propylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((E)-prop-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(ethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(3R,4S)-4-methyltetrahydrofuran-3-yl-(6-(5-chloro-7-(dimethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)carbamate;

(1S,2S)—N-(6-(5-chloro-7-(2-(dimethylamino)-2-oxoethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((2-(dimethylamino)-2-oxoethyl)thio)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-fluoroethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3,3,3-trifluoroprop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((methylamino)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((dimethylamino)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-ethyl-6-fluoro-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-ethyl-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-ethyl-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-methyl-1H-pyrrol-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1H-pyrrol-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-methyl-1H-pyrazol-5-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((1-hydroxy-2-methylpropan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-pivaloyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-cyclopropoxy-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((2-hydroxyethyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyclobutylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyclopentylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((2-methoxyethyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1,1,1-trifluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((1-hydroxypropan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((1-methoxypropan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2R,3S)—N-(6-(5-chloro-7-(dimethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-methyl-3-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide;

(1S,2S,3S)—N-(6-(5-chloro-7-(dimethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-methyl-3-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-fluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyclopent-1-en-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(morpholinoamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-isopropoxy-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(2-amino-2-oxoethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-methylprop-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((2,2-difluoroethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(2-bromo-2-fluorocyclopropyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(allylamino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-cyclopentyl-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((4-methylpiperazin-1-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((2-fluoroethyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((1,3-dihydroxy-2-methylpropan-2-yl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((1-methyl-1H-pyrazol-5-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((4-hydroxybutan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2R,3S)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-methyl-3-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide;

(1S,2S,3S)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-methyl-3-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2,2,2-trifluoro-1-hydroxyethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(pyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-hydroxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((R)-3-hydroxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-oxocyclopent-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-methoxyethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(N-methylacetamido)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyclopropyl(hydroxy)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((1H-pyrazol-5-yl)amino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1R,2R)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2R)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1R,2S)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(methyl(1H-pyrazol-5-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(methyl(1-methyl-1H-pyrazol-5-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-isobutyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-hydroxy-2-methylpropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(((1S,3R)-3-hydroxycyclopentyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-hydroxycyclopentyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1,1-difluoropropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-isobutyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-methoxy-2-methylpropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-fluoro-2-methylpropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((4-methoxybutan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((3-fluorocyclobutyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((E)-but-2-en-2-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(but-3-en-2-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(sec-butylamino)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((S)-3-hydroxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-hydroxycyclopentyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((tetrahydrofuran-3-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-methoxycyclopentyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(((1S,3S)-3-hydroxycyclopentyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1-(dimethylamino)-1-oxopropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((R)-1-(2H-tetrazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((S)-1-(2H-tetrazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1-cyanoethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1-cyanoethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(1-amino-1-oxopropan-2-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((1-fluoropropan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(furan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(isoxazol-4-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(((1R,3S)-3-hydroxycyclopentyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-hydroxycyclopent-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((3-methyl-1H-pyrazol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2,2,2-trifluoro-1-methoxyethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(methyl(tetrahydrofuran-3-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methoxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((R)-3-methoxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((S)-3-methoxypyrrolidin-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((1-cyclopropylethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((3,3-difluorocyclobutyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1R,2S)—N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-hydroxyprop-2-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(1-acetamidoethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(2-cyanopropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(5-methylfuran-2-yl)-2H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-5-(methylthio)-7-(prop-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((E)-buta-1,3-dien-1-yl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((S)-1,1,1-trifluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((R)-1,1,1-trifluoropropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((cyclopropylmethyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((R)-1-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((S)-1-methoxypropan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1-ethoxy-2,2,2-trifluoroethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1,2,2,2-tetrafluoroethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((3S,4S)-3,4-dimethoxypyrrolidin-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(furan-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(propa-1,2-dien-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2R)—N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1R,2R)—N-(6-(5-chloro-7-(cyclopropyl(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(5,6-dihydro-1,4-dioxin-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(((1R,3S)-3-hydroxycyclopentyl)(methyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—2-fluoro-N-(6-(6-fluoro-7-(prop-1-en-2-yl)-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(5-methylfuran-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-hydroxyprop-1-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(prop-2-yn-1-ylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((1,1-difluoropropan-2-yl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(4-hydroxytetrahydrofuran-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(3,3-dimethylazetid-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((3-chloro-2,2-dimethylpropyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(5-methyl-1H-pyrazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(3-methyl-1H-pyrazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(3,3-difluoroazetid-1-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyanomethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methoxyprop-1-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(2,5-dihydrofuran-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-propionamidoethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1R,2S)—N-(6-(5-chloro-6-fluoro-7-(3-hydroxypropanamido)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-formamidoethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((E)-4-hydroxybut-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methylbut-1-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methylbut-2-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((3-hydroxybutan-2-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(5,5-dimethyltetrahydrofuran-3-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((1,1-difluoropropan-2-yl)(methyl)amino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(sec-butyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1,4-dioxan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(tetrahydro-2H-pyran-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyanofluoromethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

231

(1S,2S)—N-(6-(7-(acetamido(cyano)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(6,6-difluoro-2-azaspiro[3.3]heptan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(methylsulfonamido)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1,1-difluoroprop-1-en-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-((1S,2R)-1,2-dihydroxypropyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(prop-2-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methylbutan-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-methylbut-2-en-2-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(acetamidomethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-formyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

ethyl 5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazole-7-carboxylate;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((2R,3R)-3-methoxybutan-2-yl)(methyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((2R,3S)-3-methoxybutan-2-yl)(methyl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(difluoromethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyano(hydroxy)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

N-(1-(5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)ethyl)cyclobutanecarboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-fluorocyclopropyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(tetrahydrofuran-3-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(2,2,2-trifluoroacetamido)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1,3-dimethylureido)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

232

(1S,2S)—N-(6-(5-chloro-7-((1S,2R)-1,2-dimethoxypropyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1-(2,2-difluoroacetamido)ethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(2-methyl-1H-imidazol-5-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1-(ethylamino)-1-oxopropan-2-yl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyano(2,2,2-trifluoroacetamido)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

methyl 2-(5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)-3-(cyclobutylamino)-3-oxopropanoate;

(1S,2S)—N-((5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)(cyano)methyl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyano(cyclopropanecarboxamido)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyano(2,2-difluoroacetamido)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((propan-2-yl-1,1,1,3,3,3-d6)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-ethoxy-6-fluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; and

(1S,2S)—N-(6-(5-ethoxy-6-fluoro-7-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide,

or a pharmaceutically acceptable salt or tautomer thereof.

17. The compound of claim 11, or a stereoisomer thereof, wherein the compound, or stereoisomer thereof, is selected from the group consisting of:

(1S,2S)—N-(6-(5-chloro-7-(dimethylamino)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(dimethylamino)-6-fluoro-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(dimethylamino)-6-fluoro-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(dimethylamino)-6-fluoro-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-(isopropylamino)-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-methyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide;

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-(methylthio)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide; and

(1S,2S)-2-fluoro-N-(6-(6-fluoro-7-isopropyl-5-(trifluoromethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)cyclopropane-1-carboxamide,

or a pharmaceutically acceptable salt or tautomer thereof.

18. The compound of claim **11**, or a stereoisomer thereof, wherein the compound, or stereoisomer thereof, is selected from the group consisting of:

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1R,2S)—N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2R)—N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1R,2R)—N-(6-(5-chloro-6-fluoro-7-(isopropylamino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1R,2R)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2R)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; and

(1R,2S)—N-(6-(5-chloro-6-fluoro-7-isopropyl-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide,

or a pharmaceutically acceptable salt or tautomer thereof.

19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and the compound of claim **1**, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

20. A method for modulating hematopoietic progenitor kinase 1 (HPK1) activity in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of the compound of claim **1**, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

21. The method of claim **20**, wherein the subject has cancer.

22. The method of claim **21**, wherein the cancer is selected from the group consisting of a blastoma, a carcinoma, a leukemia, a lymphoma, a melanoma, and a sarcoma.

23. The method of claim **21**, wherein the cancer is selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, bladder carcinoma, a brain tumor, breast cancer, cervical cancer, colorectal cancer, ependymoma, esophageal cancer, endometrial cancer, Ewing's sarcoma, glioblastoma, hepatocellular carcinoma, laryngeal cancer, lung cancer, medulloblastoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, rhabdomyosarcoma, rhabdoid cancer, and thyroid cancer.

24. A compound selected from the group consisting of:

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(methyl(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)amino)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((2H-tetrazol-2-yl)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(1-(2H-tetrazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((1H-imidazol-1-yl)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((1H-pyrrol-1-yl)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((1H-pyrazol-1-yl)methyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((2-methyl-1H-imidazol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(cyclopropyl(methoxy)methyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((2-methyl-1H-pyrrol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((4-methyl-1H-imidazol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-((4-methyl-1H-pyrazol-1-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((R)-1-(1H-tetrazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-((S)-1-(1H-tetrazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(1-(2H-1,2,3-triazol-2-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(1-(1H-1,2,4-triazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(hydroxy(tetrahydro-2H-pyran-3-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(1-(1H-pyrazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(4-methyl-1H-imidazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-7-(1-((1-cyanocyclopropyl)amino)ethyl)-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(9H-fluoren-9-yl)methyl(5-chloro-6-fluoro-4-(2-((1S,2S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyrazin-6-yl)-1H-indazol-7-yl)carbamate;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(4-methyl-1H-pyrazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(7-(1-(1H-imidazol-1-yl)ethyl)-5-chloro-6-fluoro-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

(1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(2-methyl-1H-imidazol-1-yl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;

- (1S,2S)—N-(6-(5-chloro-6-fluoro-7-((E)-3-(triethylsilyl)prop-1-en-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide;
- (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(3-(trimethylsilyl)prop-2-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide-1 formic acid; 5
- (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-hydroxy-3-(trimethylsilyl)prop-2-yn-1-yl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide-1 formic acid; 10
- (1S,2S)—N-(6-(5-chloro-6-fluoro-7-((methylthio)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 15
- (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(methylthio)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 15
- (1S,2S)—N-(6-(5-chloro-6-fluoro-7-((methylsulfinyl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 20
- (1S,2S)—N-(6-(5-chloro-6-fluoro-7-((methylsulfonyl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; 20
- (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(methylsulfonyl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide; and 25
- (1S,2S)—N-(6-(5-chloro-6-fluoro-7-(1-(methylsulfinyl)ethyl)-1H-indazol-4-yl)imidazo[1,2-a]pyrazin-2-yl)-2-fluorocyclopropane-1-carboxamide, 25
- or a pharmaceutically acceptable salt or tautomer thereof. 30

* * * * *